





INVESTIGATION OF MOLECULAR EFFECTS OF THE SOY-DERIVED 

















In partial fulfillment of the requirements 
 
For the Degree of Doctor of Philosophy 
 
Colorado State University 
 







 Advisor:  Kenneth Reardon  
             Co-Advisor:   Karyn Hamilton 








INVESTIGATION OF MOLECULAR EFFECTS OF THE SOY-DERIVED 
PHYTOESTROGEN GENISTEIN ON CARDIOMYOCYTES BY PROTEOMIC ANALYSIS 
The soy-derived phytoestrogen genistein (GEN) has received attention for its potential to 
benefit the cardiovascular system by providing protection to cardiomyocytes against 
pathophysiological stresses. Although GEN is a well-known estrogen receptor (ER) agonist and a 
non-specific tyrosine kinase inhibitor, current understanding of the complex cellular and 
molecular effects of GEN in cardiomyocytes is still incomplete. The overall goal of this 
dissertation is to use high throughput proteomics methodologies to better understand the 
molecular action of GEN in cardiomyocytes and to identify proteins and pathways that respond to 
GEN treatment. The first study of this project focused on the concentration-dependent proteome 
changes in cultured HL-1 cardiomyocytes due to GEN treatments. Proteins from HL-1 
cardiomyocytes treated with 1 µM and 50 µM GEN were prefractionated into hydrophilic and 
hydrophobic protein fractions and were analyzed by two-dimensional electrophoresis followed by 
protein identification using tandem mass spectrometry (MS). In total, 25 and 62 differential 
expressed proteins were identified in response to 1 µM and 50 µM of GEN treatment, 
respectively. These results suggest that 1 µM GEN enhanced the expression of heat shock 
proteins and anti-apoptotic proteins, while 50 µM GEN down-regulated glycolytic and 
antioxidant enzymes, potentially making cardiomyocytes more susceptible to energy depletion 
and apoptosis. The second study, employing a two-dimensional liquid chromatography and 
tandem MS shotgun proteomics workflow, was carried out to dissect the cellular functions 
changed in cardiomyocytes by ER-dependent or ER-independent actions of GEN. In this study, 
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primary cardiomyocytes isolated from male adult SD rats were treated with 10 µM GEN without 
or with 10 µM ER antagonist ICI 182,780 (ERA) before proteomics comparison. A total of 14 and 
15 proteins were found differentially expressed in response to the GEN, and the GEN+ERA 
treatment, respectively. Cellular functions such as glucose and fatty acid metabolism and 
cardioprotection were found to be modulated by GEN in an ER-dependent fashion, while proteins 
involved with steroidogenesis and estrogen signaling were identified as novel effectors of GEN 
via ER-independent actions. In this study, a consensus-iterative searching strategy was also 
developed to enhance the sensitivity of the shotgun proteomic approach. In the last study, an 
attempt to explore the response to a GEN stimulus in the signaling pathways, we developed a 
phosphopeptide enrichment method to assist the detection of protein phosphorylation in a 
complex peptide mixture. The quantitative performance of a sequential immobilized metal 
affinity chromatography (SIMAC) protocol was evaluated. We further conducted a preliminary 
application of this protocol in a large-scale, quantit tive, label-free phosphoproteomics study to 
explore the alterations of protein phosphorylation patterns due to ER-independent GEN action in 
the SD rat cardiomyocytes. This project demonstrates th  usefulness of proteomics methodologies 
to screen novel molecular targets influenced by GEN in cardiomyocytes. This is also the first 
investigation of the complex cellular impact of this soy-derived phytoestrogen in cardiomyocytes 
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 CHAPTER 1 
BACKGROUND AND OBJECTIVES 
 
1. Introduction 
1.1. Soy phytoestrogens and cardiovascular health  
Cardiovascular diseases (CVDs) are the leading cause of death of both men and women 
in the United States and many other western industrialized countries. Nearly 30 percent 
of U.S. mortality is related to CVDs such as heart f ilure, myocardial infarction, coronary 
heart disease, and stroke [1-3]. Lifestyle-related risk factors have been shown to be the 
major reasons of high incidence of CVD in the U.S. Considering the wide-spread reality 
of high CVD incidence and high mortality, special interest and research priority have 
been given to the early prevention of CVD and the pharmacological intervention 
providing cardiac protection to the population with high CVD risks.  
 
The connection between sex hormones and CVD has long been documented. In particular, 
the presence of endogenous estrogens was identified as beneficial factor preventing the 
occurrence of CVD. Epidemiological evidence has shown that the pre-menopausal 
women have much lower CVD incidence than comparably aged men and post-
menopausal women [4, 5]. Hormone replacement therapy or HRT [6] has been suggested 
for postmenopausal women and has been shown, in some cases, to lower the incidence of 
CVD among other benefits [7-10]. However, HRT has also been received controversial 
opinions over its adverse effects such as increasing risk in breast cancer and even slightly 
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high CVD incidence in women who received HRT [11-13]. In recent years, alternative 
approaches adopting plant phytoestrogens such as geni tein (GEN) have been advocated 
for their potential preventive role against CVD [14- 6]. The use of these phytoestrogens, 
which have weak estrogenic effects as well as anti-cancer properties, has been suggested 
to be equally effective but also safer than the conventional estrogen-based HRT. Such 
speculation was further augmented by epidemiological evidence that the intake of 
phytoestrogens, in particular the soy-derived isoflavones including GEN, is inversely 
associated with the risk of CVD [17-21]. Previous studies have explored extensively the 
effects of soy protein and soy–derived phytoestrogens to lower blood lipids and LDL 
cholesterol level, or effects to promote favorable lipoprotein profiles [22-24]. However, a 
later meta-analysis study provided contradictory conclusion that soy phytoestrogens have 
no effect on the blood cholesterol and lipid profiles [25, 26]. In 2006, the American Heart 
Association (AHA) concluded that the hypolipidemic effects of soy-derived 
phytoestrogens were non-significant [27]. Thus, other mechanisms still remain to be 
explored in order to fully understand why soy-derivd phytoestrogens afford protection 
against CVD. Among the several phytoestrogens present in soy products, the primary 
form of isoflavones, GEN in particular is considered to be the most efficacious. Recently, 
several studies have suggested that isoflavones, and in particular GEN, provide direct 
protection to cardiac myocytes against damaging pathophysiological stresses [28-33]. 





1.2. Cardiomyocytes and cardioprotection 
Cardiac muscle is a type of striated muscle mostly found in the ventricle walls of the 
heart, and it composes 90% of the total mass of a heart. The myocardiocyteal muscle cells 
or cardiomyocytes (CM) are mononuclear myocytes that comprised the basic contractile 
functional unit to generate coordinated force to pum  blood to the circulation. Individual 
myocytes are joined by intercellular junctions permitting the continuation of mechanical 
force and electrical conduction. As the functional unit of the most ‘heavy duty’ organ, 
CM almost completely rely on aerobic metabolism majorly fueled by fatty acid beta-
oxidation with mitochondria makes up to 25% of cell volume. Therefore, ischemic 
condition typically as a result of insufficient coronary blood supply can pose a great 
threat to CM survival and the sustenance of cardiac fun tion.  
 
Ischemic injury can cause CM damages which lead to oncosis manifested by the 
myocardial infarction. Prolonged infarction causes c ll death by necrosis. During sever 
acute energy depletion, the ionic channels in the cell membrane fail to function hence 
causes osmotic imbalance, cellular swelling, sarcolemmal disruption, and release of 
cytoplasmic and internucleosomal contents. Necrotic cell death leads to myocardium 
inflammation which happens within 12-24 hours after injury. Cardiac fibrosis and cardiac 
geometry remodeling may follow as the result of collagen deposition leading to reduce 
the wall thickness and stress [34, 35]. While less damaged CM may die prematurely by 
apoptosis [36, 37]. The apoptosis is a programmed cll death procedure in which 
numerous cellular signaling pathways are activated. The end effectors of those pro-
apoptotic pathways usually are caspases that cleaves several programmed death 
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substrates and activates endonuclease, leading to the characteristic fragmentation of DNA 
[35]. CM apoptosis contributes to the pathogenesis of post-ischemic left ventricular 
dysfunction, arrhythmias and congestive heart failure.  
 
To our knowledge, there is no drug or therapy to completely reverse the damages caused 
by myocardial ischemic infarctions. Moreover, if blood supply is resumed to ischemic 
areas, reperfusion injury due to sudden introduction of oxidative stress can cause even 
more tissue damages. Myocardial reperfusion can cause apoptosis as a result of the 
production of oxygen-free radicals. Patients survived from acute infarction will still 
develop chronic ischemic heart failure. Therefore, means of cardioprotection, in 
particular against ischemic-reperfusion injuries, are of critical importance to lower 
mortality and morbidity of CVDs with great medical and social implications. Procedures 
like ischemic preconditioning [38] by subjecting heart to sublethal cycles of short-term 
ischemia and reperfusion have been proved effective to ameliorate the severity of a 
subsequent lethal cardiac infarction by conferring myocytes with tolerance against 
ischemic-reperfusion [39, 40].  
 
The molecular mechanism of cardioprotection rendered by IPC is probably multi-faceted. 
Most studies have put attention on connecting the ATP depletion under ischemic 
conditions and the adenosine receptor/phospholipases-PKC signaling pathway which 
mediate multiple downstream cellular events to provide cardioprotection [41-46]. 
Mitogen-activated protein kinases (MAPK), in particular the c-Jun and p38 were 
identified as ischemic responsive in the heart [47,48]. Tyrosine kinases were documented 
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as a key downstream step of PKC signaling to afford cardioprotection by IPC against 
ischemic injuries in a rabbit model [49]. However, cardioprotection by activation of 
tyrosine kinases in parallel with PKC was observed in pig and rat heart [50-52]. 
Additionally, researchers have shown that heart adaptation via IPC approach involves the 
increasing activity of anti-apoptotic NF kappa B [53] and has been shown to be regulated 
by tyrosine phosphorylation [54]. Recent studies also demonstrated that the recruitment 
of anti-apopotic phosphatidylinositol 3-kinase-Akt pathway, namely the RISK pathway, 
contribute to the cardioprotection afford by IPC [55] and the newly described ischemic 
postconditioning procedure [56-58].  
 
The role of cytoskeleton remodeling was also characte ized to be related to 
preconditioning triggered cardioprotection. The heat shock protein 27 (HSP27) was 
found to be over-expressed as the downstream target of p38 MAPK under the cardiac 
ischemic stress [59]. HSP27 involved with actin proliferation and myofilaments 
stabilization has been shown to take role in maintaining the cytoskeleton integrity and 
contractile function in prolonged ischemia [60, 61]. On the other hand, pharmacological 
evidences have suggested that the mitochondrial ATP-dependent potassium (KATP) 
channels might be a tenable end effector of cardiopotective preconditioning [62, 63].  
 
The unraveling of many cardioprotective pathways ha r ised the speculation that 
pharmacologic activation of those pathways may enabl  one to harness similar medical 
benefits. Compare to ischemic pre-/post-conditioning procedure, novel therapeutic 
strategies based on pharmacological intervention have emerged as more applicable 
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alternatives with tenable clinical values. Estrogen was one of the examples among others 
administrated to reduce the infarct size in various in vivo models against ischemia insult 
[64-70]. The mechanistic explanations of cardioprotection afforded by estrogen were 
largely focused on the modulation of mitochondrial KATP channel and PI3K/Akt 
pathway [65, 66, 71-75]. However, despite the ability to demonstrate enhanced 
cardioprotection using estrogen in animal models, the translation to the human clinical 
application in the form of HRT has been disappointing along with other unwanted side 
effects such as high risk of developing breast cancer. Therefore, alternative approaches 
using plant isoflavones have been promoted for theipotential cardioprotective values.  
  
1.3. Genistein, chemical and biological properties 
1.3.1. Introduction 
Phytoestrogens are a diverse group of naturally synthesized chemicals found in various 
plants and have estrogenic and/or anti-estrogenic properties due to their similar structure 
to human estrogens. Classification of phytoestrogens based on structure properties results 
in two groups of compounds, the flavonoids, and the non-flavonoids. The flavonoinds 
can further be subcategorized into isoflavones, coumestans and prenyl flavonoids [76]. 
Genistein (GEN) or 4', 5, 7-trihydroxyisoflavone is a isoflavone that occurs in high 
concentration in leguminous plants like soybean, lupins, kudzu [77]. Whole soybean and 
processed soy foods and beverages are the major source  of isoflavone consumption in 
daily diet. Genistein with another less potent form the daidzein, constitute up to 90% of 
the isoflavone content in soy. However, it is noteworthy that the contents of GEN and 
other phytoestrogen differ according to species variety, location and season of harvest, 
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and also how the soy food is processed [78].  
 
Genistein is majorly present as 7-O-beta-D-glucoside form with limited bioactivity in soy 
and soy products. However, the genistein glucoside can be hydrolyzed by gut bacterial 
community prior to absorption. Some fraction of GEN will be modified by intestinal 
microflora or liver to other form of isoflavones. Similarly, other isoflavones like 
biochanin A can also be metabolized to generate GEN. Aglucone form of GEN enters 
blood stream and later either excreted in urine or bile. Consider the complexity of the 
adsorption and metabolism of isoflavones, blood stream concentration of isoflavones 
after the consumption of soy meal may vary from case to case. One report suggest that 
the intake of modest portion of soy food with 45 g soy protein containing 80 mg of 
isoflavones, results in a 20- to 40-fold increase in blood isoflavone concentrations up to 
0.5 µM [79]. In other study, dietary intake of soy foods containing 60 mg/d of isoflavones 
for 12 weeks can increase the serum isoflavones to 141.6 ng/mL or approximately 0.5 µM 
in postmenopausal women [80].  
 
Isoflavones all have similar molecular weight to that of estradiol and contain a phenolic 
ring indispensable for binding to estrogen receptors. Genistein in particular present the 
optimal pattern of hydroxylation that the distance between aromatic hydroxyl groups is 
almost identical to that on the estradiol. Therefor, genistein was documented as the most 
estrogenic component compare to other isoflavones such as daidzein, biochanin A, 
glycitein, etc. [76]. Additionally, genistein differ from other isoflavones as it also affords 




1.3.2. Concentration-dependent effects 
Genistein has been report to exert cellular impact on numerous tissue and cell types in a 
dose-dependent fashion. Interestingly, cellular respon es to GEN are not linearly 
proportional to the concentration of treatment. In most cases, distinctive arrays of 
molecular effectors were found response to GEN treatm nt at different concentrations. 
Such biphasic phenomenon was largely attributable to the estrogenic effects of GEN at 
low concentration and tyrosine kinase inhibitory effects at high concentration. In 
adipocytes, GEN was found to inhibit adipogenesis at low concentration but stimulate 
adipogenesis at high concentration [81, 82]. The same group found that in osteoblasts 
cells, GEN stimulates osteogenesis at low concentration nd inhibit osteogenesis at high 
concentration [82, 83]. Similar biphasic phenomenon was also found in prostate cancer 
model, in which low-dose GEN (0.5 µM) decreased cell proliferation, invasion which 
were inversely promoted by 50 µM of GEN [84]. In myocardium, low dose GEN 
treatment tends to protect the CM but high dose treatm nt induces more myocyte death 
during ischemic infarction [85] as being discussed later in this chapter.  
 
1.3.3. Estrogenic effects 
The biological effects of estrogens and other estrogenic agents are mostly mediated by 
two estrogen receptor (ER) isoforms, ERα and ERβ. Both isoforms are expressed in 
neonatal [86] and adult [87] mouse CM. Interestingly, there is no significant difference in 
the ER abundance and localization between male and female [87, 88]. It was also shown 
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that ERα isoform located more on caveolae [89] and T-tubular membrane [90], suggest 
that ERα mediates most non-genomic estrogenic signaling, while t e ERβ is heavily 
localized in nucleus and cytosol mediating most gene transcriptional regulation [87].  
 
The acute estrogenic effects are typically mediated via a non-genomic mechanism in 
which the membrane-bound ERs upon activation and G-protein signaling which can 
further activate the phosphatidylinositol 3-kinase (PI3K) pathway [28, 91, 92]. The ERα 
based acute activation of estrogenic signaling was reported to provide cardioprotection 
against I/R injuries [69, 93]. Similar to estrogen, GEN was also reported to modulate 
cAMP-PKA signaling in a non-genomic fashion [94, 95]. On the other hand, the 
estrogenic genomic-wide changes are triggered by the recruitment of ERs in particular 
the ERβ isoforms located in nuclear membrane. Upon the binding of estrogenic 
compounds, ERs dimerize and translocate to the nucleus where they bind to estrogen 
response elements (ERE) on DNA and work as transcription factors. As the result, 
multiple estrogenic responsive genes including some cardioprotective genes such as nitric 
oxide synthase, heat shock proteins, and antioxidant enzymes (AOEs) are up-regulated 
[96, 97]. 
 
Although the binding affinity of GEN to both 1, 2 are 10-100 lower than endogenous 
hormone counterpart 17β-estradiol (E2) [76], the physiological concentration of GEN in 
the circulation after a typical soy-based meal can reach up to the range around 
micromolar, approximately 1000 times higher than that of endogenous estrogen. 
Genistein at such concentration (1-10 µM) has been shown to be effective for binding to 
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both ER subtypes [98-100]. However, there have verylimited knowledge on whether the 
GEN at a physiological relevant concentration can cuse similar signaling pathway or up-
regulate cardioprotective genes in CM.  
 
1.3.4. Tyrosine kinase inhibitory effects 
Despite the fact that tyrosine phosphorylation is less widespread compared to serine and 
threonine phosphorylation, tyrosine kinase signaling nevertheless regulates many key 
cellular functions. There are two major groups of tyrosine kinases: receptor tyrosine 
kinases, such as EGFR, insulin receptor, and cytosolic tyrosine kinases, such as Src, Erk, 
Jak. The former group plays a major role on external signaling transmitting across the cell 
membrane, while the later group controls a wide array of signal transduction cascades 
and transcriptional regulations. Genistein have shown the capability to compete for the 
ATP-binding site of tyrsosine kinases [101]. Methodol gically, GEN is being used as a 
non-specific protein tyrosine kinase (TK) inhibitor in many molecular biology 
experiments, typically at concentrations >10 µM. This concentration can be reached in 
the circulation if GEN is administrated as a form of pharmacological intervention. This 
property is unique to GEN, as compared to estrogen or other form of plant isoflavones. 
The TK inhibitory effects were also used to explain the anti-estrogenic or ER-
independent effects of GEN in other cell types such as endothelium cells [102, 103], 
adipocytes [81, 104], breast cancer [105], and prostate cancer cell lines [84].  
 
In cardiomyocytes, GEN was also widely used as a signaling diagnostic tool to 
understand the involvement of tyrosine kinase signaling in cardioprotection [106-109]. 
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Baines et al [49] and Fryer et al [52] have shown that inhibition of tyrosine kinase by 
GEN can effectively block the downstream signaling of PKC pathway triggered by IPC. 
Similarly, genistein were also used to block cardioprotective PKC pathway stimulated by 
brief alcohol exposure [110], St Thomas’ solution [111] and octreotide treatment [112]. 
Additionally, tyrosine kinase signaling was also shwn as the downstream cascade step of 
cardioprotective PI3K/Akt pathway, thus can be blocked by GEN incubation [113, 114]. 
Shikrut et al found 50 µM of GEN used as tyrosine kinase inhibitor can effectiv  block 
pro-apoptosis Fas-signaling triggered by hypoxia in murine ventricular myocytes [115]. 
Other signaling pathways involved with tyrosine phosphorylation, including the 
JAK/STAT pathway [116-118], were also shown to play a critical role in cardioprotection 
during ischemic pre- and/or post-conditioning. But no study has shown how GEN affects 
those complex pathway networks in a systematic approach.  
 
On the other hand, tyrosine kinase was also a key regulator of multiple ion channels 
essential for myocyte contractile function. Genistein as a PTK inhibitor attenuates the L-
type Ca2+ current in rat [119] and guinea pig [120-122] ventricular myocytes. Genistein at 
50-80 µM also prevents activation of the swelling-activated Cl- current in canine 
myocytes in a PTK dependent mechanism [123]. However, other studies have 
documented the activation the cardiac cAMP-dependent Cl channel by GEN in guinea 
pig CM [120, 124, 125].  The opening of triphosphate-sensitive potassium (K(ATP)) 
channels are key contributor of ischemic or pharmacological preconditioning. There were 
also few studies investigating PTKs inhibition of K(ATP) channels using GEN. GEN can 
elicit K(ATP) current by inhibit the PTKs [126] while its inactive analog daidzein   did 
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not have the same effect [127]. Gao et al also found that the voltage-dependent potassium 
channels in rat CM was regulated PTK-dependent fashion and can be inhibited by GEN 
[128].  
 
1.3.5. Antioxidant property 
Genistein, like many other plant-derived isoflavones, is considered as an antioxidant [129, 
130]. Early researches have been concentrated on the direct antioxidative effects of 
isoflavones in particular to reduce the susceptibility of low-density lipoprotein to 
oxidation [131, 132]. However, such mechanism was later determined as ineffective in 
vivo possibly due to the fact that physiological concentration of isoflavones in circulation 
is too low to afford any significant antioxidative benefits. Recently, attention has been 
drawn to the ability of isoflavones to stimulate antioxidant enzymes (AOEs) in 
cardiovascular system [133-136]. Genistein in particular has been shown to up-regulate 
endothelial NO synthase (eNOS) in rat vascular endothelial cells[137], glutathione 
peroxidase in human prostate cancer cells [138], MnSOD in human mammary gland 
tumor cell [139].  
 
The impacts of isoflavones on AOE system are mostly considered as a part of their 
estrogenic effects. Studies have shown ERs upon binding of endogenous estrogen induces 
numerous antioxidant genes with antioxidant response element including MnSOD, HO-2, 
thioredoxins, and phase II detoxification enzymes like  GST and NQO1 as summarized 
by Siow et al [133]. Such activation of antioxidative genes is likely through the activation 
of PI3K-Nrf2 pathway [133, 140] and ERK1/2-NFκB pathway [139]. In another study, 
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E2 and phytoestrogens including equol, GEN and daidzein was found to acutely up-
regulate eNOS phosphorylation via ERK1/2-PI3K pathway probably independent of ER 
binding [141]. However, genistein triggered phosphorylation of eNOS possibly via PKA 
signaling independent of ERK and PI3K activation was also observed [142]. Recently, 
direct binding of ER dimmers to the ARE promoter region was discovered by Bianco et 
al suggesting the estrogenic agents can up-regulate antioxidant genes independent of Nrf2 
activation [143]. In summary, it is very likely that isoflavones can affect the cellular 
redox balance in multiple mechanisms working in convergence.  
 
It is notable that most of abovementioned investigations on the antioxidative action of 
isoflavones were mainly carried out in endothelial ce ls. Whether similar antioxidant 
benefits of GEN can apply to CMs are still in obscure.  
 
1.3.6. Is genistein cardioprotective?  
Numerous animal studies and epidemiological evidence advocate that soy phytoestrogens 
are beneficial for cardiovascular system. However, too much topics still left for debate on 
what mechanism is behind this cardioprotection effects in both physiology and molecular 
biology level. Genistein in particular have drawn attentions for its direct protection on 
CM against ischemic injuries [28, 29, 31, 33]. However, given the fact that most cellular 
effects of GEN is dose-dependent, it is logical to ask whether the cardioprotection of 
GEN was rendered only at physiological relevant concentration or can GEN at 
pharmacological concentration can be used in preconditi ing or postconditioning 
intervention procedures effectively and safely. It is especially important to point out that 
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GEN at higher concentration has been reported to induce more CM death and block the 
cardioprotective effects of ICP or other pharmacological preconditioning [49, 106, 108-
114, 144-147]. To date only few studies have systema ically document the dose-
dependent molecular targets of GEN in CM. Giving that a huge pool of molecules that 
can be affect by GEN have already been identified an  possibly with more still remain 
unknown, oversimplified explanation from one single angle may compromise our 
comprehensive appreciation on the whole picture of the molecular basis of GEN’s action 
in CM.  
 
1.4. Proteomics and phosphoproteomics 
Proteome was defined as the protein complement of an rganism’s genome in a particular 
physiological state. The assessment of whole proteome, i.e. the proteomics attempts to 
capture snapshots of a comprehensive protein profile  an ever-changing system, i.e., 
any organism, tissue or cell in response to either nt nal or external signals/perturbations. 
The idea of –omics type global analysis was first initiated by microarray based mRNA 
expression survey (transcriptomics). This popular technique has being used in biomedical 
researches, among many other fields, to study disease development and drug effects. 
However, evidence shown the mRNA level does not correlate with the actual protein 
level. There are significant differences in dynamic range and rates of production and 
degradation between proteins and mRNAs molecules. Rgulation on translation and post-
translational events such as alternative splicing ad protein modifications make the 
proteome more complex and dynamic than the transcriptome. Different from 
transcriptomics, the proteomics directly measure the presence and absence of proteins 
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that execute the actual molecular functions which ultimately determine the state of a 
biological system.  
 
With the completion of the genome of the target organism, identification of literally any 
protein in a mixture without the use of antibody can be achieved by interpreting the 
peptide fragmentation patterns in a highly accurate mass spectrometry. Large-scale 
separation techniques like two-dimensional electrophoresis (2DE) or multidimensional 
liquid chromatography (MDLC) allow us to fractionate the complex proteome into much 
simpler protein/peptide subsets that can be easily characterized by mass spectrometry, 
often quantitatively. Nowadays, a typical differential proteomics study can quantify the 
relative abundance of many hundreds or even thousands of proteins across multiple 
samples.  
 
In recent years, proteomic approaches are increasingly employed to unravel the 
complexity of isoflavones effects on numerous cell and tissue types. Fuch et al 
demonstrated the usefulness of proteomics to investigate the effect of GEN on the human 
endothelial cells stressed by pro-atherogenic stimuli such as oxidized LDL [148] and 
homocysteine [149, 150]. In another case, Zhang et al carried out a dose-dependent and 
time–dependent proteomics study to discover key tumorigenesis pathways modulated by 
of GEN on human leukemia cells [151]. Sotoca et al use both transcriptomic and 
proteomic approach to shown that GEN exerted similar estrogenic effects as estradiol on 
breast cancer cells [152]. Similarly, Wang et al [153] and Rowell et al [154] performed 
two 2DE based proteomics studies to identify key proteins involved in cell proliferation 
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related pathways to understand mechanisms of action in breast cancer chemoprevention 
afforded by GEN. In all these studies, proteomics not only allow researchers to observe 
multiple up- or down-stream gene products regulating or being regulated by the treatment 
that are known, it also unveils the molecular events that were not expected with and that 
would otherwise not be discovered via conventional methods.  
 
In recent years, efforts have been made to use new mass spectrometry techniques to 
characterize the post-translational modifications (PTMs) of proteins, which can never be 
assessed by transcriptomics. PTMs are vital for the proteins to function correctly and are 
related to regulations in many cellular processes. Among 200 different forms of PTMs, 
protein phosphorylation at serine, threonine and tyrosine residues, are the most widely 
studied. GEN can trigger non-genomic signaling cascade via the binding of membrane 
ERs and also serves as a non-specific tyrosine kinase modulator in particular at high 
concentration. Both scenarios involve changes in phos orylation status of multiple 
proteins that can be surveyed by proteomics techniques specialized to characterize 
protein phosphorylation: the phosphoproteomics. Like other branches of proteomics, 
phosphoproteomics employ high throughput separation techniques and mass 
spectrometry to provide protein phosphorylation profile in a global scale. For detailed 
review of phosphoproteomics techniques and applications on cardiovascular research, 
please refer to chapter 2.  
 
1.5. Models  
Both HL-1 cultured CM and primary CM isolated from ale Sprague Dawley (SD) rat 
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will be used as in vitro models in the studies. Compare to in vivo animal model, the use 
of HL-1 cells or primary cells enable us to focus on the molecular effects of GEN only on 
CM in a relatively clear-cut experimental setting where the concentration of the treatment 
can be easily controlled and maintained during the whole experiment. Such in vitro 
model also avoids the protein contamination from other cell type and abundant proteins 
from muscle connective tissue which tend to dominate over low abundant but important 
proteins such as transcription factors during proteomics analysis. Moreover, as the 
proteomics is inherently sensitive to biological background noise, the low sample 
variability provide by homogenous cell population ehances the proteomic discovery 
power by avoiding identifying false positive expression level changes.  
 
HL-1 cell line represents a well-characterized contractile CM culture that can divide 
continuously as well as maintain a differentiated cardiac phenotype. These cells are 
derived from mouse atrial CM and have highly organized sarcomere structures and 
intracellular ANF granules similar to adult mouse atrial CM [155]. Moreover, HL-1 cells 
maintain the gene expression profile similar to that of adult mouse CM and, thus, they 
represent a reliable in vitro model to study the cellular metabolism of CM [156]. However, 
inexplicable results on HL-1 cells may expected due to the cellular resources shift 
towards other functions such as proliferation which may interfere with the interpretation 
of GEN’s effects on CM. Such drawback can be compensated by employing the 
unproliferable primary cell which is considered to be more biological relevant to in vivo 
model. Nonetheless, due to the lack of tissue archite ture and cell-cell interaction with 
other cell types, it is inevitable that both primary and HL-1 cell models abolish some 
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cellular functions based on tissue context. 
 
In this dissertation, I will use HL-1 cells as preliminary model to test if the GEN have 
different impact on cardiac proteome at different concentrations, as HL-1 are generally 
less sensitive to external stimulus and can withstand GEN treatment with large 
concentration span, so we can isolate differential expressed gene products at two 
concentrations with distinctive effects. I will further use primary CM isolated from adult 
female SD rats as the main model to study GEN’s effects on cardiac proteome and 
phosphoproteome via ER-dependent and ER-independent m chanism. Moreover, one 
shall keep in mind that simplified cell culture or primary cell milieu cannot reflect the 
complexity and dynamics of physiological environment of CM, in particular it cannot be 
used to assess the bioavailability and dynamics of the presence of GEN, nor it can assess 
hundreds of other possible synergistic/antagonistic effects provided by other in vivo 
stimulus sources such as endogenous hormones. Those discoveries of molecular targets 
altered by GEN treatment from this cell-based proteomics study certainly need to be 
further validated by in vivo experiments.  
 
2. Objectives and Contributions of This Dissertation 
The overall goal of this dissertation is to use high throughput proteomics and 
phosphoproteomics approaches to investigate the global effects of GEN treatments on 
CM that are mainly due to estrogenic and non-estrogenic effects. Based on previous 
knowledge that it is mainly the concentration that de ermines whether GEN works as an 
estrogenic or PTK inhibitory agent, we first hypothesize that GEN may cause CM 
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proteome alteration in a concentration-dependent fashion. Through the analysis of 
proteins activation or inhibition, key pathways and cellular functions related to 
concentration-dependent cardioprotection of GEN can be identified.  
 
Further, we hypothesize that the under the pharmacologi al relevant concentration, the 
GEN influence CM most likely by both estrogenic and on-estrogenic effects 
concurrently. In order to measure proteome changes by GEN’s via each mechanism 
separately, estrogen receptor antagonist can be used to block proteome changes due to 
estrogenic effects of GEN. Further, I hypothesize that non-estrogenic effect mainly due to 
the PTK inhibitory property of GEN can be reflected by the alteration in CM singling 
pathways especially in the form of widespread changes in the pattern of protein 
phosphorylation. The use of phosphoproteomics methodology can enable me to identify 
key signaling pathway changes that undergirding the molecular action of GEN on CM.  
 
Overall, with both high throughput proteomics and phosphoproteomics data, we can 
better assess the extent of molecular targets altered by GEN treatments and by which 
pathway they were targeted. By setting reductionist-style thinking aside and to look at the 
system as an integration of many complex compartments interacting with each other, we 
gain a much-expanded view of GEN’s effects on CM, which is required for the rationale 
of new hypotheses in next steps. However, one should always bear in mind that at least 
by itself, proteomics or any type of -omics study was not meant to be a tool to prove any 
detailed hypothesis in mechanistic fashion, rather, it provide us a comprehensive way to 
observe the global changes in a biological system so we can better rationale our tentative 
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hypothesis about the mechanism, which indeed still need to be addressed by a 
reductionist approach. Hence, all the proteomics discoveries included in this dissertation 
need to be viewed as no more than faithful observations. Further, all biological 
interpretations discreetly drawn from our proteomics and phosphoproteomics data will 
only be considered as cornerstone to establish future hypotheses which still need to be 
validated by other methods. 
 
To our knowledge, no published research exists investigating the influences of soy-
derived phytoestrogens on the proteome or phosphoproteome of CM. We expect that 
these data-driven proteomics studies will provide vital clues and a rational foundation for 
future hypothesis-driven mechanistic studies of cardiac protection afford by GEN and 
other isoflavones in general. Eventually we hope the molecular detail discovered in those 
proteomic studies can further help physiologists to pr vide recommendations if soy or a 
soy-based diet can be considered as beneficial for cardiovascular system and whether 
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 CHAPTER 2 
PHOSPHOPROTEOMICS AND MOLECULAR CARDIOLOGY: TECHNIQUES, 
APPLICATIONS AND CHALLENGES 
 
1. Introduction 
The reversible, covalent binding of phosphate groups to proteins is the most common 
post-translational modification involved in many cellular processes. It has been estimated 
that close to 50% of the proteins in the mammalian proteome can potentially be 
phosphorylated. There are more than 100,000 predicted phosphorylation sites in the 
human proteome of which fewer than 2000 are documented [1, 2]. O-phosphorylation on 
serine (~90%), threonine (~10%) and tyrosine (~<1%) [3] are the most frequent form of 
protein phosphorylation, whereas N/S- phosphorylations on histidine and cysteine [4-6] 
exist in much lower quantities. 
 
Phosphorylation usually causes a protein conformation l change for specific functions, or 
forms motifs recognized by other molecules for interactions including the assembly and 
dissociation of protein complexes [7-9]. Protein phosphorylation is regulated by kinases 
and phosphatases, which work in an opposing manner to maintain a particular 
phosphorylation state. When an internal or external stimulus occurs, many 
kinases/phosphatases themselves are activated via phosphorylation and cause the 
phosphorylation of other proteins on a timescale of seconds to minutes. Such signaling 
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can further be amplified, followed by propagation t downstream kinases, or by cross-
talking to many other pathways, which eventually leads to changes in cellular functions 
such as enzyme activity modulation, cytoskeleton remodeling, and gene expression 
regulation. Disruptions of these signaling cascades have been linked to several 
cardiovascular diseases such as ischemia/reperfusion injury and cardiac hypertrophy [10, 
11].  
 
Phosphoproteomics, characterizing protein phosphorylation in large-scale with modern 
high-throughput protein separation and mass spectrometry technologies, has played a 
significant role in our attempt to unveil the complexity of protein phosphorylation 
networks and how they link to cardiac pathological processes. Compared to standard 
proteomics approaches, phosphoproteomics poses some additional challenges as it tries to 
identify, and in some cases to quantify, the dynamic and reversible phosphorylation 
process with low in vivo occurrence. Phosphoproteomics is a multifaceted and open-
ended field where a tremendous amount of new technologies and applications have been 
introduced every year to broaden the coverage of the phosphoproteome, to measure or 
quantify phosphorylation stoichiometry and dynamics more accurately, and to extract 
biological relevance and significance from large-scale phosphoproteomics data. Fig 2.1 
summarizes some of the most important technical breakthroughs in the field of MS-based 
phosphoproteomics. Fig 2.2 summarizes a sequential scheme of typical 
phosphoproteomic workflows from sample preparation t  data analysis. Given the 
sizeable variety of phosphoproteomic techniques and applications, here we focus on the 
most mainstream techniques and strategies in this rapidly evolving endeavor with 
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illustrative phosphoproteomic applications in the field of molecular cardiology.  
 
2. General Sample Preparation Strategies 
As is the case in a standard proteomics workflow, a phosphoproteomics workflow usually 
starts with protein extraction from tissue samples, cell cultures, or subcellular 
components by sonication, liquid nitrogen grinding, or homogenization with a lysis 
buffer that can dissolve and often denature proteins. However, there are two critical 
aspects that need to be considered during the initial sample preparation in order to detect 
protein phosphorylation using MS. First, as phosphoproteins only represent a very tiny 
portion of the total proteome, phosphoproteomic analysis usually requires a large amount 
of starting material, typically in the range of 1-10 mg of protein. However, successful 
detection of protein phosphorylation is still possible using a few hundred micrograms of 
protein if an appropriate enrichment strategy is used and the mass spectrometer has 
superior sensitivity [12]. Another key aspect of sample preparation is the choice of lysis 
buffer. Protein extraction should be accomplished at low temperatures in the presence of 
both protease and phosphatase inhibitor cocktails to prevent proteolysis and 
dephosphorylation during protein extraction. Typical protease inhibitors are 
phenylmethylsulfonyl fluoride (PMSF), aminoethyl benzylsulfonyl fluoride (AEBSF), 
ethylene diamine tetraacetic acid (EDTA), pepstatin, benzamidine, leupeptin, and 
aprotinin [13, 14]. Phosphatase inhibitor cocktails contain components such as sodium 
ortho-vanadate, imidazole, sodium tartrate, EDTA, okadaic acid, β-glycerophosphoric 
acid, and sodium pyrophosphate [14, 15]. Chaotropic agents such as HCl-guanidine or 
urea, and detergents such as SDS are included in lysis buffers to dissolve hydrophobic 
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proteins and to denature proteases and phosphatases relea ed during the lysis procedure. 
It is also suggested that metal parts should be avoided during sample preparation 
chromatographic workflow to minimize unwanted sample loss due to affinity adsorption 
of phosphoproteins to metals [14].  
 
3. Subcellular Fractionation 
Over the last few years, most phosphoproteomic studies have been carried out to 
document the extent and dynamics of protein phosphorylation in subproteomes of 
cardiomyocytes. As in eukaryotes, the proteome are very complex with over 10,000 
proteins - a number that is beyond the resolving power of most proteomic techniques. 
Additionally, many regulatory kinases and phosphatases have an uneven spatial 
distribution, and many signaling pathways are regulated in a spatial manner. Many 
proteins that are phosphorylated or dephosphorylated in different cell compartments carry 
out vital molecular functions such as protein translocation and protein complex 
scaffolding. Thus, to portray the spatial occurrence of protein phosphorylation and its 
corresponding biological significance, it is essential to study the phosphoproteome with 
spatial-temporal resolution by incorporating subcellular fractionation procedures into the 
workflow. Trost and coworkers have provided a thorough review on the applications of 
subcellular phosphoproteomics [15].  
 
Differential density centrifugation is currently the most popular method for organelle 
enrichment. The easy setup of centrifugation makes it an ideal fit into a proteomics 
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workflow. Briefly, after homogenization, nuclei, other organelles, and cytosol are 
fractionated by gradient centrifugation in a solution such as sucrose. Proteins that are 
extracted from each fraction are representative of the different cellular compartments [16]. 
Other techniques such as electromigration, free-flow electrophoresis, recombinant-
protein pull down, coimmunoprecipitation, epitope-tagged proteins and tandem affinity 
tags have also been successfully applied for organelle isolation. A comprehensive 
overview of the application of these different subcellular fractionation methods has been 
reviewed previously [16-21].  
 
The major challenge in subcellular phosphoproteomics is sample availability for 
successful phosphopeptide enrichment. The total amount of protein from each subcellular 
fraction is far less than that in the total lysate, and this is further complicated by the fact 
that some phosphoproteins are usually present in very low amounts in individual 
subcellular fractions. The enrichment of phosphopeptid s for a typical multidimensional 
LC-MS analysis often requires at least 1-30 mg of total lysate, a quantity that is difficult 
to obtain for many subcellular structures. Thus, sample scale-up must consider the 
relative proportion of target organelle to cell mass, which can range from less than 1% 
(peroxisome) to 10% (the nucleus) [16]. 
 
Compared to other cellular organelles, the phosphoproteome of mitochondria has been 
studied the most [22-29], as the mitochondria play vital roles in energy metabolism, 
oxidative radical species production, apoptosis, ion balance, calcium signaling, and 
myofibril organization, as well as metabolism of amino acids, lipids, and iron [30-32]. 
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Links between mitochondria physiology and cardiac diseases such as 
ischemia/reperfusion injury and cardiomyopathy have be n well documented [31]. The 
proteasome is also of interest. Several studies of the cardiac proteasome 
phosphoproteome have shown the importance of phosphorylation of certain components 
in the dysregulation of protein degradation and accumulation of toxic aggregates 
associated with many cardiac diseases [33-35]. Althoug  most subcellular proteomics and 
phosphoproteomics studies focus mainly on cardiac mitochondria and proteasome, it is 
also worthwhile to investigate other cardiac cellular components such as the plasma 
membrane, lipid rafts, golgi apparatus, and endoplasmic reticulum that have significant 
impact on cardiac functions. 
 
4. 2DE Workflow 
Complex protein mixtures can be mapped and characterized by high-resolution two-
dimensional electrophoresis (2DE) gel analysis. In a 2DE workflow, the proteins are first 
separated according to isoelectric point by immobilized pH gradient (IPG)-gel based 
isoelectric focusing (IEF) and then separated by molecular weight via regular SDS-PAGE 
gel [36]. Proteins separated by 2DE can be visualized by a variety of staining protocols 
that have been summarized by Steinberg [37]. Phosphoproteins can be visualized by 32P / 
33P autoradiography, phosphospecific stains or by western blotting techniques. Protein 
phosphorylation/dephosphorylation usually lead to changes in pI, thus cause horizontal 
shift in spot position. After gel image analysis, spots of interest can be excised from the 
polyacrylamide gel, and digested by proteases such as trypsin. The proteolytic peptides 
extracted from gel plugs are then identified by MALDI-MS/MS or LC-ESI-/MS/MS. An 
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optional enrichment procedure can be used prior to MS/MS analysis to increases chances 
for the detection of phosphopeptides and determinatio  of phosphosites.  
 
Although 2DE remains a most popular tool in the field of proteomics and 
phosphoproteomics, there are multiple limitations as ociated with this method. First, the 
inherently limited resolving power of 2DE only allows separation of proteins within 
certain isoelectric point and molecular weight boundaries. Second, 2DE is generally 
biased against hydrophobic proteins, e.g. membrane proteins and nuclear proteins [38]. 
Third, none of the gel-based methods can be multiplexed to quantify protein 
phosphorylation from more than two samples. Finally, 2DE is labor intensive and hence 
difficult to automate, such that significant variance and artifacts are generated during the 
procedure. Gel-free LC-based techniques coupled to MS overcome some of these 
problems as discussed later in this review.  
 
4.1. Autoradiography  
Despite the tediousness of the procedure, in vivo or in vitro autoradioactive 32P/33P 
labeling of phosphate groups is the most sensitive method for detecting phosphoprotein 
on gels [39-41]. Moreover, this unbiased labeling technique gives the direct evidence of 
the presence of phosphor group in all kinds of amino acid residues and sequence motifs 
[40, 42]. Employing autoradiography, Chu et al. [43] resolved 120 phosphoproteins from 
300 µg of protein extracted from 32P-labeled mouse cardiomyocytes. The authors also 
suggest the 32P- autoradiography demonstrates sensitivity superior to silver staining for 




4.2. Phosphoprotein stains 
Compared to autoradiography, phosphor-specific fluorescent stains are easy to use and 
can detect phosphoproteins in any cellular state as hey do not require protein turnover for 
the incorporation of the radioactive phosphate. TheMS-compatible fluorescent dye, Pro-
Q Diamond (Molecular Probes) [44, 45], binds specifically to phosphoproteins with 
sensitivity at the nanogram level. Hopper et al. [26] applied both Pro-Q Diamond stain 
and 32P-labeling to detect phosphoproteins from 500 µg of porcine cardiac mitochondria 
extract. Over 200 phosphoproteins were resolved via fluorescent staining, demonstrating 
comparable sensitivity to that of radioactive labeling. However, the author also reported 
notable differences in the stain patterns between two methods. A similar conclusion was 
drawn in another cardiac mitochondria phosphoproteomics study from the same research 
group [22] comparing the commercial fluorescent stain Phos-Tag 540 (Perkin-Elmer) [46] 
with 32P-labeling.  
 
4.3. Immunoblotting 
Immunoblotting can also be used for detection of phos oproteins in a 2D gel. General 
procedures and antibody choices has been reviewed in detail [47, 48]. Most western-
blotting based phosphoproteomic studies use only anti-p-Tyr antibodies, which are more 
specific than anti-p-Ser/Thr antibodies. However, global analysis of all Ser/Thr/Tyr 
phosphosites by western blotting is achievable. Feng et al. [25] successfully detected and 
quantified 61 rat cardiac mitochondrial phosphoproteins using monoclonal anti-p-
Ser/Thr/Tyr antibodies (LuBioScience) on native BN-PAGE gel. In another study by 
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Zong et al. [34], three different anti-p-Ser, anti-p-Thr and anti-p-Tyr antibodies were used 
to survey the phosphorylation pattern of the cardiac 20S proteasome complex. Of 14 
subunits, two were detected by all three antibodies, three were only detected by anti-p-
Ser antibodies and one only by Pro-Q phosphostain. Despite successes in small-scale 
organelle phosphoproteomics studies, it is apparent that the major drawback of antibody-
based approaches is the variation in sensitivities and specificities of antibodies, which 
limits the use of western blotting as a high-throughput quantitative approach [41]. 
Perhaps the true merit of western blotting-based visual zation comes when one desires to 
study the phosphorylation targets of a known kinase or kinase group. Antibodies against 
specific phosphorylation sites or motifs within the substrate sequence of a certain kinase 
can unveil highly specific targeted information relevant to the architecture of the 
signaling network. Using anti-p-Tyr antibody blotting, Schwertz et al. [29] demonstrated 
the link between p38 MAP kinase inhibition and tyrosine phosphorylation reduction of 
troponin T, VDAC-1 and HSP73 which contribute to the cardioprotection of rabbit 
cardiomyocytes from I/R injury.  
 
5. Liquid Chromatographic Methods 
The multidimensional liquid chromatography (MDLC) method was first introduced as a 
separation method alternative to 2DE [49], and has now been widely utilized in almost 
every branch of proteomics including phosphoproteomics. Compared to a 2DE workflow, 
LC-based methods have a greater ability to separate peptides with similar chemical 
properties compare to proteins, thus making them a ore high-throughput method 
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compared to gel-based approaches. Other advantages of MDLC workflows include easy 
automation, minimum sample loss, and high reproducibility [50-53]. Most MDLC-based 
proteomic workflows, or ‘shotgun’ workflows [50], consist of two dimensions of LC 
separations that ideally are orthogonal to one another to enhance the overall resolution 
and minimize MS instrumental undersampling. Briefly, a protein mixture is first digested 
by a protease or two, in some cases. The resulting peptide mixture is fractionated, 
typically by strong cation exchange (SCX) chromatography. Individual fractions of the 
peptide mixture can be collected off-line prior to a second LC separation coupled with 
ESI-MS/MS. Alternatively, peptides eluted from the first LC separation can be directly 
fed into a 2nd LC system in a MudPIT fashion [51]. As the last LCseparation is usually 
coupled with ESI-MS/MS using reverse phase (RP) HPLC and thus differentiates 
peptides on the basis of hydrophobicity, current MDLC protocols for fractionation of 
phosphopeptides use a first dimensional chromatography that capitalizes on the one of 
two distinctive properties of phosphopeptides: the additional negative charges and higher 
hydrophilicity of phosphopeptides due to the presence of the phosphate group. Strong 
cation exchange (SCX), strong anion exchange (SAX), hydrophilic interaction liquid 
chromatography (HILIC), and electrostatic repulsion hydrophilic interaction 
chromatography (ERLIC) have been selected for phospproteomics applications. The 
goal of developing a successful first dimension LC separation is two-fold: to concentrate 
peptides, including phosphopeptides, into less complex mixture fractions for downstream 
procedures like phosphopeptides enrichment [53, 54]; and to partially isolate 
phosphopeptides from non-phosphorylated peptides. The reader is referred to excellent, 




5.1. Strong cation exchange liquid chromatography 
Strong cation exchange (SCX) fractionation has been used extensively for the 
fractionation of phosphopeptides [15, 56-58]. A typical SCX procedure separates 
peptides according to their electrostatic properties by increasing ionic strength in the 
mobile phase. At low pH (<2.6), the majority of tryptic peptides have at least two 
positive charges because all amino groups from the N-t rminus and Arg/Lys side chains 
will be protonated, and all acidic carboxyl groups will also be protonated. Protonated 
peptides will be strongly retained by the SCX stationary phase surface, which displays 
negative charges. Phosphopeptides bearing negatively charged phosphate groups are 
either 1+, neutral, or negatively charged at pH 2.6, and therefore will elute out from SCX 
earlier than other species [57, 58]. Theoretically, b  carefully selecting the pH of the 
mobile phase, SCX can isolate phosphopeptides from the abundant acidic peptides that 
would otherwise compete with phosphopeptides in a metal-affinity enrichment step. 
However, since phosphopeptides have been identified n all SCX fractions in most 
phosphoproteomics studies, SCX fractionation is usually coupled with other enrichment 
methods, such as metal oxide affinity chromatography (MOAC) [59-63]. This is possibly 
due to the fact that tryptic phosphopeptides may have 2+ charges if they contain His or 
multiple Arg/Lys groups due to partial digestion, which is more common for 
phosphopeptides [58]. Despite the claims of success of using other chromatographic 
method for separating phosphopeptides such as HILIC or ERLIC, SCX still shown 
superior performance to cover large amount of phosppeptides in a recent comparison 
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study paralleling SCX-TiO2, HILIC-TiO2, ERLIC-TiO2 to enrich phosphopeptides from 4 
mg of HeLa protein [64]. 
 
5.2. Strong anion exchange liquid chromatography 
As phosphopeptides tend to be more negatively charged than other peptides, strong anion 
exchange (SAX) chromatography is a natural choice for their fractionation. Theoretically, 
phosphopeptides have stronger retention in an SAX column than other unmodified 
peptides which interact weakly with SAX materials. This means that SAX alone can 
isolate phosphopeptides from a mixture, and fractionate these compounds under gradient 
elution [65]. Dai, et al. developed a fully automatic SAX/RP-LC-MS/MS MudPIT 
procedure using an MS-compatible mobile phase utilizing a pH gradient to enrich and 
separate phosphopeptides from 0.5 mg HeLa cell total lys te, from which 1561 phos-
phopeptides were identified [66]. In another automatic SAX/RP-LC-MS/MS MudPIT 
system, Wang, et al. identified 1554 unique phosphopeptides from 1.5 mg of human liver 
tissue extract. Recently, different groups have described protocols combining SAX 
separation combined with other enrichment methods such as MOAC or IMAC [67, 68]. 
Nie, et at., developed a strategy based on SAX fractionation followed by flow-through 
enrichment by TiO2 (AFET), by which 2466 unique phosphopeptides were identified 
from only 0.5 mg of protein digest from HeLa cell [68]. In another interesting case 
describing a ‘Yin-Yang MDLC’ procedure, Dai et al. combined the isolation effect of 
SCX and the separation power of SAX by loading a phos opeptide enriched flow-
through fraction from SCX into an SAX for separation. In this protocol, over 800 
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phosphopeptides were identified from one mg of mouse liver tryptic digest without any 
further IMAC/MOAC enrichment [69]. Similarly, Motoyama et al. described a 
SAX/SCX MudPIT method to enhance the phosphopeptide identification using a salt step 
elution [70]. 
 
5.3. Hydrophilic interaction liquid chromatography  
Previously used for the enrichment of glycoproteins and small polar metabolites, 
hydrophilic interaction liquid chromatography (HILIC) [71] is now drawing attention due 
to its applications in separating phosphopeptides. HILIC takes advantage of the greater 
hydrophilic nature if phosphopeptides compared to other peptides [23, 72-79]. In the 
HILIC procedure, as opposed to RPLC, peptides are int oduced in a mobile phase that is 
relatively high in organic content interacting with the neutral hydrophilic stationary phase 
via hydrogen bonding. By gradually decreasing the organic contents in the mobile phase, 
peptides elute in order of increasing hydrophilicity [71, 72]. HILIC is considered to be 
truly orthogonal to reverse-phase chromatography and to offer much higher separation 
resolution than ion-exchange based LC methods [80].Such resolution is critical in the 
HILIC application for separating multiphosphorylated peptide isomers as they are more 
likely to coelute in RPLC resulting in ambiguous MS/  identifications [76]. Therefore, 
a HILIC-RP system can potentially yield much higher overall peak capacity and 
resolution than other 2DLC procedures. Unlike ion exchange methods, HILIC uses a 
mobile phase system based on an organic solvent gradient, and thus it can minimize 
sample loss by avoiding a desalting step. In fact, HILIC is directly compatible with ESI- 
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MS/MS [76]. Although HILIC provides good separations for phosphopeptides, alone it 
cannot separate phosphopeptides from other species. HILIC requires a pre- or post-
enrichment step such as IMAC or MOAC in order to islate phosphopeptides from 
complex backgrounds [23, 72-75, 77]. Using HILIC prefractionation, McNulty, et al. 
achieved IMAC selectivity over 95% [75]. Also, when using an IMAC-HILIC protocol, 
Wu, et al. identified 2857 unique phosphorylation sites in 1338 phosphoproteins from one 
mg of cell lysate [73].  
 
5.4. Electrostatic repulsion hydrophilic interaction chromatography  
Electrostatic repulsion hydrophilic interaction chromatography (ERLIC) is a relatively 
new LC method showing good applications in phosphoproteomics [81-83]. ERLIC 
utilizes both hydrophilic interactions and electrosatic repulsion as the separation 
mechanisms, and thus can potentially enrich and fractionate the phosphopeptides in one 
step [83]. ERLIC is achieved by operates a weak anion exchange (WAX) column with a 
high organic content (70% ACN) mobile phase at a low pH. Under such conditions, the 
anionic phosphopeptides can be selectively retained  the WAX column, while non-
ionized peptides will be washed out by the organic solvent, and peptides with protonated 
carboxyl groups are electrostatically repulsed by the column [83]. Gan, et al., compared 
ERLIC to SCX-IMAC for the enrichment and fractionation of phosphopeptides [82]. In 
their study, ERLIC alone and SCX/IMAC coupled with the MS3 identification strategy 
detected 926 and 1,315 unique phosphopeptides, respectively, from a total of 10 mg of 
human epithelial carcinoma cell lysate. Interestingly, ERLIC identified a higher number 
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of multiple phosphorylated peptides when compared to the SCX/IMAC procedure. The 
results suggest that both methods are complementary to each other, as there was only 
12% overlap of unique phosphopeptides identified by both methods [82]. This 
phenomenon was reported in another paper suggesting a ERLIC-TiO2 procedure can be 
used to enrich the flow-through fraction from SCX to reach better coverage for 
multiphosphorylated peptides [64].    
 
6. Affinity Enrichment Strategies 
6.1. General considerations of using enrichment strategy  
As researchers have gained experience with strategies to identify protein 
phosphorylations from a complex protein mixture, such as mammalian cell or tissue total 
lysate, there has been a trend to implement some form of enrichment technique(s) in 
order to separate phosphopeptides or phosphoproteins from un-modified peptide species 
before MS analysis. This is mainly attributed to the following reasons:  
• Most key phosphoproteins to the biological process in question, such as signaling 
molecules and transcriptional factors, are predominantly in low levels;  
• Often with any given biological state, very few protein species containing potential 
phosphorylation sites are actually phosphorylated, or are phosphorylated in a low 
stoichiometry. Further, not all phosphosites are modified on proteins containing 
multiple phosphorylation sites. The technical difficulty resulting from low 
stoichiometry of phosphorylation is obvious: the proteolytic digest of phosphoprotein 
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generates more non-phosphorylated peptide species than phosphorylated species, and 
other peptides are generated from unphosphorylated proteins;  
• Phosphopeptides are generally difficult to ionize using mass spectrometry, as they can 
easily be ion-suppressed by non-phosphorylated counterparts under positive-mode 
ionization, thus resulting in low signal intensities in a complex mixture.  
 
The methods for phosphoprotein or phosphopeptide enrichment fall into three major 
categories, namely, antibody-based approaches, affinity-based approaches, and chemical 
derivatization approaches [84]. In general, the following suggestions have been given for 
development of a practical enrichment protocol for phosphoproteomics:  
• Since different methods tend to exhibit bias towards certain peptide populations, and 
each only reveals a portion of the whole phosphoproteome, a combination of different 
methods should be used in order to expand the coverage of phosphopeptide species;  
• For complex samples such as mammalian cells or tissue lysates, a pre-fractionation 
step such as 1D-SDS-PAGE, SCX or HILIC chromatography is recommended prior 
to any enrichment step, as samples with high complexity may introduce severe non-
specific binding or /reactions during enrichment step ;  
• Use large amounts of starting material to ensure sensitivity within sample and 
budgetary constraints;  
• Limit sample-handling steps to minimize sample loss. Compromise between these 
various tradeoffs must be made in order to balance the sensitivity, selectivity, 




6.2. Immunoaffinity method 
Antibody-based methods, e.g. immunoprecipitation and immunoaffinity chromatography, 
are targeted to certain types of phosphorylation events, such as the anti-P-Tyr antibody 
approach [85-88], or to known motifs such as the substrate sequences of a certain group 
of kinases. Generally phosphoproteins or phosphopeptides bind to antibodies by sequence 
specific interactions at normal physiological environment, and such interaction can be 
disrupted by high level of detergent with phosphor analog such as phenylphosphate or by 
heat for elution. It is noteworthy that anti-P-Tyr antibody provides very highly specific 
solution for targeting tyrosine kinase signaling over other nonspecific enrichment 
methods. This is because p-Tyr only occurs in extremely low frequency and is hard to 
detect if analyzed with large amount of p-Ser/Thr posphopeptides in a LC-MS/MS 
experiment. On the other hand, one should be cautious when using anti-p-Ser and anti-p-
Thr immunoaffinity chromatography due to their limited specificity [89].  
 
6.3. Immobilized metal affinity chromatography  
Immobilized metal affinity chromatography (IMAC) isa universal enrichment technique 
capable of non-specific capture of phosphopeptides, regardless of the phosphorylation 
type and the local sequence. Immobilized ferric ion(III) was first utilized to purify 
phosphoproteins and phosphopeptides [90, 91]. Other multivalent metal cations, such as 
gallium (III) [92], aluminum (III) [93], zirconium (II) [94], nickel (II), and titanium (IV) 
[95] were found to have similar binding affinities with protein-bound phosphates at low 
pH. Typically, metal cations are immobilized to a supporting matrix via chelation with 
either nitriloacetic acid (NTA) or iminodiacetic acid (IDA). Phosphopeptides generally 
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bind to immobilized metal cations through electrostatic interactions at low pH (<3), and 
dissociate at a higher pH (>7). Currently, a variety of different IMAC resins are 
commercially available in LC-column, SPE column, spin column, LC-tip and magnetic 
bead formats, comprising various types of immobilized metal ions, all of which 
demonstrate different enrichment efficiencies and specificities. However, a significant 
challenge associated with the IMAC method is non-specific binding of peptides rich in 
acidic amino acids to the IMAC. One way to alleviate this problem is O-methyl 
esterification of all carboxylate groups prior to IMAC enrichment [96]. This procedure 
has not been adopted by many researchers as the reaction conditions are difficult to 
control and incomplete esterification, unwanted byproducts and significant samples 
losses have been reported [97]. Another way to circumvent the non-specific binding of 
acidic peptides is to use endoproteinase glu-C rathe  than trypsin for protein digestion. As 
glu-C cleaves the protein at the C-terminus of Glu and Asp residues, the resulting 
proteolytic peptides only carry one acidic amino acid residue. Another challenge reported 
recently is that the IMAC is less efficient for enrichment of mono-phosphorylated 
peptides than for multiple phosphorylated species [98, 99]. In order to obtain the 
complete set of phosphopeptides from a complex sample, Ndassa et al. developed an 
improved IMAC protocol giving much higher recovery rates for peptides of single and 
multiple phosphorylations by modifying the binding and washing buffer conditions (0.1% 
acetic acid in 1:1:1 acetonitrile/methanol/water) [100]. In another case, Thinghole et al. 
reported a protocol using IMAC in conjunction with a TiO2-MOAC procedure, which is 
biased towards the mono-phosphorylated peptides [101]. Using this sequential IMAC 
(SIMAC) technique, they were able to enrich 186 multiple and 306 single phosphorylated 
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peptides from a human mesenchymal stem cell lysate digest.  
 
6.4. Metal oxide affinity chromatography  
Recently, much attention has been drawn to the use of metal oxide affinity 
chromatography (MOAC) for phosphopeptide enrichment from large complex samples 
due to its high recovery rate and selectivity [102-111]. A typical MOAC material 
includes a multivalent metal oxide such as titanium dioxide (TiO2) [112], zirconium 
dioxide (ZrO2) [113], aluminum oxide (Al2O3) [114], aluminum hydroxide (Al(OH)3  
[110] and niobium oxide (Nb2O5) [115]. Similar to the IMAC procedure, positively 
charged metal oxides can selectively capture phosphopeptides at low pH (<3) and release 
them at higher pH (>7). Like IMAC, MOAC also experiences non-specific binding of 
acidic peptides. However, because the phosphopeptides interact with metal oxides via a 
“bridging bidenatate” mechanism, a quenching agent like salicylic acid or 2,5-
dihydroxybenzoic acid (DHB) must be used to competitiv ly occupy binding sites on the 
MOAC resin to prevent adsorption of nonphosphorylated peptides [107, 109]. Using this 
quenching effect of DHB, Christensen, et al. successfully characterized over 10,000 
phosphopeptides from digested cell extracts pre-fractionated by SCX prior to TiO2-
MOAC enrichment [116]. However, it is noteworthy tha  in a LC-ESI-MS experiment, 
residual DHB or salicylic acid co-elutes with phospho eptides and may cause clogging in 
the RP column and may introduce ion suppression in the ESI source. Sugiyama et al. also 
reported that aliphatic hydroxy acids, such as lactic acid, β-hydroxypropanoic acid (HPA), 
phthalic acid, gallic acid, and glycolic acid also serve as “nonphosphopeptide excluders” 
by forming a cyclic chelate complex with the metal oxide [117, 118]. They suggest that 
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chelation between aliphatic hydroxy acids and metal oxides are weaker than that between 
phosphates and metal oxides but stronger than between the carboxylic group of amino 
acids and metal oxides. Because these acids are more hyd ophilic than DHB, they can be 
removed by a C18 desalting procedure. Using lactic ac d as an excluder in loading and 
washing steps, Sugiyama et al. identified over 1,100 phosphopeptides from less than one 
mg of HeLa cell cytoplasmic extracts with no additional LC pre-fractionation [117].  
 
6.5. Chemical derivatization methods 
Several chemical derivatization procedures have been introduced to assist in 
phosphopeptide enrichment [119], amongst which the three most widely used approaches 
are O-methyl-esterification of carboxylate groups, β-elimination of phosphorylated 
Ser/Thr, and phosphoramidate chemistry (PAC) [39, 40]. O-methyl esterification [96] was 
introduced as a method to alleviate non-specific binding of acidic peptides during 
IMAC/MOAC enrichment as discussed in section 6.3.  
 
Using β-elimination at high pH, labile phosphoester bonds of modified Ser/Thr residues 
can be cleaved to form dehydroalanine and β-methyldehydroalanine respectively. By 
nucleophilic addition of free sulfhydryl groups to the unsaturated bonds via Michael's 
addition, the side chain of Ser/Thr can form stable thiol-based derivatives that can further 
be cross-linked to a biotin tag [120]. Once the phosphate group has been replaced by 
biotinylated moieties, the formerly phosphorylated proteins or peptides can be enriched 
by immobilized avidin affinity chromatography [120]. However, sample losses have been 
reported as biotin−avidin interaction is very strong and modification of peptides may 
cause changes in fragmentation patterns in the tandem MS that are difficult to interpret 
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[121]. Alternatively, McLachlin et al. demonstrated that after β-elimination and Michael’s 
addition, the derivitized thiol group itself can becaptured by thiol–sepharose affinity 
resins [121]. In another interesting application of β-elimination using cysteamine for 
Michael’s addition, Knight et al. converted phosphorylated Ser/Thr residues into 
aminoethylcysteine and β-methylaminoethylcysteine, respectively. Both modifie  
residues are lysine analogs that can be cleaved by lysine-specific proteases, e.g. trypsin 
and Lys-C [122]. In this way, peptides cleaved at modified Ser/Thr sites can be used to 
map sites of phosphorylation. However, due to the formation of diastereomeric 
aminoethylcysteine, only 50% of modified sites will be cleaved as trypsin only cleaves 
the R stereo-isoform of aminoethylcysteine. Moreover, when developing β-elimination 
based protocols, caution should be paid to side reactions that occur on glycopeptides, 
sulfopeptides, alkylated cysteine residues and some unmodified serine residues under the 
same conditions [123-125]. It is also noteworthy that all β-elimination based methods 
only apply to peptides with p-Ser/The, but not to peptides with p-Tyr.  
 
In contrast, phosphoramidate chemistry (PAC) enables th  derivatization of all types of 
phosphorylated amino acids. Instead of transforming phosphate groups to thiol moieties, 
the PAC approach directly forms a reactive phosphoramidate that can be coupled to glass 
beads [126] or to a dendrimer [127]. Phosphate groups are eventually regenerated by 
hydrolysis with an acid such as TFA. Bodenmiller t al. suggested multiple 
phosphopeptide enrichment strategies including PAC, IMAC, and TiO2-MOAC 
approaches are complementary to each other as they all reproducibly enriched disparate 
and partially overlapping segments of phosphopeptid populations from a D. 
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melanogaster Kc167 cells lysate [128].  
 
7. Identification of Phosphopeptides by Tandem Mass Spectrometry 
7.1. General considerations 
Application of cutting-edge tandem MS technologies with high sampling speed and high 
sensitivity have enabled researchers to characterize thousands of peptides from a wide 
variety of biological contexts including enriched phosphopeptide mixtures that would be 
impractical using other sequencing techniques such as Edman degradation.  
 
In a common shotgun-based tandem MS phosphoproteomics experiment, a 
phosphopeptide-enriched mixture is first separated according to hydrophobicity in a 
nano-LC column filled with a reverse-phase (C18) materi l. In some cases, the LC 
separation is carried out in an automated LC-on-chip system which incorporates sample 
loading, peptide trapping, and LC separation in onemechanical unit [129-131]. The LC 
eluent is directly introduced into the mass spectrometer by electrospray ionization (ESI), 
which immediately disperses the sample, evaporates the olvent, and protonates peptides 
at multiple sites [132]. However, simple phosphopeptide mixtures from digests of single 
or small numbers of proteins can also be analyzed by matrix-assisted laser 
desorption/ionization (MALDI) [133] in which peptides are protonated via a matrix agent 
i.e. DHB, sinapic acid, excited by laser beams [134, 135]. The positively charged peptide 
ions then enter the mass analyzer where the mass-to-charge ratio (m/z) and intensity of 
the intact peptide precursor are first recorded by a full MS scan. Then, different 
precursors with specific m/z values are automatically selected for fragmentation by 
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MS/MS, usually in a data dependent acquisition (DDA) mode. However, some coeluting 
peptides might not be selected in the DDA mode as a result of undersampling. One study 
has demonstrated that multiple injections of the same enrichment fraction can 
significantly increase the number of unique phosphopeptide IDs [128, 136]. The resulting 
fragment spectrum can further be interpreted and matched to peptide sequences by a 
protein database search engine. However, loss of labile phosphate groups and poor 
backbone fragmentation has made the sequencing of phosphopeptides and the assignment 
of the phosphorylation sites very challenging. Among many MS/MS fragmentation 
strategies made to characterize phosphopetpides [119, 137-139], two major fragmentation 
methods have been used widely in the field of phospproteomics: neutral loss with 
collision-induced dissociation MS/MS/MS, and electron transfer dissociation. A more 
thorough discussion of MS aspects of phosphoproteomics can be found in reviews [119, 
136-140].  
 
7.2. Collision-induced dissociation with neutral loss scan  
Collision-induced dissociation (CID) is the most widely used collision mode in 
commercial mass spectrometers for peptide sequencing [141-143]. Peptide cations are 
accelerated and selected to be bombarded by neutral gas molecules such as helium or 
argon, which causes the cleavage on peptide bonds. Peptide ions then dissociate into a 
series of b- and y-type ion fragments, forming the MS/MS spectra that can be further 
interpreted to obtain the peptide sequence [142, 144 5]. An example of using CID 
MS/MS to characterize cardiac phosphopeptides was made by Ruse, et al [146]. However, 
the CID of phosphopeptides usually causes the loss of a phosphate group (H3PO4, −98 Da) 
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on Ser and Thr and has shown lower efficiency for breaking the peptide backbone [147, 
148]. The phosphate group on Tyr is more stable than ose on Ser and Thr, but partial 
neutral losses (HPO3, -80Da) have also been reported [135, 149, 150]. Thus, most 
MS/MS spectra of phosphopeptides contain dominant neu ral loss peaks and a relatively 
low abundance of y- and b- fragment peaks, which make the interpretation of backbone 
sequence and the phosphosite assignment difficult. Nonetheless, some strategies have 
been developed to take advantage of this distinctive fragmentation behavior of 
phosphopeptides, namely, by use of mass spectrometers capable of neutral loss scanning. 
In a quadrupole ion trap (IT) instrument, the neutral loss precursor ion originating from 
the loss of phosphate group during MS/MS can be selcted for further fragmentation by 
MS3 in order to provide additional sequence information [58]. Palmisano et al. identified 
six novel phosphorylation sites from bovine heart mitochondrial oxidative 
phosphorylation complex I using MS3 fragmentation with neutral loss scanning mode for 
98, 49 or 32.7 Da on a linear IT-Fourier transform (LIT-FT) mass spectrometer [27]. In 
another strategy implemented on quadrupole IT or linear IT-Orbitrap instruments, called 
multi-stage activation (MSA), a neutral loss ion ca be simultaneously activated and form 
a composite MS/MS spectrum with significantly enhanced intensity of backbone 
fragments peaks [151]. However, both MS3 and MSA strategies result in an increasing 
duty cycle and undersample more than the conventional MS/MS approach [136, 152, 
153]. Also, the newer generation of mass spectrometers such as hybrid LTQ-Orbitrap is 
capable of generating enough backbone structure information on MS/MS-only mode to 
make the MS3 a less attractive option for high-throughput phosphoproteomics 
experiments [153, 154].  
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7.3. Electron transfer dissociation 
Recently, electron capture dissociation (ECD) [155, 156] and electron transfer 
dissociation (ETD) [157, 158] have received increasing attention as promising alternative 
fragmentation modes to characterize phosphopeptides. ECD, which typically requires an 
FT-ICR instrument, directly adds a low-energy free l ctron to the multiprotonated 
precursor ions. In ETD, which is widely compatible with other IT instruments, a radical 
gaseous anion such as fluoranthene is used to transfe  an electron to the peptide cation. 
Unlike CID, ECD/ETD methods allow the preservation f labile phosphate groups 
because fragmentation occurs solely on the phosphopeptide backbone with more 
thorough and uniform fragmentation patterns in the form of c- and z- ion series [159, 
160]. Also, as ETD fragmentation tends to perform better with larger peptides that 
have >+3 charges, CID and ETD offer coverage over different peptide populations [161]. 
Interestingly, reports have shown that phosphopeptid s are more likely to have 
miscleavages during proteolytic digestion steps. Thus phosphopeptides tend to have 
longer sequences and carry more charges [162, 163], which gives ETD further 
advantages over CID fragmentation for phosphopeptid analysis [164]. Similarly, 
alternative proteases such as Lys-C [165, 166] or Lys-N [167] which generate longer 
peptide fragments, are a logical choice for phosphoprotein digestion when teamed with 
ETD type instruments. Nevertheless, the biased fragmentation preference against +2 
charged species also comprises the ability of ETD to unveil the diversity of proteolytic 
peptide populations [168]. Two strategies have been applied to specifically address the 
low rate of interpretation of +2 charged peptides in the ETD approach. One way is to pair 
ETD and CID fragmentation. This strategy can achieved ia analyzing the same sample 
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in separate instruments exemplified by Lu et al. [33], Deng et al. [24] and Zong et al. [35], 
or using an instrument capable of alternating betwen CID and ETD modes automatically 
[164, 169, 170] . It is also noteworthy that CID and ETD generate different series of 
fragment ions (y+b vs. z+c) which can later be combined to get improved coverage of 
backbone information. However, similar to the MS3 approach, ETD-CID modes also 
have longer duty cycles, leading to undersampling issues when handling complex 
mixtures. Reports also have shown the add-on modifications of the mass spectrometer to 
perform the CID-ETD mixed mode can increase the detctor noise level [171, 172]. The 
second approach to enhance ETD fragmentation efficiency of small doubly charged 
peptides was proposed by Swaney et al. [165] to use s pplemental low energy collisional 
activation of +2 charged species (ETcaD). In this method, after electron transfer, non-
dissociative ions can be further activated by collisional energy to form useful c- and z-
type fragments. However, this might actually additionally cause neutral loss of the labile 
phosphate group [165]. Wu et al. also introduced another variation to ETcaD, the charge-
reduced CID (CRCID), in which a charge-reduced electron transfer species is isolated 
and fragmented to generate cleaner and easier-to-interpret spectra [173].   
 
8. Bioinformatics for Phosphoproteomics 
8.1. General procedure 
In general, raw spectra files generated by tandem mass spectrometry are centroided and 
deisotoped to generate experimental peak lists withm/z and intensities of ions and ion 
fragments in open formats such as mgf, pkl, dta, mzXML or mzData. When using MS3 
methods, MS2 and MS3 spectra from the same phosphopeptide can either be analyzed 
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separately or merged together for a single search [154, 174]. For ETD raw data, studies 
have shown that the post-acquisition removal of over-abundant peaks of precursors, 
charge-reduced precursors, and neutral losses from charge-reduced precursors can make 
the ETD MS/MS spectra interpretable to a greater extent by common search engines 
[175].  
 
After peak list extraction, spectra files can be submitted to a search algorithm of choice to 
compare against amino acid sequences in protein databases for determination of the 
peptide sequence from observed mass spectra. Despite the fact that common search 
algorithms yield identifications of phosphopeptides, the localization of phosphosites from 
these algorithms generally have very low confidence level. Thus, the identification of 
phosphopeptides from mass spectra should be further augmented by additional scripts to 
locate phosphosites on the peptide sequences. Only unambiguous identification of 
phosphosites together with peptide sequences can be used for further motif analysis and 
kinase-substrate predication in order to generate biological meaningful data.  
 
8.2. Peptide identification  
Search algorithms using various scoring models have be n developed to assess the 
likelihood of a mass spectrum match with a particular peptide sequence. Popular search 
algorithms include Mascot [176], OMSSA [177], Sequest [178], Spectrum Mill (Agilent), 
Phenyx (GeneBio), ProteinLynx (Waters), InsPecT [179], ProteinProspector [180], and 
X!Tandem [181]. Reviews of search algorithms can be found elsewhere [182, 183]. As 
details of each algorithm differ greatly from one another, each search engine has its own 
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scoring system. Identification selectivity and sensitivity varies among the different search 
engines as well and are performed under different co ditions. As most search engines 
provides results that are complementary, consensus earching strategies using 
combinations of multiple search algorithms are used to improve the sensitivity and 
specificity of peptide identification from complex samples [184, 185]. A typical search 
process is carried out within constrains set by experimentally and instrumentally 
specified search parameters such as species, enzyme specificity, fixed and dynamic 
chemical modifications, fragmentation rules, and mass tolerance on both the MS and 
MS/MS level. For phosphoproteomics data, either dynamic modification of p-S/T/Y 
should be specified, or water loss on S/T/Y should be used in neutral loss CID data unless 
a specific chemical derivatization method was used for transformation phosphate groups 
into other forms. Since MSA- or ETD-based phosphoproteomic experiments are carried 
out in IT instruments, Sequest, OMSSA, X!Tandem or Protein Prospector should be used 
as search engine in order to better interpret low mass accuracy data [136, 186]. However, 
it is also reported that Mascot and Spectrum Mill perform better for ETD data [187]. One 
should keep in mind that the performance of search lgorithms differ from case to case, 
and the best choice of database search strategies only come by trial and error. It is not 
possible to compare search results from different sarch algorithms because they report 
the score in different scales and also because conventional score thresholds are generally 
too stringent for phosphopeptide identification. Instead, the use of the estimated false 
discovery rate (FDR) as a universal indicator of the specificity of the search strategy has 
gained popularity in recent years. In this strategy, the search, regardless of which 
algorithm is used, is repeated using an identical parameter against a random or reversed 
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database (the decoy) that has the same size and complexity of the forward database in 
order to predict the number of false positive identifications made during the target 
database search [188, 189]. The decoy search option is available in most popular database 
search algorithms including Mascot, X!Tandem, Sequest, and OMSSA [190] and 
automatically estimates the possible error associated with the target search. Alternatively, 
only one search will be carried out against a forward-reverse concatenated database to 
estimate the FDR. De novo interpretation of MS/MS spectra has also shown potential 
applications for phosphoproteomics and may be the best solution for identification of 
phosphopeptides in the absence of a complete genome/proteome database. Commercial 
de novo sequencing packages like PEAKS® (Bioinformatics Solution Inc.) are now 
capable of processing both CID and ETD data types from a wide selection of tandem 
mass spectrometers [191, 192]. However, real application of de novo sequencing in 
phosphoproteomics is still lacking a robust estimaton of the value of this approach.  
 
For large-scale shotgun based phosphoproteomics studie , additional scripts like public 
PhosphoPIC [193] and DTASelect [194] can be used to remove non-phosphorylated 
peptide IDs and compile them according to predetermined false discovery rates.  
 
8.3. Phosphosite determination 
Due to the fact that many phosphopeptides may contain multiple phosphosites, common 
search engines may generate ambiguous reports about the exact location of 
phosphorylation during a database search. A number of bioinformatic tools have been 
developed to re-interpret the tandem MS spectra and to compute confidence scores 
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associated with the localization of each phosphorylation site. Beausoleil et al. published 
the Ascore algorithm, in which a probability score is calculated to confirm the presence 
of each possible phosphosite on identified peptides via assessment of the likelihood of 
finding phosphosite-determining ions within the mass spectrum [195]. This algorithm is 
available as a stand-alone script (h tp://ascore.med.harvard.edu) and also is implemented 
within other search packages such as Sequest Sorcerer (Sage-N Research, CA), Scaffold 
PTM (Proteome Software, OR) and ArMone 
(http://bioanalysis.dicp.ac.cn/proteomics/software/AMone.html) [196]. Balley et al, 
developed the SloMo algorithm based on Ascore for localization of user specified protein 
modifications from on ETD/ECD data [197]. Ruttenberg t al. described another open 
source tool, PhosphoScore, using a scoring model that localizes phosphosites based on 
pdMSn data processed in Sequest environment [198]. A similar package, MSQuant, 
(http://msquant.sourceforge.net) was developed for confidence assignment of 
phosphosites from pdMSn spectra processed by Mascot [107, 199].  
 
8.4. Protein phosphorylation database 
Compared to conventional detection methods of protein phosphorylation, current studies 
using high-throughput shotgun MS-based surveying technologies can generate hundreds 
or even thousands of protein phosphorylation identifica ons. To make these data more 
accessible and easier for data mining and sharing, many web-based depositories now 
accept phosphoproteomics data directly from the public research community. Examples 
of such depositories includes Phosida (www.phosida.com) [200], Phospho.ELM 
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(http://phospho.elm.eu.org) [201], PhosphoSite (www.phosphosite.org) [202], and 
dbPTM (http://dbptm.mbc.nctu.edu.tw) [203]. These databases also incorporate the 
phosphorylation sites documented in universal protein databases such as UniProt 
(www.uniprot.org) as well as accepting other published phosphoproteomics data.  
 
However, concerns have been raised over the quality of publically submitted datasets to 
these databases since the confidence of phosphosite identification in each study varies 
depending on the choice of instrument, search engin, identification criteria, and, to a 
large extent, the judgment of each investigator in determining which criteria should be 
used.  
 
8.5. Phosphosites motif analysis and kinase prediction 
Although high-throughput phosphoproteomics provides a global view of the 
phosphorylation status of the proteome, such large-scale ‘dot’ surveys usually do not 
reflect the ‘dot-to-dot’ signaling context or functional significance of identified protein 
phosphorylations. It was estimated that in a eukaryote organism there are close to 500 
kinases [204, 205] responsible for several thousand of phosphorylations across the entire 
proteome via the reorganization of specific local or global amino acid sequences. 
However, large portions of these kinase-substrate relationships still have not been 
characterized [206]. Hence, when processing datasets that contain large amounts of 
protein phosphorylation identifications, it is worthwhile to extract phosphorylation motifs 
overrepresented in the datasets and to predict kinases responsible for the observed 
phosphorylation pattern via in silico approaches. An example software that provide 
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sequence motif analysis of phosphorylated peptides is Motif-X (http://motif-
x.med.harvard.edu/) [207]. Popular kinase prediction tools include Scansite 
(http://scansite.mit.edu/) [208], Predikin (http://predikin.biosci.uq.edu.au/), NetPhosK 
(http://www.cbs.dtu.dk/services/NetPhosK/) [209], NetworKin (http://networkin.info) 
[210], and KinasePhos (http://kinasephos.mbc.nctu.edu.tw/) [211, 212]. 
 
9. Quantitative Phosphoproteomics 
9.1. General considerations 
Quantitative phosphoproteomics usually involves therelative quantitation of protein 
phosphorylation variance, comparing samples from two or more pathological stages, 
external stimuli, or pharmacological treatments. Gel-based image analysis is still a 
popular procedure for surveying changes in the phosproteome for many molecular 
cardiology studies due to its simplicity [25, 26, 29, 43, 213, 214]. However, gel-based 
methods often solely quantify a small number of phosphoproteins, lack the ability to 
‘zoom-in’ for investigation of the abundance of phosphorylations on specific 
phosphosites, and are not readily suited for multi-sample comparisons. Large-scale, LC-
based phosphoproteomic studies have demonstrated the ability of MS to monitor the 
temporal dynamics of thousands of protein phosphorylations in response to stimulation. 
Although mass spectrometry provides an excellent tool for peptide structure 
characterization, quantitation using only ion abundance in MS is unreliable because 
ionization efficiency is highly variable from peptide to peptide. Thus, quantitative 
phosphoproteomic techniques usually refer to quantitation of relative changes in protein 
phosphorylation between samples. The more challenging issue is elucidation of the 
74 
 
stoichiometry of phosphorylation. Comparison of theabundance of phosphorylated and 
unphosphorylated peptide isoform in MS is generally not suitable, as they behave 
differently during LC separation and MS ionization. However, one can still normalize 
phosphoproteomics data using protein abundance inferred from other peptide fragments 
derived from the same phosphorylated protein to determine whether or not the change in 
phosphorylation abundance is due to protein synthesis, degradation or solely to 
phosphorylation. Several shotgun-based quantitation approaches have been implemented 
for phosphoproteomics, including popular stable-isotope labeling techniques and some 
label-free strategies as summarized in Fig 2.3.  
 
9.2. Metabolic labeling  
When and how a label is introduced into a given sample varies amongst different labeling 
techniques. It is generally advisable to incorporate isotopic tags and to pool samples as 
early as possible such that risks of systematic errors during further sample processing are 
minimized. Metabolic labeling, such as 14N/15N labeling [215], is advantageous, as it 
generally involves culturing cells in a medium contai ing stable isotopes such that 
synthesis of necessary amino acids can incorporate those isotope compounds via protein 
turnover. A protocol that utilizes stable isotope labeling with amino acids in a cell culture 
(SILAC) [216, 217] is now the most popular metabolic encoding method employed in 
phosphoproteomic studies [116, 218-222]. Briefly, cultured cells are propagated in 
medium containing isotope-encoded arginine (normal Arg, 13C6-Arg or 
13C6/
15N4-Arg) or 
lysine (normal Lys, 2H4-Lys or 
13C6/
15N2-Lys). Subsequent trypsin mediated digestion 
theoretically allows for each proteolytic peptide to carry only one SILAC encoded Lys or 
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Arg. As peptides with isotope variants are chemically identical and not separable 
chromatographically, they are assayed by MS simultaneously with distinctive mass 
increments in MS spectra. Relative peptide abundance from different samples can be 
obtained through comparison of the ion intensities of isotopic doublet or triplet peaks 
derived from corresponding SILAC tagging. Repeat measurements are made via 
calculation of the SILAC ratio from consecutive MS scans across the chromatographic 
peak of a given peptide. Although a maximum of three different samples can be 
compared in one SILAC experiment, it is still possible to use a common reference sample 
to bridge several SILAC experiments for further multiplexing. SILAC was initially 
restricted to cell culture studies, but in vivo labeling using a SILAC protocol for rat [223] 
and mice [224] models was reported. Notably, a variant SILAC protocol using a 13C9-
tyrosine tag was described by Cantin et al. for quantification of phosphotyrosine-
containing peptides [225].  
 
9.3. Chemical labeling 
Post-extraction labeling of proteins or peptides allows for the use of much broader 
sample sources. Most chemical labeling techniques initially introduced to quantitative 
proteomics have found an application in phosphoproteomics. However, not all proteomic 
labeling techniques can be successfully transferred. For example, isotope-coded affinity 
tags or ICAT [226] only label cysteine residues and were developed for protein 
quantitation. However a particular phosphopeptide may not contain a cysteine group, thus 
be undetectable. The isobaric tag for relative and bsolute quantitation (iTRAQ) 
technology [227] was also unavailable for quantitative phosphoproteomics due to the 
76 
 
incompatibility of the fragmentation mechanism for iTRAQ quantitation and the 
phosphorylation identification because iTRAQ was typically implemented on a Q-tof 
platform, while most IT instruments for phosphoproteomic applications have low-
molecular cut-off issues. Fortunately, the new generation LTP-Orbitrap with higher-
energy C-trap dissociation [23, 228] and linear IT instruments equipped with the pulsed-
Q dissociation (PQD) technique [229] is now used for quantification of iTRAQ labeled 
peptides. Additionally, ETD instruments have been shown to be compatible with iTRAQ 
quantitation [230-232]. Although there is still no report on the application of ETD alone 
towards quantification of iTRAQ labeled phosphopeptides, several studies have taken 
advantage of CID/ETD hybrid MS/MS modes in which ETD was used to enhance 
phosphopeptide identification, while PQD or HCD provide improved quantification of 
iTRAQ-labeled phosphopeptides [233, 234].The iTRAQ reaction solely targets the N-
terminus and lysine groups of tryptic peptides. Each isobaric tag contains an isotope-
encoded reporter group as well as a counter balancing group in order to ensure all tags 
have the same molecular weight, such that peptides from different samples labeled with 
different iTRAQ tags are indistinguishable in MS spectra. Only upon fragmentation, will 
the reporter ions be released and form reporter isotopic peak clusters in the 113-121 m/z 
region. Relative peptide abundance may be obtained by comparison of the intensities of 
the reporter ion peaks within the cluster that has a 1Da mass shift. iTRAQ was developed 
to accommodate up to four samples and further multiplex ng can be achieved by 
constructing a reference sample for use in several iTRAQ experiments. Recently, 8-plex 
iTRAQ [235] was introduced, capable of assaying eight samples for further simplification 
of experimental design. In particular, for time-dependent signaling dynamic studies or 
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projects with multiple replicates. However, one should be cautious when using iTRAQ 
for quantification of phosphopeptides, as it often r lies on very few replicates of the 
MS/MS spectrum instead of taking advantage of the wole chromatographic profile as 
compared to SILAC or label-free quantitation. Data compressing issues associated with 
iTRAQ, possibly due to the precursor selection window of up to several m/z ratios, has 
made quantification less sensitive to small changes [236].    
 
Recently, another isobaric amine-reactive labeling technique, the tandem mass tag or 
TMT [237] was successfully implemented for quantitative phosphoproteomic purposes 
[238]. O18 labeling [239], achieved by incorporation of 18O into the peptides during 
protease digestion, can also be used for phosphoproteomic applications [239-241].  
 
9.4. Label-free quantitation 
To a lesser extent, label-free methodologies have been applied to the quantification of 
protein phosphorylation, specifically, when isotope tags are not compatible with the study 
subjects or the MS instrument. One common label-fre approach utilizes the positive 
correlation of the analyte concentration and the MS signal intensity of ESI instruments. 
Briefly, all samples are first surveyed by LC-MS to d cument significant changes of 
chromatographic peak areas of unknown precursors. As each analyte investigated with 
MS bears a unique m/z ratio and retention time, an accurate mass and retention time 
(AMT) tag should be assigned to each component. Usually, visualization via two-
dimensional images of ion intensities in the span of retention times and m/z ratios from 
LC-MS are used to assist in data mining of peptide sp cies with significant changes. 
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Later an AMT list of precursors of interest is generat d and fed back to the MS. An 
additional LC-MS/MS run with exactly the same chromatographic conditions is 
conducted for characterization of those compounds on the AMT “wanted” list [242]. A 
variant of this method for quantitative phosphoproteomics employs the direct comparison 
of selected ion intensities of compounds in LC-MS/M runs, based on which the 
identification and quantification of phosphopeptides is achieved simultaneously [243]. 
Spectral counting is a popular yet less complicated strategy for use in label-free 
quantitative phosphoproteomics [244]. It makes use of the number of spectra matched to 
peptides as the surrogate semi-quantitative measurement of the peptide abundances. In 
the shotgun proteomics setting, several studies have demonstrated good agreement 
between protein quantification via spectral counting a d quantification via MS intensities 
[245, 246]; however, such agreement has not been proven in the phosphoproteomic 
setting. Regardless of the strategy used, label-fre quantification does not allow a sample 
pooling step and all samples including biological replicates are necessarily separated by 
LC and analyzed by MS individually. Thus, label-free quantification data with potential 
large run-to-run variability must be normalized by overall chromatographic intensity or 
by spiking of a known amount of protein standard prior to analysis [243, 247-249].  
 
10. Phosphoproteomics in Cardiac Molecular Research 
10.1. Protein phosphorylation and cardiac diseases 
Protein phosphorylation has been studied widely in the field of molecular cardiology. 
One aspect is to study the abnormalities of key signal ng pathways in respect to their 
roles in the pathogenesis of cardiovascular disease. For example, hyperactivation of 
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Ras/MEK/ERK1/2 has also been linked to the pathogenesis of cardiac hypertrophy and 
increased contraction [11, 250]. Disregulation of PKA signaling [251, 252] and GPCR-
activated protein kinase signaling, in particular the CaMKII pathway [10, 253], has been 
shown to cause hypertrophic dysfunction and sudden ath. A variety of signaling 
pathways are activated during ischemic-reperfusion (I/R) stress, mainly triggered by the 
release of endogenous reactive oxygen species (ROS). ROS stimulate Src tyrosine 
kinases [254, 255] and mitogen-activated protein kinases (MAPKs) such as JNKs, BMK1, 
ERK1/2, p38-MAPK during I/R insult [254, 256, 257]. Among them, some signaling 
proteins such as p38 have been described as being valuable therapeutic targets for 
preservation of cardiac function and inhibition of cytotoxic effects from cytokines 
released during myocardial reperfusion injury [258-260]. In addition, many cardiac 
diseases were found to be related to hormone-induced signaling triggered by noradrenalin, 
endothelin, and angiotensin all of which are mediated by cellular phosphorylation 
networks [261-264].  
 
Conversely, it is also interesting to investigate signaling pathways that initiate 
cardioprotective action for their potential therapeutic value. For example, JAK-STAT 
pathway plays an essential role in the development of ischemic preconditioning to 
prevent myocardial infarction [265-268]. Protein kinase B/Akt signaling [269-271] and 
protein kinase C (PKC) signaling [272-280] has been proven to provide cardioprotection 
against ischemic insult. Recent studies have proposed a comprehensive view of 
reperfusion injury salvage kinase (RISK) pathway [281] which interconnect prosurvival 
(PI3K)-Akt and the p42 (Erk1/2) signaling mediating the cardioprotection provided by 
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I/R and pharmacological preconditioning as reviewed by Hausenloy et al. [282, 283].  
 
Other than the signaling pathway, attention has been drawn to the aberrant regulation of 
phosphorylation of other key functional components i  cardiomyocytes and their roles in 
cardiomyopathy development. Cardiac contractile machinery contains phosphorylated 
proteins such as troponin I [284, 285], and myosin light chain 2 [286], myosin-binding 
protein C [287, 288], with an altered phosphorylation pattern found in many 
pathophysiological conditions [289]. Functions of major ion channels in cardiomyocytes 
such as ryanodine-sensitive calcium (Ca2+) channels [290, 291], voltage-gated L-type 
Ca2+ channels [292], and delayed rectifier potassium (K+) channels [293] are also 
regulated via protein phosphorylation [294].  
 
Given the breadth of protein phosphorylation in many critical cardiac functions as well as 
the implication of protein phosphorylation in cardiac disease development, kinase 
modulators have emerged as a main class of cardiovascular drugs [10, 295, 296]. 
However, despite what is already known, it is likely that only the tip of the iceberg has 
been found for both the complexity and the dynamics of the cardiac phosphoproteome. 
Global approaches making the use of systems biology t ols have the potential to provide 
a vital perspective to resolve the complexity of global phosphorylation pattern changes. 
Perhaps more practically, phosphoproteomics can be applied to selection of putative 
targets with therapeutic values and to verify the true global impact of novel 
pharmacological intervention on the phosphoproteome.  
81 
 
10.2. Examples of phosphoproteomics applications in the field of molecular 
cardiology 
In recent decades, the application of functional genomics approach like proteomics has 
been increasingly used to unveil the molecular events related to many cardiac research 
topics as showed in Fig. 2.4. Among these studies only few nevertheless targeted on the 
signaling transduction aspect of cardiac proteome. For example, early quest on 
prosurvival PKC signaling by Edmondson and others using a standard proteomics have 
successfully identified 93 proteins constituting the PKC signalosome in ischemic mouse 
heart [297]. However, the phosphorylation pattern of the PKC protein complex is still 
missing. Despite the current momentum in the application of phosphoproteomics on other 
fields, the number of phosphoproteomic studies in cardiac research is stagnantly low. 
Here we want to review some examples to demonstrate how phosphoproteomics can be 
helpful to dissect the molecular events underlying some critical cardiac physiological and 
pathological changes.  
 
In the quest to investigate global impacts of I/R stress on the signaling pathway, Chou et 
al. [298] implemented a p-Tyr specific phosphoproteomic approach to study the response 
of H9C2 cardiomyocytes to oxidative stress. Using p-Tyr based immunoprecipitation 
approach and LC-MS/MS, the authors further identified 23 H2O2-induced tyrosine 
phosphorylated proteins including novel targets like platelet-derived growth factor 
receptor-β and γ-adducin. Interestingly, many identified phosphoproteins modulated by 
oxidative stress in this study confirmed the known role of Src kinase to mediate ROS 
signaling in cardiomyocytes [298]. Fernado et al. [299] employed a novel 2DE-based 
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kinase assay coupled with mass spectrometry for inte rogation of kinase signaling in the 
biological context of cardiac hypertrophic adaptation dictated by the MKK6-p38 pathway. 
In this study, the authors first compared the kinase ctivity map from transgenic mice 
with congenital cardiac hypertrophy overexpressing MKK6 with that from the wild type. 
Using a 2DE gel cross-linked with a ubiquitous kinase substrate, they were able to 
identify new kinase candidates affected by MKK6 in the myopathic signaling cascade, 
including 5’-AMP activated kinase (AMPK) [300], Rho-associated kinase (RAK) [301], 
and protein kinase N (PKN) [302]. The authors also surveyed the direct substrates of 
MKK6 from the total cardiac protein lysate separated by 2DE. Some new candidate 
proteins previously reported to be associated with cardiac hypotrophy, including α-
adducin [303] and semaphorin [304], were identified by MS as novel downstream 
substrates of MKK6 in this study. Calcineurin signali g pathway has been documented as 
a positive regulator of cardiac hypertrophy [305]. In an attempt to understand the role of 
calsarcin-1 a negative regulator in calcineurin mediat  cardiac hypertrophy, Paulsson et 
al. launched a small scale proteomics study to characte ize the phosphorylation status of 
calsarcin-1 during cardiac injury. Using ETD-CID hybrid MS, the authors determined 
multiple novel phosphorylation sites on calsarcin during hypertrophy which provides 
more detailed insight into molecular mechanism triggers cardiac hypertrophy [306]. 
 
Global phosphoproteomics has also been used to resolve the complexity of hormone-
regulated signaling networks. As a member of seven-transmembrane receptors (7TMRs), 
the angiotensin II type 1 receptor (AT1R) was documented to exhibit functional 
selectivity upon binding to different ligands [307]. Using quantitative phosphoproteomics 
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based on the SILAC metabolic labeling technique, Christensen et al. [116] compared 
Gαq-dependent AT1R signaling and Gαq-independent signaling in cardiomyocytes using 
full AT 1R agonist angiotensin II (Ang II) and biased agonist SII angiotensin II (SII Ang 
II). Totally over 10,000 phosphorylation sites were id ntified using a SCX-TiO2 shotgun 
phosphopeptides enrichment protocol combined with a high-resolution LTQ-Orbitrap MS 
operated under MSA mode. Among this large amount of ewly discovered phosphosites, 
1183 sites from 500 phosphoproteins were regulated by Ang II or its analogue SII Ang II. 
As expected, 36% of those sites were only modulated by SII Ang II which proved the 
hypothesis that the Gαq protein-dependent and -independent pathways activated distinct 
groups of kinases. Moreover, this conclusion was confirmed by further analysis of 
phosphorylated sequence motifs. Motifs flank the Gαq protein-dependent and -
independent phosphorylated sites shown different types of consensus sequences and 
hence indicate the involvement of different kinases groups. Moreover, 
phosphoproteomics data led to the discovery of protein kinase D as a critical 
intermediator for both Gαq protein-dependent and -independent signaling and was
suggested to take an important role on the development of cardiac hypertrophy [116].  
 
Over the last few years, there have been trends to issect the phosphoproteome within the 
subcellular compartment from cardiomyocytes, such as mitochondria and 20S 
proteasome and myofilament. Given the importance of mitochondria in critical cardiac 
functions such as energy metabolism, apoptosis regulation, and Ca2+ homeostasis, great 
attention has been drawn to the portrayal of signalng dynamics in mitochondria. Three 
gel-based studies have been carried out to define the extent of the mitochondrial 
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phosphoproteome [22, 26, 308], in which phosphorylations on several proteins of from 
respiratory chain complexes and enzymes involved in intermediary metabolism were 
identified. Quantitative phosphoproteomics using 2DE with ProQ staining allowed 
Hopper et al. to identify the dynamic changes in phosphorylation patterns in 
mitochondrial matrix proteins following Ca2+ stimulation, most notably the 
dephosphorylation of PDH, manganese superoxide dismutase, and F0 1-ATPase [26]. In 
another study, Boja et al. isolated mitochondria from a porcine heart and enriched the 
phosphopeptides by a novel SCX/HILIC-TiO2 procedure. Using iTRAQ labeling 
techniques combined with LTQ-Orbitrap ETD-HCD hybrid nstrument, the author 
quantified phosphorylation pattern changes in proteins such as pyruvate dehydrogenase 
(PDH), branched chain α keto-acid dehydrogenase (BCKDH), ATP synthase and mitofilin 
upon Ca2+ stimulus, de-energization, and treatment with dichloroacetate, a drug candidate 
for the treatment of genetic mitochondrial diseases by as a PDH complex inhibitor [23]. 
In another study aiming to reveals regulatory pathwys of cardiac mitochondria, Deng et 
al. identified 210 novel phosphorylation sites on a CID-ETD hybrid MS platform from 
multiple murine cardiac mitochondrial proteins including components of the electron 
transport chain (ETC) complexes. Furthermore, the author suggested that calcium 
overload can compromise ETC activities via phosphorylation modulation, and illustrated 
that this type of mitochondria injury can be restored by enhanced phosphorylation of 
ETC using phosphatase inhibitors [309]. Cardiac myofilament contains multiple 
contractile related proteins that are heavily regulated by phosphorylation. Yin et al. 
performed a proteomics study to map the protein phos rylation on myofilemental 
subproteome from murine cardiomyocytes stimulation with endothelin-1 and 
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isoproterenol both as inducers of myofilament phosprylation. Using LTQ-Orbitrap with 
ETD capability, 5 phosphorylation sites were identified from 3 contractile proteins. 
Moreover, over 600 additional proteins were identified in the myofilament subproteome 
including many previously unrecognized kinases and phosphatases indicating a complex 
network of myofilament regulation via protein phosphorylation [310]. Functional 
difference between neonatal and adult cardiomyocytes r flect by differential 
phosphorylation on sarcomeric proteins was known but with limited knowledge on how 
protein phosphorylation changes during cardiac development. Using a 2DE with Pro-Q 
Diamond stain protocol, Yuan et al analyzed sarcomeric phosphoproteome difference 
between neonatal and adult rat hearts [214]. Phosphoprotein from neonatal and adult 
heart sample were further labeled by O16/ 18 and enriched by TiO2 prior to LTQ-FT MS 
analysis from which several phosphosites on myofilamental proteins like myosin-binding 
protein and tropomyosin were found to be differentially phosphorylated at two different 
stages [214]. There are also some applications of ph sphoproteomics on cardiac 20S 
proteasome to explore the molecular basis involved with the regulation of myocardial 
proteolytic system. Zong et al. [34] employed immunoprecipitation with anti-p-
Ser/Thr/Tyr antibodies coupled with Q-TOF MS/MS to survey the phosphorylation 
pattern of the cardiac 20S proteasome complex. Based on phosphoproteomics data, 2 
novel signaling partners associated with cardiac 20S complexes were found: protein 
phosphatase 2A, and protein kinase A. The authors also found that the peptidase activity 
of 20S proteasome can be enhanced by site-specific phosphorylation. The role of PKA in 
governing 20S phosphoproteome was further investigated by Lu et al. [311]. In this study, 
the authors first identified 20 phosphosites from the murine heart 20S proteasome using 
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IEF/SDS-PAGE-TiO2 protocol combined with CID and ETD MS analysis, from which 13 
phosphosites were identified. Moreover, the author recorded changes in the 
phosphorylation pattern and peptidase activity of 20S proteasome upon PKA activation 
[214].  
 
High-throughput phosphoproteomics has also emerged as a novel screening technique for 
potential diagnostic biomarkers with clinical implications. Using a fluorescent 
phosphostain-based 2DE workflow, Dubois et al. [312] successfully detected 69 
differentially phosphorylated proteins in sample from the left ventricles of rats as the 
result of myocardial infarction. Within these altered phosphoproteins, they further 
demonstrated that the phosphorylation of serine207 on troponin T (TnT) was significantly 
decreased both in rat LV and plasma samples with myocardial infarction and left ventricle 
remodeling (LVR). The authors further confirmed that the serine207-phosphorylated 
TnT/total TnT ratio was also significantly low in human plasma samples from patients 
with intermediate or high LVR suggesting that phosphorylated troponin T in circulation 
can be used as a potential biomarker for LVR [312].  
 
11. Challenges 
Phosphoproteomics is still facing numerous technical challenges, particularly with 
samples of high complexity. Low coverage of the phosphoproteome is probably the 
biggest issue inherent to the MS-based phosphoproteomics technique itself. First, there is 
no enrichment strategy that can guarantee complete extraction of phosphopeptide species 
from complex samples with low sample loss and high selectivity against interfering 
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compounds like acidic peptides. Secondly, since MS is usually used in a DDA mode, 
some peptide species, especially those in low abundance, are likely to be ‘ignored’ due to 
undersampling issues. Third, identification of phosphopeptides from a tandem MS 
spectrum is still a difficult task, as not all search engines can effectively interpret spectra 
from phosphoproteomics-oriented instruments, such as MSA or MS3-CID or ETD. There 
is still a general dearth of strategies to localize phosphosites, even given successful 
peptide backbone identification. Last but not least, the field of phosphoproteomics lacks 
universal identification criteria for reliable data quality and general guidance of how 
phosphoproteomics data should be processed, stored, and published. This was evidenced 
by dramatic variations in the number of phosphopeptid  IDs identified in different 
phosphoproteomics studies with similar procedures on imilar subjects.  
 
Considerable challenges in the application of phospproteomics still remain to be 
addressed, particularly the data-mining and interpretation of massive amounts of high-
throughput information. Current advances in enrichment and MS methodologies for 
large-scale phosphoproteomic applications can help to reveal large numbers of 
phosphorylation sites from complex whole cell or tissue extract samples. However, the 
functional significance of the vast majority of identified phosphosites still remains to be 
determined and associated with a dynamic signaling network. Despite the emergence of 
protein databases with functional annotations and new generations of in silico pathway 
analysis packages, most information is still obtained via non-experimental means. In a 
typical quantitative analysis of phosphoproteome with d ffering patho-physiological state 
or pharmaceutical perturbations, the biological causal linkage between biological input 
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and the observed changes in phosphorylation patterns r mains difficult to characterize. 
Moreover, systematic approaches still lack the power to confirm the relevance of 
pathways to disease pathology or other downstream phenotypic endpoints. The key 
question that remains to be answered is whether the changes in those pathways identified 
from a phosphoproteomic study is the contributing factor or a side-effect of the diseases. 
For this usually non-global methodology are complementary to proteomic approaches. 
 
Another significant concern in the phosphoproteomics f eld is sizeable data variability. 
One inherent disadvantage of MS-based phosphoproteomics is the accuracy of 
identification and quantitation. Compared to standard proteomics for analysis of protein 
expression levels, the identification and quantification of protein phosphorylation often 
relies on individual peptide species with very low numbers of MS spectrum replicates. 
Also, the number of samples that can be compared is lim ted, even with multiplexing 
labeling techniques. Lack of biological or technical replicates tends to introduce 
systematic noise and to yield measurements with large variability. This restriction also 
signifies that the researcher must choose the conditi s to be compared very carefully, as 
there is limited room for multiple conditions and time points in the experimental design, 
which eventually restricts the power of phosphoproteomics for assessment of the 
dynamics of signaling networks.  
 
However, as an ever-evolving research field, new enrichment methods, new quantitation 
strategies, new instrumentation, and new bioinformatics tools have been rapidly 
introduced to the analysis of the phosphoproteome yielding much higher throughput, 
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accuracy, coverage, and sensitivity for quantitation of changes in protein phosphorylation 
on a large scale, as well as higher capabilities for illustration of kinase-substrate 
interactions. Also, more efforts are needed to make phosphoproteomic techniques less 
complex, amenable, and cost-effective for researchers with limited experience. These 
advances would be particularly useful in clinical settings to assist diagnosis, prognosis, 
and treatment of cardiovascular diseases.  
12.  Concluding Remarks 
Distortion in protein phosphorylation patterns can lead to the onset and progression of 
many cardiac diseases. Technically, phosphoproteomics provides time-efficient, less 
tedious and high-throughput identification of protein phosphorylation; conceptually, it 
permits the evaluation of the complexity of protein phosphorylation in a non-biased 
global perspective with little a priori knowledge. This review provides a nonspecialist 
working in the field of molecular cardiology an introduction to up-to-date 
phosphoproteomics tools, workflows, and examples of phosphoproteomics applications 
in a range of cardiac research topics. We foresee that phosphoproteomics will become a 
vital tool contributing to the mechanistic understanding of the signaling and regulatory 
aspects of cellular functions under normal or cardiopathological status, as well as 
identification of pivotal kinases or protein phosphorylation sites, thereby allowing the 





Figure 2.1. The past decade has witnessed the rapid development of large-scale phosphoproteome 
methodology using enrichment techniques and high accur y mass spectrometry. Here only key technical 





Figure 2.2. An overview of typical large-scale phosphoproteomics workflow. Most current 
phosphoproteomics procedures consist of at least two-dimensional orthogonal separation of proteins (2DE 
protocol) before proteolytic digestion or peptides (2DLC protocol) after proteolytic digestion. Typically a 
step of enrichment procedure is used to isolate phos hopeptides from complex mixture. Simplified 
fractions containing phosphopeptides are then introduced into mass spectrometry to determine the peptide 





Figure 2.3 Comparison of isotopic labeling and label-free quantitative shotgun workflows. Different 
labeling strategies pool samples for relative quantit tive at different sample processing steps. After pooling, 
peptides from different samples will be analyzed toge her within the same MS or MS/MS spectrum. Label-
free workflow introduces no sample pooling, comparing MS signal or number of MS/MS spectra from 






Figure 2.4. Compare to the general increasing trend in phosphoproteomics application found in PubMed on 
other research topics in the recent decade, there are still very few number of publications using 
phosphoproteomics for cardiac research purpose. However, the application of standard proteomics in the 
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 CHAPTER 3 
CONCENTRATION-DEPENDENT EFFECTS OF THE SOY PHYTOESTROGEN 
GENISTEIN ON THE PROTEOME OF CULTURED CARDIOMYOCYTES 
 
1. Introduction 
Epidemiological evidence suggests that the intake of dietary soy-derived 
phytoestrogens may lower the incidence of cardiovascul r disease (CVD) [1]. 
Recently, several studies have suggested that isoflavones, particularly genistein 
(GEN), an abundant phytoestrogen in soy, may provide protection to cardiac 
myocytes against ischemic stress [2-7]. However, th underlying mechanisms are still 
elusive and may involve diverse cellular processes in a concentration-dependent 
manner as previously reported in various cell types [8-10].  
 
GEN is known for its estrogenic [11] and anti-estrogenic properties [12]. Specifically, 
GEN at low concentration (1-10 µM) has been shown to be an effective agonist for 
both estrogen receptors (ER) 1 and 2 [13, 14]. Experimentally, estrogen has been 
shown to reduce the infarct size in various in vivo models against ischemia insult [15-
21]. Natural estrogen analogs like GEN have been proposed as a candidate for 
hormone replacement therapies and have been shown to have cardioprotective effects 
via the modulation of PI3K/Akt and mitochondrial permeability [3]. Like estrogen, 





[22, 23].  
 
However, in addition to estrogenic bioactivity, GEN also acts as a non-specific 
protein tyrosine kinase (TK) inhibitor [24], typically at concentrations >10 µM. 
Tyrosine kinase signaling has been shown to play critical roles in preconditioning or 
pharmacological cardioprotection and this signaling can be blocked by GEN [25-37].  
 
Given the complexity of known cellular consequences and other possible biological 
impacts of GEN treatment, a proteomic approach was chosen to provide a 
comprehensive view of the molecular impact of GEN on cardiomyocytes. HL-1 cells 
were used as a model because they maintain a similar gene expression profile and a 
differentiated cardiac phenotype to that of adult mouse cardiomyocytes [38, 39]. To 
elucidate the concentration-dependent alteration in protein expression profile 
modulated by GEN exposure, we analyzed the proteome f HL-1 cells treated with 
physiologically relevant (1 µM) and pharmacological (50 µM) concentrations of GEN 
compared to that of a control group via two-dimensio al electrophoresis (2DE). In 
this protocol, proteins were first pre-fractionated by two-stage sequential protein 
extraction technique followed by 2DE-silver stain procedure for proteomic analysis. 
We identified 25 and 62 differentially expressed proteins via tandem mass 
spectrometry and database matching in the low- and high-concentration treatments, 
respectively. Subsequent Gene Ontology (GO) and pathway analyses were launched 
to discover the links between differentially expressed protein responses to GEN 





first systems biology investigation on the cellular effects of GEN in cardiomyocytes. 
 
2. Material and Methods 
2.1. Cell culture and treatments  
HL-1 cardiomyocyte cells [39] were cultured in T75 flasks pre-coated with gelatin 
and fibronectin. Claycomb medium [39] supplemented with 10% fetal bovine serum, 
100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM norepinephrine, and 2 mM L-
glutamine was changed daily. Upon confluency, cells were treated with either 1 or 50 
µM of GEN for 24 h before harvesting. Control cells were treated with the same 
volume (<3 µL/mL of medium) of DMSO. Each treatment was performed in triplicate. 
For each condition, approximately 107 cells were collected by trypsinizing.  
 
2.2. Two-stage hydrophilic and hydrophobic protein extraction 
The cell suspension was washed twice with pH 7.4 PBS and centrifuged at 300 xg for 
3 min before protein extraction. Protein extraction was achieved with a two-stage 
hydrophilic/hydrophobic solubilization protocol. Water-soluble proteins were first 
extracted by ultrasonication for 5 min in 1mL hydrophilic extraction solution 
containing 10 mM Tris-HCL (pH 8.0), 0.5 mM Pefabloc, 5 mM magnesium acetate, 
and 0.01% Triton X-100. Samples were centrifuged at 17 000 x g for 20 min which 
the supernatant was designated as the hydrophilic protein fraction. The resulting 
pellet was further washed twice with 0.5 mL of hydrophilic extraction solution then 





(pH 8.0), 7 M urea, 2 M thiourea, 0.5 mM Pefabloc, 5 mM magnesium acetate and 
4% CHAPS. After centrifugation at 17 000 x g, the supernatant was collected as the 
hydrophobic protein fraction. Total protein concentration of both hydrophilic and 
hydrophobic protein fractions was determined using the RC-DC protein assay kit 
(Bio-Rad, Hercules, CA, USA) according to the instruc ions from the manufacturer. 
Bovine serum albumin (Sigma-Aldrich) was used as protein assay standard.  
 
2.3. Two-dimensional electrophoresis  
For the hydrophilic protein fraction, 300 µg of protein was brought up to a volume of 
400 µL (1:3 or greater dilution) with rehydration buffer (8 M urea, 4% CHAPS, 10% 
glycerol, and 0.3% dithiothreitol). Eight microliters of IPG buffer (Bio-Rad) were 
added before loading the sample into a 18-cm pH 4-7 IPG ReadyStrip (Bio-Rad). For 
the hydrophobic protein fraction, 200 µg of protein were loaded using the same 
procedure. IPG strip was rehydrated in an Immobiline DryStrip tray (GE Healthcare, 
Piscataway, NJ, USA) for 16 h. IEF was performed using a Multiphor II 
electrophoresis system (GE Healthcare) at 20 oC. The IEF voltage was programmed 
to increase to 500 V linearly within 1 min, followed by a linear increase to 3500 V 
over 5 h, and then maintained constant at 3500 V for 17.5 h. Proteins were reduced by 
submerging the IPG strips in 3 mL equilibration buffer (6 M urea, 30% v/v glycerol, 
2% w/v SDS, and 24 mM Tris-HCl pH 6.8) supplemented with 2% w/v dithiothreitol 
for 15 min. Alkylation was performed by submerging the strips in 3 mL equilibration 
buffer supplemented with 2.5% w/v iodoacetamide and trace of bromophenol blue 





(18 cm x 20 cm x 1 mm). The second dimension of electrophoresis was performed at 
a constant current of 40 mA per gel for 4.5 h in a Protean II XL 2-D Multi-Cell 
system (Bio-Rad).  
 
A MS-compatible silver stain protocol was used to visualize gel spots. Briefly, gels 
were first fixed in 40% v/v ethanol and 10% v/v acetic acid for 30 min, followed by 
sensitization in 30% v/v ethanol, 0.2% w/v sodium thiosulphate, and 7% w/v sodium 
acetate for 30 min. After gels were washed three times with Nanopure water 
(Barnstead, Garner, NC) for 5 min, a 20-min staining was carried out in a 0.25% w/v 
silver nitrate solution. Gels were washed twice with Nanopure water for 1 min each 
and visualized with 0.074‰ formaldehyde in a 2.5% w/v sodium carbonate solution. 
After visualization, gels were preserved in 1.5% w/v EDTA. In all steps, a total 
volume of 250 mL of solution was used per gel. Digital gel images were created using 
the UVP Bioimaging System and further processed by LabWorks 4.6 (UVP LLC, 
Upland, CA). Gel images were analyzed with Delta 2D v3.4 image analysis software 
(Decodon GmbH, Greifswald, Germany). Briefly, image wrapping and spot matching 
was performed automatically and manually validated afterward. After background 
subtraction, a fused image was created by adding all spots from all images as a 
collective universal proteome map. A unique-spots ID list was created based on the 
proteome map and reassigned back to each individual gel to assure complete spot 
matching. To prevent identification of false spots, spots were removed from 
consideration if the spot quality was < 0.25 and if the spot percent volume in the 





changes based on percent volume (% voli = voli/∑voln) of all spots resolved in the gel, 
where voli is the volume of spot i in a gel containing n spots. Statistical analysis was 
carried out with the Student's test included in the Delta 2D package, using a cut-off 
value of p < 0.05. Three biological replicates each with two technical replicate gels 
were performed for each sample. Spots with significantly densitometric value 
changes were further checked visually to exclude false spots, mismatches, and spots 
showing evidence of co-migration. All spots from both hydrophilic and hydrophobic 
fractions with significantly altered intensity were used to visualize the change in 
global expression pattern upon GEN treatments. Hierarchical cluster analysis 
employing Euclidean correlation and average linkaging was performed with Gene 
Cluster v3.0 [40]. The resulting heat map was displayed using TreeView v1.6 [41].  
 
2.4. Protein identification 
Gel spots were cut with a spot picker with 1.5 mm or 3.0 mm diameter PDM tips (Gel 
Company, San Francisco, CA) depending on spot size.Excised spots were destained 
with 80 µL 1:1 solution of 30 mM potassium ferricyanide and 100 mM sodium 
thiosulfate for 15 min, and washed twice for 15 min in 100 µL 100 mM ammonium 
bicarbonate [42], and dehydrated with 100 µL 100% ACN. The supernatant was 
removed and gel plugs were dried in a SPD SpeedVac (Thermo Electron, Waltham, 
MA). Tryptic digestion was accomplished by incubation of the gel spots with 0.6 µg 
sequencing-grade trypsin (Promega, Madison, WI, USA) in 40 µL of 100 mM ABC 
for 12 h at 37 oC. After the incubation, the supernatant was collected. Peptides were 





(FA) in 50% ACN, 0.1 % FA in 70% ACN, 40 mM ABC, and 100% ACN each for 
15 min. The pooled supernatants from these steps were dried by SPD SpeedVac to a 
final volume of 10 µL. Peptides were desalted using ZipTips C18 pipette tips 
(Millipore) and reconstituted in 10 µL of 0.1% FA with 3% ACN prior to analysis on 
a ESI-Q-TOF (Agilent 6150, Santa Clara CA). Desalted protein digests were injected 
onto a G4240-62001 C-18 HPLC-Chip (40 nL enrichment column, 75 µm x 43 mm 
analytical column, 5 µm C-18SB-ZX, 300 Å, Agilent) interfaced with the ESI. 
Peptides were separated during a 30-min gradient of 16–90% ACN in 0.1% FA at 4 
µL/min. Peptides were analyzed using the data-dependent MS/MS mode over the m/z 
range of 59–3000. Three precursor ions were selected for MS/MS following each 
survey scan and only ions exhibiting a detection intensity exceeding 1000 counts 
were selected for MS/MS fragmentation by collision induced dissociation (CID). 
MS/MS data were acquired in centroid mode. MS/MS spectra were converted into 
Mascot generic format (.mgf) and uploaded to Mascot v2.3.01 (Matrix Science, 
London, UK) for database searching against a target-reverse concatenated 
International Protein Index (IPI, European Bioinformatics Institute, 
http://www.ebi.ac.uk/IPI) mouse database (v3.74, 113868 sequences). The search 
parameters were set to allow for up to two missed cleavages, 
carboxyamidomethylation on cysteine and variable modification of oxidation on 
methionine, a peptide tolerance of 0.2 Da, and an MS/MS tolerance of 0.1 Da. All 
identifications from Mascot were transferred into Scaffold v3.00.03 (Proteome 
Software, Inc., Portland, OR) for validation, where p ptides that met the following 





score must be equal to or higher than the identifica on score from each individual 
Mascot search result, and (2) the score of a +2, +3, or +4 ion must be equal or higher 
than 34, 37 or 40, respectively. For protein identification, the match with the highest 
protein score (must be p < 0.05) and with at least with two unique peptide matches 
screened by the aforementioned peptide criteria wasconsidered as the protein 
identification. Common contaminants such as keratins a d trypsin were excluded 
from the results.  
 
2.5. Bioinformatic analysis 
To better enhance the biological significance of the quantitative proteomics results, 
lists of differentially expressed proteins from eith r the 1 µM or 50 µM GEN-treated 
samples vs. the control samples were analyzed using MetaCore software (GeneGO). 
The MetaCore database was constructed by abstracting interconnecting information 
from a large fraction of biomedical literature on the functions of genes, protein, and 
compounds, interactions of biological molecules, and disease inter-relationships, and 
is mainly focused on mice, rats, and humans. Once the list of altered proteins from 
either comparison was uploaded to MetaCore, the most relevant biological process 
was enriched based on public GO databases. Moreover, the size of the intersection 
between the subset of uploaded proteins and the prot ins on all pre-built pathway 
maps in the MetaCore database was computed. In order to know whether the 
experimentally identified proteins had an association o a particular biological process 
GO or a pre-built canonical pathway, a p-value was computed based on the 





having a given biological process GO or a pre-built network to be associated with the 
experimentally-identified proteins simply by chance. The p-value was calculated 
using the formula: 
 
where N is the total number of objects (i.e. all mouse genes), in the MetaCore 
database, R is the number of network objects corresponding to the list of differentially 
expressed proteins identified from the experiment, n is the total number of nodes in 
each small network, and r is the number of proteins from the experimental data that 
associate with each small network. The most relevant GO biological processes and 
pathways were then prioritized based on their statistical relevance with respect to the 
uploaded data sets. For GO enrichment, a false discovery rate (FDR) threshold of 
0.01% was used to select significant processes considering the p-value of each 
associated process with respect to the total number of process in the public database. 
In order to maintain specificity in the GO analysis, GO terms within the top three 
ancestor terms in the GO Hierarchical rank and GO terms specifically designated to 
biological process in other cell types were dropped. Additionally, network 
construction based on Dijkstra's Shortest Path Algorithm was used to portray the 
potential interaction between GEN-responsive proteins. A maximum of two steps in 
each path were pre-set so that if there were no direct interaction between two proteins, 
an intermediate component connecting to both proteins was be added to the map to 





3. Results and Discussion 
3.1. Effect of genistein treatment on the proteome of HL-1 cardiomyocytes 
For both soluble and insoluble protein fractions, a representative 2-D proteome map 
was generated by Delta 2D using the image fusion function in the union mode (Fig. 
3.1). Overall, approximately 1,500 spots and 800 spots were visualized in gels from 
water-soluble and insoluble protein fractions, respectively. Among these 2,300 spots, 
39 and 99 spots had different volumes (t-test, p<0.05) in samples from the low and 
high concentration GEN treatments compared to the untreated cells. Fig. 3.2A/B 
shows volcano plots of the entire data, set highlightin  proteins expressed at 
significantly different (t-test p < 0.05) levels in the two GEN-treated HL-1 samples vs. 
controls. The global proteomic change patterns in GEN-treated groups vs. control 
populations were visualized by cluster analysis (Fig.3.2C). As expected, the six 
replicates in each experimental group cluster together, and the expression alteration 
pattern differs between the 1 µM GEN-treated and the 50 µM GEN-treated groups.  
 
In total, 25 and 62 proteins were successfully identifi d by ESI-MS/MS from the low 
and high concentration GEN groups, respectively. Some f the spots were very faint 
and close to the limit of 2DE detection. Consequently, after gel excision and digestion, 
these spots were below the sensitivity of the MS instrument. Identified spots are 
summarized in Appendix I, along with protein name, IPI ID, number of unique 
peptide IDs, molecular weight, the fold-changes of b th low and high concentration 
treatment versus control, and associated biological process GO terms are listed. 






To assess the global trends of changes in cellular f nctions, lists of differentially 
expressed proteins in both low and high concentration GEN treatments were analyzed 
by MetaCore (GeneGO). The top 20 GO processes affected by 1 µM and 50 µM GEN 
treatment are summarized in Figure 3.3, and the complete list of significant relevant 
GO processes can be found in the Appendix III. Interestingly, both levels of GEN 
exposure had significant impacts on the energy metabolism GO processes, including 
glucose catabolic process and regulation of ATPase activity. According to the GO 
analysis, the low concentration GEN treatment also significantly impacted the anti-
apoptosis process.  
 
GeneGO pathways strongly associated with GEN treatmnts are summarized in Table 
3.1. Several pathways, including cytoskeleton remodeling and hypoxia induced Akt-
HIF1 activation, were highly enriched in both low and high concentration GEN-
treated samples. The glycolysis and gluconeogenesis pathways were also enriched in 
the high-level GEN treatment. In Figure 3.4, interactive networks of the identified 
proteins that are modulated by GEN treatments are shown. Through analysis of these 
two networks, core transcriptional factors that hypothetically could mediate the GEN-
induced protein expression alteration can be selected for future investigation. 
Transcription factors including estrogen receptor 1 (ER1), androgen receptors, jun 
proto-oncogene (AP-1/c-Jun), SP1 transcription factor, heat shock transcription factor 
1 (HSF1), tumor protein p53, and vitamin D receptor (VDR) were found to be 





myelocytomatosis viral oncogene homolog (c-Myc), E2F transcription factor 1, early 
growth response 1 (EGR1), forkhead box O3 (FOXO3A), hypoxia inducible factor 1 
(HIF1), signal transducer and activator of transcription 3 (STAT3), and YY1 
transcription factor may also be involved with the expression regulation of genes 
induced by the high concentration of GEN, while cAMP-responsive element binding 
protein 1 (CREB1) may be involved with expression regulation of genes response to 
low concentration GEN treatment.  
 
In the following sections, proteins and pathways involved in six functional areas are 
described and their potential linkages to the observed cardioprotective role of GEN 
discussed. 
 
3.2. Stress response and protein folding machinery 
The proteins identified in this study suggest that GEN treatment can affect the 
expression level of chaperones or heat shock proteins. Among the differentially 
expressed chaperones is heat shock 70 kDa protein 5 (GRP78 or Bip), the expression 
of which was enhanced by the high-concentration GEN treatment (+1.53 fold). This is 
consistent with previous findings that exposure to 100 µM GEN can significantly 
induce GRP78 expression in an ER-independent mode in both estrogen receptor-
positive (MCF-7) and ER-negative (MDA-MB-231) cells [43]. GRP78 is known to 
work with protein disulfide-isomerase to fold misfolded proteins. GRP78 is also 
considered to be an anti-apoptotic factor since it can deactivate several pro-apoptotic 





complexes with pro-caspases such as caspase-7 and caspase-12, preventing the 
activation of the pro-apoptotic caspase cascade [45]. Also, a study employing HeLa 
cells confirmed that suppression of GRP78 via siRNA silencing can cause apoptosis 
[46].  
 
Another chaperone, the heat shock protein beta-1 (or HSP27), was also induced by 
high concentration GEN (+1.36 to +3.98 fold). Interestingly, in cells exposed to the 
low concentration of GEN, the expression pattern of HSP27 suggests potential 
changes in the HSP27 distribution (+1.33 fold in soluble fraction, -1.36 in insoluble 
fraction). Another mitochondrial chaperone involved in protein folding, the stress-70 
protein (mitochondrial HSP70, 75 kDa glucose regulated protein, or GRP 75), was 
found to be up-regulated by the low-concentration GEN treatment (+1.57 to +2.06-
fold). Jayakumar et al. indicated that up-regulation of HSP70 protects mitochondrial 
function in rats during cardiac ischemia-reperfusion injury [47]. Mitochondrial 
chaperone 60 kDa heat shock protein (HSP60) was up-regulated in the high-
concentration GEN treatment (+1.63 to +4.42-fold). HSP60 is known for its 
important role in mitochondrial protein transport and assembly, and it also prevents 
polypeptide misfolding under stress conditions in the mitochondrial matrix. HSP60 is 
also considered to be an apoptosis regulator via its bility to form complexes with 
pro-apoptotic factors such as BAX, BAK, and Bcl-XL [48]. Interestingly, estradiol 
treatment was shown to activate heat shock factor-1 (HSF-1) [49]. HSF-1 is known to 
be the transcription regulator of HSP60 [50], and our results suggest that GEN may 





regulated protein 1 (NDRG1) was observed in cells exposed to 1 µM GEN (+1.38-
fold). NGRG1 is inducible under hypoxic conditions and has been shown to play a 
protective role against hypoxia [51]. Interestingly, AP-1, which is positively regulated 
by ERs, was documented as a transcription enhancer of NDRG1 [52].  
 
3.3. Cellular redox balance 
Free radicals and oxidative stress are common mediators of cardiac ischemic injury 
[53]. Genistein, like many other plant-derived isoflavones, is considered to be an 
antioxidant [54]. Moreover, isoflavones have been shown to stimulate the antioxidant 
enzyme system (AOEs) in the vasculature [55-57]. In particular, GEN has been 
shown to have the ability to up-regulate endothelial nitric oxide synthase in rat 
vascular endothelial cells [58]. However, our observations suggest that GEN may 
have an overall negative impact on cardiac antioxidant enzyme system.  
 
Peroxiredoxin-4 was slightly down-regulated in the low-GEN treatment (-1.31-fold). 
The peroxiredoxin family works with thioredoxin to remove hydroperoxides and to 
reduce oxidized proteins. The presence of GEN, an antioxidant [59], may have led to 
the feedback inhibition of the endogenous AOE system. Both the protein disulfide-
isomerase (PDI) precursor, prolyl 4-hydroxylase subunit, and the protein disulfide 
isomerase A3 precursor were found to be significantly i hibited in cells dosed with 
the high level of GEN (-3.39 and -6.01-fold). Since they are key players in 
maintaining cellular redox homeostasis, and also members of the unfolded protein 





induced apoptosis in cardiomyocytes in a mouse in vivo model, and in protecting 
against cardiac ischemia [60]. The significant decrease observed for PDIs may 
contribute to the attenuation of cardioprotection by GEN at high concentrations. 
Interestingly, glutathione synthetase was found to be overexpressed (+3.65-fold) in 
cells from the high-concentration GEN treatment. High levels of cellular antioxidant 
GSH can be induced by hypoxic stress and have been shown to provide cardiac 
protection against apoptosis-induced oxidative stres  [61].  
 
3.4. Apoptosis 
Our 2DE data suggest that GEN treatment influences th  apoptosis pathway in 
cardiomyocytes. Mitochondrial voltage-dependent anion-selective channel protein 2 
(VDAC-2) was up-regulated by GEN at both concentrations (+1.52-fold at 1 µM, and 
+1.36-fold at 50 µM). VDACs help small hydrophilic molecules such as ATP move 
through the mitochondrial membrane and help to maintain the membrane integrity. In 
recent years, it was also found that VDACs participate in the regulation of apoptosis. 
Other than the fact that VDACs can deactivate pro-ap ptosis factors such as BAK 
[62], VDACs per se may have a more direct impact on apoptosis via their 
open/closed status [63]. However, evidence for this ypothesis is inconsistent 
between reports [64] and goes beyond the scale of this proteomics study.  
 
Another mitochondrial membrane protein up-regulated in the low GEN treatment 
group (+1.38-fold) is the import inner membrane translocase subunit TIM50. TIM50 





mitochondrial inner membrane. Loss of TIM50 causes p rmeabilization of the 
mitochondrial membrane and release of cytochrome c, which initiates apoptosis [65].  
 
Bcl-2-associated athanogene-2 (BAG2) expression was lower in cardiomyocytes 
treated with 50 µM GEN (-1.72-fold). BAG inhibits HSC70 by binding to HSC70 as 
a competitive antagonist of the co-chaperone Hip [66]. Thus, it has been proposed 
that BAG promotes cell survival by coordinating the function of these chaperones 
with the proteasome [67]. One study on rat primary cardiac myocytes showed that the 
oxidative stress-induced over-expression of BAGs can provide cardioprotection 
against apoptosis triggered by hypoxia [68]. Over-expr ssion of the acidic protease 
cathepsin D was found in the 50 µM GEN-treated group (+1.61-fold). Cathepsin D is 
emerging as an apoptotic contributor of cardiomyocyte death under oxidative stress, 
which may cause lysosomal destabilization and acidifi at on [69]. Interestingly, in 
other cell model, GEN was shown to trigger apoptosis via the ER-dependent up-
regulation of cathepsin D [70]. Our analysis suggests that high levels of GEN may 
induce apoptosis in cardiomyocytes accordance with previous reports on other cell 
types treated by GEN [70-73].  
 
3.5. Energy metabolism 
Four critical enzymes that convert glucose to pyruvate were down-regulated in 
cardiomyocytes exposed to 50 µM GEN (but not at the lower level): triosephosphate 
isomerase (-5.01-fold), phosphoglycerate kinase 1 (-1.47 to -2.00-fold), alpha-enolase 





glycolysis was inhibited by the 50 µM GEN treatment but not by the 1 µM GEN 
treatment. Interestingly, the alpha subunit of pyruvate dehydrogenase E1, which 
converts pyruvate to acetyl-CoA, was up-regulated in cells exposed to both GEN 
levels (+1.59, +2.34-fold), suggesting that the cells might shift to other catabolic 
pathways to generate pyruvate upon GEN treatment.  
 
A significant decrease in the level of NADH dehydrogenase [ubiquinone] 
flavoprotein 2 was found in the 50 µM GEN treatment (-1.23 to -3.59-fold), while 
another important component of electron transfer chain, electron transfer flavoprotein 
subunit beta (ETF), was up-regulated in the same cells (+1.65-fold). ETF carries 
electrons generated from fatty acid and amino acid catabolism to the electron transfer 
chain in mitochondria. Interestingly, two enzymes involved with fatty acid and amino 
acid catabolism were up-regulated in 50 µM GEN-treated cells. Aspartate 
transaminase (AST) was induced by exposure to 50 µM GEN (+2.33-fold). One key 
enzyme in the beta-oxidation of unsaturated fatty acid, the delta(3,5)-delta(2,4)-
dienoyl-CoA isomerase, which also has enoyl-CoA hydratase activity, was up-
regulated by the 50 µM GEN treatment (+1.52-fold). These changes suggest that the 
bioenergetics of cardiomyocytes shift from glycolysis to fatty acid and amino acid 
catabolism upon treatment with 50 µM GEN. Such a shift in energy utilization may 
render the cardiomyocytes even more unprepared for anaerobic metabolism upon 






3.6. DNA integrity and RNA transcription/processing 
The levels of two proteins involved in RNA transport and processing, heterogeneous 
nuclear ribonucleoproteins (hnRNPs) A/B and H, were impacted by GEN. The 
hnRNP A/B was under-expressed in the 1-µM GEN-treated cells (-1.97-fold). These 
hnRNP proteins form the core of the ribonucleoprotein complex that associates with 
pre-mRNA splicing, and nucleo-cytoplasmic export of nascent mRNAs. It is also 
involved with DNA replication and repair [74]. In addition, hnRNP H was up-
regulated in cells exposed to both low and high concentrations of GEN (+1.48 and 
1.58-fold). The hnRNP H has been shown to modulate the expression of several 
genes in a tissue-specific fashion [75], Interestingly, hnRNP H was shown to be up-
regulated by GEN in leukemia HL-60 cells in a proteomics study [76]. Another 
proteomics study [77] showed that hnRNP H was also up-regulated when human 
U937 cells were exposed to hydrogen peroxide. However, little is known about the 
functional significance of hnRNP isoforms in cardiomyocytes.  
 
A decrease in prohibitin expression was found when the cells were treated with 50 
µM GEN (-1.51 to -2.19-fold). Prohibitin is known to inhibit DNA synthesis and thus 
inhibit cell proliferation. Little is known about its role in differentiated cells; however, 
two recent studies revealed that it can suppress estrog n signaling [78] and androgen 
signaling [79]. Another protein involved with DNA synthesis/repair, the proliferating 
cell nuclear antigen (PCNA), was altered in cells treated with GEN. In contrast to 
previous reports of enhanced expression of PCNA by estrogen treatment [80], PCNA 






3.7. Cytoskeletal remodeling mobility/contractility 
The actin-related protein 2/3 (Arp2/3) complex is known to mediate the formation of 
branched actin networks. Arp2/3 subunit 5 was found to be up-regulated in 
cardiomyocytes exposed to 1 µM and 50 µM GEN (+1.51-fold and +2.27-fold). 
However, little is known about the exact role of this p16 subunit. Interestingly, tubulin 
beta-5, one subunit of cytoplasmic microtubules, was down-regulated by exposure to 
1 µM GEN. The actin thin filament binding protein, tropomyosin, regulates actin 
mechanics and muscle contraction. The low-level GEN treatment slightly increased 
the expression (+1.32-fold) of tropomyosin alpha chain, while a decrease in the 
amounts of both alpha and beta chain of tropomyosin was observed in the high-
concentration GEN treatment (-1.61 and -1.48-fold). Several isoforms of contractile 
protein myosins such as myosin light chain 2, 6, and heavy chain 6 were all up-
regulated (+1.79, +1.39, and +6.47-fold, respectively) in the 50-µM GEN treatment, 
although myosin light chain 4 was down-regulated (-2.18-fold). Contractility 
modulator calponin-3 was also down-regulated by 50 µM GEN (-1.47-fold). Calponin 
has been shown to inhibit Mg2+ ATPase activity in a reconstituted actomyosin system, 
thereby inhibiting the unloaded shortening velocity [81]. Based on these findings, 
exposure to GEN at the 50 µM level may have an important effect on the cell 
morphology and contractility of cardiac myocytes. 
 
3.8. Protein phosphorylation and cellular signaling 





that GEN may affect the phosphoproteome via another m chanism. A significant 
change in the level of low molecular weight phosphotyrosine protein phosphatase was 
observed in cells exposed to GEN at both concentrations (+2.14 and +2.34-fold). This 
phosphatase can non-specifically hydrolyze the phosr group from phosphor-
tyrosine residues. This evidence further supports the conclusion that GEN can 
suppress the cellular signaling via tyrosine phosphrylation.  
 
Another signaling protein, the growth factor receptor-bound protein 2 (Grb2) was 
down-regulated (-2.59-fold) in the 50-µM GEN treatment. Grb2 contains one SH2 
domain, which recognizes and binds to the phosphorylated tyrosine motif of multiple 
signaling partners [82]. This suggests that the high level of GEN treatment may block 
the Grb2-related signaling.  
 
4. Concluding Remarks 
Genistein has been suggested to protect cardiomyocytes against adverse stress in 
recent years. Although GEN is a well-known estrogenic component and a tyrosine 
kinase inhibitor, our understanding of the complex c llular and molecular impact of 
GEN on cardiomyocytes is still incomplete. In this study, a global expression analysis 
using 2DE-based proteomics revealed the molecular impact of GEN in HL-1 
cardiomyocytes on a concentrations dependent fashion. The use of two-stage 
hydrophilic and hydrophobic protein extraction significantly improves the coverage 





proteins in response to low and high concentrations f GEN were identified, 
respectively. The protein expression profile suggests that exposure to 1 µM GEN 
enhances expression of heat shock proteins and anti-apoptotic proteins. At 50 µM, 
GEN down-regulates glycolytic proteins and antioxidant enzymes and potentially 
makes cardiomyocytes more susceptible to energy depletion and apoptosis. 
Significant expression changes in cytoskeletal protein machinery were also observed 
with the 50 µM-GEN treated cardiomyocytes. Moreover, MetaCore GOanalysis 
suggests that GEN at low concentration significantly influences the anti-apoptosis 
process and both low- and high- concentration of GEN treatment have significant 
impact on glucose catabolic process and regulation of ATPase activity. Pathways 
analysis shown cytoskeleton remodeling and hypoxia induced Akt-HIF1 activation 
was represented by proteins responding to both low-and high- concentration GEN 
treatments. Enzymes of the glycolysis and gluconeogenesis pathway were also 
enriched following the high concentration GEN treatment. Although proteomics 
discoveries require further validation works, we hope this study serves as a valuable 















Figure 3.1.  Representative 2DE map of hydrophilic (A) and hydrophobic (B) protein extracts from HL-1 
cardiomyocytes. Three-hundred µg (hydrophilic fraction) or 200 µg (hydrophobic fraction) were 
separated in a pH 4-7 IPG strip as the first dimension and SDS-PAGE gels (13.5% acrylamide) in the 
second dimension. Gels were visualized by silver nitrate staining. From the analysis with the Delta 2D 
software, approximately 1500 spots and 800 spots were d tected from the gels with the hydrophilic and 
hydrophobic fractions, respectively. From these 2,300 spots, 39 and 99 spots (labeled) were differentially 
expressed (p<0.05) in cells treated with low (1 µM) and high (50 µM) concentrations of GEN compared 








Figure 3.2.  Proteomic patterns with spots from hydrophobic and hydrophilic fractions merged 
together. A/B. Volcano plots of the entire set of spot  quantified during 2DE image analysis 
comparing Gen 1 vs Con and Gen 50 vs Con. Each point represents the fold-change in log2 
scale between Gen treated group vs control group plotted against the level of statistical 
significance in log10 scale. Solid lines represent the significance threshold of p < 0.05 
(Student's t-test). Spots above this line were considered as differentially expressed. C. Heat 
map representation of clustering analysis. Experimental samples are clustered on the horizontal 
axis and protein spots on the vertical axis with a rel tive color scale ranging from -0.75 (green) 
to +0.75 (red). Compared to control group, Gen 1 and Gen 50 shown distinctive global 
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Figure 3.3.  High-scored biological processes in 1 µM GEN treated (A) and 50 µM GEN treated (B) 













Figure 3.4.   Biological network analysis of proteins differentially expressed response to 1µM (A) and 
50 µM (B) GEN treatment using the Build Network tool provided by MetaCore. The network was 
generated using Dijkstra's shortest path algorithm o find the shortest directed interactions between 
proteins, with maximum of 2 intermediate steps. All connections were curated by MetaCore database. 
Network legend (C): Nodes represent proteins or compounds, lines between nodes indicate molecular 
interaction. For each interaction, the biological consequences, either activation or inhibition, were 
indicated by red or green color. Gray line means interaction with unspecified effect. Experimentally 
identified proteins that are modulated by GEN are denoted by a circle around the nodes. Both 






Table 3.1. Differentially altered proteins identified in 1µM and 50 µM GEN treated cardiomyocytes 
were grouped for GeneGO MetaCore pathway analysis. A hypergeometric distribution probability test 
was carried out to decide if the experimentally identified proteins (objects) were involved with a 
particular biological pathway in the GeneGO MetaCore database. The p-value represents the odds of 
having a given pre-built network be associated with the list of experimentally- identified proteins 
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 CHAPTER 4 
QUANTITATIVE PROTEOMIC PROFILING OF ESTROGEN RECEPTOR-
DEPENDENT/INDEPENDENT TARGETS OF GENISTEIN USING ISOBARIC 
TAGS 
1. Introduction 
Hormone replacement therapy or HRT has been adopted to lower the incidence of 
cardiovascular disease (CVD) among other benefits for postmenopausal women [1-4]. 
However, HRT is also controversial due to potential adverse effects such as increasing 
risk in breast cancer [5, 6]. Therefore, phytoestrogen-based approaches have been 
advocated as a potential alternative to HRT [7-9]. Such speculation was further 
augmented by epidemiological evidence that the intake of phytoestrogens, in 
particular the soy-derived isoflavone genistein (GEN), decreased CVD risk [10-14]. 
The phytoestrogens or isoflavones is a group of compounds bearing weak estrogenic 
effects as well as anti-cancer properties. Among the bioactive compounds present in 
soy products, GEN is the most abundant phytoestrogen. S veral laboratory studies 
have suggested that GEN can provide direct protectin to against damaging stresses 
in cardiac myocytes (CM) [15-20].  
 
The estrogenic attributes of GEN have been emphasized as the main explanation for 
its cardioprotective role. Genistein at physiological relevant concentrations (1-10 µM) 





little is known on which group of proteins or pathways are the downstream effectors 
of GEN via ER-dependent mechanism and whether those prot ins are related to the 
cardioprotective role of GEN.  
 
It is also noteworthy that GEN at concentrations greater than 10 µM can also trigger 
ER-independent effects, in particular non-specific nhibition of protein tyrosine 
kinases (PTK). The PTK inhibitory effects of GEN have primarily been explored as 
experimental methodology to block key PTK activation that mediate the 
cardioprotection signaling triggered by ischemic preconditioning procedure [24-28]. 
Therefore, it is possible that ER-independent PTK inhibition contributes to the 
biological effects of GEN provide cardioprotection in a dose-dependent biphasic 
fashion as high-dose GEN is detrimental to CM survival.  
 
Here we introduce a high throughput quantitative shotgun proteomic approach based 
on isobaric tag multiplexing technology (iTRAQ) to identify molecular end effectors 
of GEN co-incubated with or without ER antagonist ICI 182,780 on primary cardiac 
myocytes isolated from adult male SD rat. Using this approach, 509 unique proteins 
were identified using a consensus/iterative database searching strategy. By contrasting 
the proteome alteration in these two conditions relative to the control samples, we 
identify cellular function changes by ER-dependent or ER-independent action of 







2. Materials and Methods 
2.1. Isolation of rat primary cardiomyocytes  
All laboratory animal protocols were approved by the CSU Institutional Animal Care 
and Use Committee in accordance with the National Istitutes of Health Guide for the 
Care and Use of Laboratory Animals. Primary cardiomyocytes were isolated from 
male Sprague-Dawley rats weighing 300-350 g (n=4). Hearts were surgically 
removed according to the protocol described previously (Hamilton, Gupta, Knowlton, 
JMCC, 2004). Excised hearts were subject to retrograde-perfusion of Joklik solution 
(Sigma, MO) containing 0.8 mg/mL type II collagenase (Worthington Biochemical, 
NJ). Following tissue digestion, the cell suspensio was filtered and pelleted in a 
solution containing 10% bovine serum albumin (BSA, igma, MO), 111 mM NaCl, 
5mM KCl, 10 mM NaH2PO4, 1 mM MgSO4, 50 uM CaCl2, 5mM HEPES, 60 mM 
taurine and 20 mM creatine. The pellet was then resuspended in Joklik solution with 
6% BSA and CaCl2 was gradually reintroduced to final concentration of 1 mM. After 
incubation with CaCl2 for 20 mins, cells were collected by centrifugation (~300 rpm 
for 3 min) and resuspended in M119 medium supplemented with 10% fetal bovine 
serum (Sigma, MO), 10 mM butanedione monoxime (Sigma, MO), 2 mM glutamine 
(Invitrogen, CA), 100 U penicillin and 100 mg/ml streptomycin (Invitrogen, CA). 
Cells were then plated on 0.01% laminin-coated dishes followed by incubation at 






2.2. Treatment protocols 
Myocytes from each animal were divided into 3 separate groups for treatments. 
Treatment experiments were performed by replenishing cells with fresh supplemented 
M119 medium containing 10 µM genistein without (GEN) or with 10 µM ICI 
182,780, a full estrogen receptor antagonist (GEN+ERA). Control (CON) cells were 
treated with DMSO vehicle only. Myocytes were then incubated in at 37°C with 
5%CO2 for 12 hrs.  
 
2.3. Protein extraction 
Following treatments, cells were gently washed by 5 mL PBS twice each for 10 sec. 
Lysis solution (1 ml) containing 10 mM Tris-HCL (pH 8.0), 7 M urea, 2 M thiourea, 
1X protease inhibitor cocktail (Sigma, MO), 5 mM magnesium acetate and 1% 
CHAPS were then directly applied to the cells for quick protein extraction. Protein 
solutions were then collected in falcon tubes subjected to ultrasonication for 5 min in 
ice bath. Protein samples were centrifuged at 17 000 x g for 15 min and the 
supernatant was collected. Total protein concentration for each sample was 
determined using the RC-DC protein assay kit (Bio-Rad, Hercules, CA, USA) 
according to manufacturer’s instruction. Bovine serum albumin (Sigma) was used as 
protein assay standard.  
 
2.4. iTRAQ multiplexing and HILIC separation  
One-hundred microgram of protein from each sample was directly reduced by 10 mM 





min in dark. Alkylation was quenched by adding dithio reitol to final concentration 
of 20 mM. Protein was then precipitated by 2DE Ready Prep clean up kits (Bio-Rad) 
according to manufacturer’s protocol. The resulting protein pellet was reconstituted 
by 20 µL 50 mM triethyl ammonium bicarbonate supplemented by 4 µL 1% 
ProteaseMAX. Once the pellets was dissolved completely by votexing, 110 µl 50 mM 
triethyl ammonium bicarbonate and 5 µg trypsin (Promega) was added to the sample. 
Digestion was carried out in 37 ºC for 5h and stopped by adding 10 µL 10% 
trifluoroacetic acid. Tryptic peptides were cleaned up by 200 mg C18 Sep-Pak SPE 
column (Waters) and then dried by Speed Vac (Thermo Electron). Peptides were then 
resuspended by 20 µL iTRAQ dissolution buffer (0.5 M triethyl ammonium 
bicarbonate) and labeled according to manufacturer’s protocol (Applied Biosystems). 
Two separate 8plex iTRAQ sets were used to accommodate samples from 4 
biological replicates each with 3 treatments using the design summarized in Fig 4.1. 
Briefly, all treatments from rat 1 and 3 were arranged in the run A and all samples 
from rat 2 and 4 were arranged in the run B with randomized order within each run. 
Two common channels (113 and 119) were used in eachrun as run-to-run referent 
channel. Referent sample was constructed by pooling CON and GEN samples from 
rat 1 and 4. Following 2 h incubation with iTRAQ tags, all samples within each run 
were then pooled and concentrated by Speed Vac to approximately 30 µL. Samples 
were then diluted by 30 µL 100 mM ammonium formate at pH3 and then 340 µL of 
acetonitrile (ACN) added incrementally with votexing. For peptide fractionation, 4 
injections each with 100 µL of 8-plexed sample was injected into a 





separation under hydrophilic interaction chromatography (HILIC) mode with flow 
rate at 0.5 mL/min. The peptides were resolved by agradient first maintained at 100% 
buffer B (85% ACN, 15 mM ammonium formate, pH 3) for 5 min and then to 10% 
buffer A (15 mM ammonium formate, pH 3) in 2 min, then 40% A in 48 min and to 
100 % A in 3 min and holding at 100% A for 1 min, ad finishing up by ramp back to 
100% B in 2 min. Fractions were collected every 2 min for the middle 48 min 
separation period and the starting and stripping eluents were pooled to the final 
fraction. All fractions were dried and re-dissolved in 10 µL of 3% ACN, 0.1% formic 
acid before LC-MS/MS analysis. 
 
2.5. Protein identification by ESI-Q-TOF MS/MS  
Each HILIC fraction was injected in triplicates ont he G4240-62010 LC-chip 
(Agilent) hyphenated with a 6150 hybrid ESI-Q-TOF (Agilent). Nano-LC was 
performed with a 43 min gradient flowing at 500 nL/min starting with 97% solvent A 
(0.1% formic acid) and 3% solvent B (0.1% formic acid in 90% ACN) to 25% B over 
2 min, from 25 to 30% B over the next 13 min, and to 40% B over 21 min, and to 
100% B over the next 3 min and maintained for 1 min, and finishing up by drop back 
to 0%. Mass spectrometric analysis was performed on under the positive mode with 
nanoelectrospray generated at 2.1 kV. The m/z response of the instrument was 
calibrated regularly with standards from manufacturer. Precursor scan and product ion 
spectra were acquired in centroid mode using data dependent data acquisition in 
MassHunter (Agilent) with the following parameters: mass ranges for MS and 





spectrum was scanned, followed by maximum five product ion spectra. The switching 
from TOF-MS to MS/MS is triggered by precursors with ion intensity >1000 counts 
with dynamic exclusion for 30 sec. The collision energy was set with 5 V/100 Da 
slope offset with 2.5 V.  
 
2.6. Spectrum analysis and iTRAQ quantification  
The data analysis workflow combined consensus-iterat v  search strategy with 
iTRAQ quantitation is summarized in Fig 4.2. Briefly, peak lists in mgf format were 
generated from raw .d files by Mascot Distiller 2.3.  (Matrix Science) for peak 
deisotope and charge state determination. Peak lists were then submit to Mascot v2.3 
(Matrix Science) at local server in CSU and X!Tandem Cyclone v 2010.06.01.6 for 
consensus search against a target-reverse concatenated I ternational Protein Index 
(IPI, European Bioinformatics Institute, http://www.ebi.ac.uk/IPI) rat protein database 
(v3.70, 79158 sequences). The search parameters were set to allow for up to two 
missed cleavages, carboxyamidomethylation on cysteine, iTRAQ 8plex tag on N-
terminus and lysine as fixed modifications, oxidation on methionine, iTRAQ 8plex 
tag on tyrosine as variable modifications, a MS mass tolerance of 100 ppm and 
MS/MS mass tolerance of 0.05 Da on monoisotopic mode. No iTRAQ quantitation 
was carried out in this searching step. All identifications from Mascot and X!Tandem 
were compiled by Scaffold v3.00.03 (Proteome Software, OR) for peptide and protein 
identification probability calculation [29]. All spectra with good quality but fail to 
pass a preliminary probability filter with 90% peptide probability and 20% protein 





conducted by Mascot and X!Tandem adding more dynamic parameters: three missed 
cleavages, deamidation on asparagine and glutamine, ethylation on aspartic acid 
and glutamic acid as variable modifications, a wider MS mass tolerance of 300 ppm. 
In X!Tandem iterative search, additional variable modifications such as acetylation on 
lysine, oxidation on tryptophan, dioxidation on methionine and tryptophan were also 
included. Iterative search results were then merged with previous search results using 
Scaffold and peptide and protein probability was recalculated. Finally consensus-
iterative search results from both run A and B were merged in Scaffold. Using the 
same filter, an excel spectrum report consist of good peptide identification results 
were exported. Scan with ambiguous/multiple protein hits was excluded. Proteins 
with only one peptide hit across both run A and B were discarded from the sequential 
quantitative analysis. Following the scan filtering, false discover rate (FDR) was 
calculated dividing the number of false hits by thenumber of all hits as summarized 
by table 4.1: 
All target hits = all hits above the filtering criteria 
False positives (FP) = Decoy hits 
True positives (TP) = All target hits - FP 
FDR = FP/(FP+TP) 
 
An in-house Fortran 90 script was written to extract raw iTRAQ intensity from the 
original mgf peak list. Briefly, the script searches for peak iTRAQ 8plex tag peaks 
(113.1, 114.1, 115.1, 116.1, 117.1, 118.1, 119.1, 12 .1) within each MS/MS scan with 





mass ± 0.02 Da mass window or m/z shows the minimum mass shift from the tags. 
Once the tag peaks are detected and the tag intensities are extracted from a MS/MS 
scan, the script will add 8plex intensities to corresponding scan in the spectrum report 
by matching the unique scan ID from the mgf. Quantit tive analysis was done in 
Excel according the following steps: relative tag intensity was generated by 
normalizing the tag raw intensity to the reference channel in each spectrum; relative 
intensities in the form of 11x/reference ratio in log2 scale were normalized again by 
force the medium value to 0; log2(11x/reference) from all scans that belongs to the 
same protein ID were averaged to generate relative protein intensity in log2 scale 
within each run; log2(protein intensity) for all 3 treatments from both run A and B 
was then used in a paired t-test to select protein ID with significant (p < 0.05) changes.  
 
2.7. Pathway analysis 
To identify the potential biological significance of the quantitative proteomics results, 
lists of differentially expressed proteins as the results of ER-dependent and –
independent action of GEN were analyzed by Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems, Inc.). The IPA database was constructed by abstracting, 
interconnecting information on functions of gene/protein/compound, interaction of 
biological molecules, and disease inter-relationship  from a large fraction of 
biomedical literature covering various species including rodents. Once the list of 
GEN altered proteins via ER-dependent and –independent action were uploaded to 





its proprietary database. A p-value was computed based on the hypergeometric 
distribution probability test. The p-value represents the odds of having a given pre-
built pathways be associated with the list of experim ntally- identified proteins 
simply by chance. The p-value is calculated using the formula: 
where N is the total number of nodes, i.e. all rat genes in this case, in IPA database, R 
is the number of network objects corresponding to the list of differentially expressed 
proteins identified from the experiment, n is the total number of nodes in each small 
network that associate with the list, r is the number of proteins from the experimental 
data that associate with each small network generated from the list.  
 
3. Results  
3.1. Protein identification  
Before combining the results, Mascot and X!Tandem analyses identified 365 and 521 
peptides, respectively, with 321 common protein IDs (data not shown). When 
compiling the peptide IDs from both search results sing Scaffold, single peptide hits 
from either search engine get chance to pair up with single peptide hits from the other 
search engine which add 16 marginal gains on protein IDs. The iterative search by 
both engines with loose search parameter gave 110 additional protein identifications. 
To this point, the consensus-iterative search strategy has shown superior sensitivity to 





which 89.3% and 32.6% more protein IDs than using Mascot and X!Tandem alone 
(Fig 4.3A). It is a known issue that consensus search may introduce high error rate as 
the total decoy hits are very likely the sum of those from each individual search 
algorithms [30]. In order to effectively estimate the combined FDR for this 
consensus-iterative search protocol, we constructed a target-reverse concatenated 
protein database so that each search engine can search the same decoy database to 
pool all false hits by the end. Under the current identification criteria, this searching 
protocol provided overall excellent accuracy that the final FDR of run A and B were 
1.43% and 2.26%, respectively, as summarized by table 4.2. At this point, 568 and 
632 unique protein identification were generated from run A and B, from which 509 
common IDs were selected for iTRAQ quantitation (Fig 4.3B). 
 
3.2. iTRAQ quantitation 
Raw iTRAQ label intensities were extracted directly from the spectra for all 509 
proteins. An example of MS/MS spectrum with iTRAQ report ion regions was given 
in Fig 4.4. All spectrum been used in the quantitation of those proteins were 
summarized in Appendix IV. Overall, label intensities shown consistency between all 
channels across two iTRAQ runs as shown by Fig 4.5A. Instrumental variance 
between run A and B was corrected by normalizing the intensity of each channel 
(11X) against the referent 119 channel in run A and 113 channel in run B. The 
relative intensity of all channels has shown no data skewing towards over-expression 
or under-expression in meeting the assumption that the majority of proteins remain 





of log2 relative intensity to be 0 as shown in Fig 4.5B. An average log2 relative 
intensity of all spectra was used for protein quantit tion. Poor dynamic range of 
iTRAQ quantitation was reported, and concern has been raised that iTRAQ 
quantitation may underestimate the true biological variance between samples [31, 32]. 
In this experiment, the abundance differences of majority of 509 proteins between 
any groups fell within ±2 fold-change window (Fig 4.6) including those been deemed 
as significantly changed proteins. Using pair wised t-test, 14 and 15 proteins was 
found differentially expressed in GEN and GEN+ERA trea ed groups, respectively, 
compare to the vehicle group. For those differentially expressed proteins, we also 
performed the pair wised t-test between GEN and GEN+ERA treated group to further 
evaluate if the protein expression alteration is solely triggered by ER -dependent or –
independent mechanism. Additionally, expression pattern was analyzed to further 
divide GEN responsive gene into 5 groups: 
• ER-dependent only 
Protein expression changes in the GEN treated group but such change was 
completely abolished in the ERA+GEN treated group; comparing to the 
ERA+GEN group, the GEN treated group shown change with the same 
magnitude as comparing to the control group.  
• ER-dependent, possibly with ER-independent in synergism 
Protein expression changes in the GEN treated group but such change was 
abolished in the ERA+GEN treated group; however, statistical analysis shown 
no significant difference between ERA+GEN and GEN treated groups. 





GEN and GEN+ERA cause changes with same direction and s me magnitude. 
• ER-independent and ER-dependent in antagonism 
GEN alone result in no chances, but the addition of ERA cause changes; 
comparing to the GEN group, the GEN+ERA treated group shown change 
with the same magnitude as comparing to control group.   
• ER-independent, possibly with ER-dependent in antagonism 
GEN alone result in no chances, but the addition of ERA cause changes; 
however, statistical analysis shown no significant difference between 
ERA+GEN and GEN treated groups. 
 
For each protein identification, protein name, IPI D, molecular weight, number of 
unique peptide and number of spectrum used for quantitation, associated biological 
function GO terms and the fold-changes of GEN, GEN+RA versus control, together 
with the fold-changes of GEN versus GEN treated group were summarized in 
Appendix V. MS/MS spectra and identification details for each spot can be found in 
supporting information.  
 
The IPA pathway analysis reports 5 top canonical pathw ys that were significantly 
associated with the gene differentially changes by GEN via ER-dependent and –
independent mechanisms as summarized by table 4.3. Interesting, both groups of 
genes hit glucose and fatty acid metabolism as the most significantly relevant IPA 





4. Discussion  
4.1. A novel proteomic workflow using consensus-iterative searching strategy 
with iTRAQ quantitation 
In this study, we developed a shotgun proteomics baed on HILIC-RP 2DLC 
separation coupled with high resolution Q-tof MS/MS and iTRAQ multiplexing 
technology to quantify protein expression changes in primary rat CM. By 
constructing a reference sample to be used in the common normalization channel in 
each iTRAQ experiment, this protocol can be extended to accommodate more 
samples into multiple parallel iTRAQ experiments for meta-analysis. The use of 
HILIC separation for peptide fractionation has been advocated for its high 
orthogonality to reverse-phase LC and higher separation resolution compare to ion-
exchange based LC [33]. However, very few studies have tested the applicability of 
HILIC separation for iTRAQ-labeled peptides. Peptides with iTRAQ tags are 
generally more hydrophobic than their underivatized p ptide counterparts especially 
with 8plex iTRAQ tags. Therefore, the HILIC gradient start with 85% ACN and the 
majority of iTRAQ-tagged peptides were separated in a long 85%-50% ACN gradient 
over 55min to ensure thorough fractionation. Ammonium formate instead of 
trifluoroacetic acid was used to prevent making peptid s more hydrophobic and 
enhance peptide retention in the HILIC column. Therefore, peptides were identified 
from all middle 23 fractions (data not shown) suggesting a thorough separation using 
the current HILIC protocol.     
 





maximize the identification sensitivity for better p oteome coverage [34, 35]. The 
number of peptide-spectrum matches (PSM) using Mascot alone was 37274 and 
38760 run A and B, respectively, while using or X!tandem alone gave 57112 and 
58343 PSMs in run A and B. When using consensus-iterativ  search strategy, total 
number of PSMs was 60741 and 63443 in run A and B respectively. The additional 
PSMs enhance the sensitivity by adding more low abundant protein IDs as most of 
them are based on 2 unique peptides with low number of PSM. However, there has no 
direct application of consensus search strategy with protein quantitation such as 
iTRAQ. This is largely due to the fact that different search engines may or may not 
support iTRAQ data, even they do, they used different data process routine for 
iTRAQ quantitation. Thus, in our consensus searching procedure, a stand-alone 
Fortran 90 script was introduced to circumvent the problem by directly extract the 
iTRAQ report ion intensities from the raw MS/MS spectra and combine them to the 
final identification report. Moreover, this procedure generates no negative value as in 
the case of iTRAQ quantitation in Mascot and also gives the user full control of the 
downstream data analysis.  
 
Despite the improved sensitivity and overall large number of PSMs assigned, the 
number of unique peptide and protein IDs from both run A and B are lower than we 
expected. This is probably due to the presence of high abundance proteins from the 
myocytes. Peptides from cytoskeleton and myofibril proteins occupied a large portion 
of the assigned PSMs. For example myosin-6 alone gerates 9578 and 8589 PSMs in 





and B were assigned by 18.58% and 15.17% of total spectra while PSMs from all 
protein IDs from run A and B occupied 44.99% and 43.33% of total spectra, 
respectively.  
 
4.2. ER-dependent proteome alteration 
The estrogenic properties of GEN have been postulated s a contributing factor for its 
cardioprotective role. However, which end effectors a e targeted by GEN in an ER-
dependent fashion is still poorly understood. Here we report two glycolysis proteins 
the fructose-biphosphate aldolase A and α-enolase were up-regulated in GEN treated 
group but not in the GEN+ERA treated group, possibly resulted as the ER-dependent 
effects of GEN. It is long being known that heart depends on glycolysis for energy 
production to survival under ischemic conditions, thus enhanced glycolysis provides 
critical cytoprotection for CM against ischemic-reperfusion insults [36, 37]. Therefore, 
the argument of glucose metabolism by estrogen treatment has been contribute to the 
direct cardioprotective efficacy of estrogen [38]. This evidence strongly support that 
the cardioprotective effects of GEN, particularly in the ischemic heart, may also be 
partly attributed to the ER-dependent up-regulation of glucose metabolism.  
 
We also found that two mitochondrial membrane proteins involved in fatty acid 
metabolism were affected by GEN. The translocation of fatty acyl-CoA across the 
mitochondrial membrane for β-oxidation requires its conjugation with carnitine. 
Carnitine palmitoyltransferase 2 (Carnitine O-palmitoyltransferase2, mitochondrial, 





regulated by 1.08 fold. In contrast, mitochondrial c rnitine/acylarnitine carrier protein 
(carnitine/acylcarnitine translocase, solute carrier family 25 member 20, Slc25a20) 
which transport acylcarnitine across the membrane into mitochondria and shuttle 
carnitine back to cytosol was down-regulated 1.21 fold by GEN treatment. Notably, it 
is well documented that transcription of fatty acid metabolism related genes like Cpt2 
and Slc25a20 can be activated by peroxisome prolifeator-activated receptors α
(PPARα) [39-42]. Further, genistein and other isoflavones have been shown to 
activate PPARs in bone cells [43] and macrophages [44]. It has been suggested that 
the activation of PPARs contributes to the antiestrogenic effects of GEN [45]. Given 
that fact that estrogen generally promotes glycolysis while activation of PPARs 
generally promote fatty acid metabolism and inhibit the glucose metabolism, the non-
uniform expression patterns of energy metabolism genes after GEN treatment shown 
in our data lead us to speculate that GEN triggers the concurrent modulation of 
energy utilization in rat CM via both PPARα and ER-dependent pathways.  
 
In addition to proteins involved in energy metabolism, we also found two proteins 
that may relate to cardioprotection were modulated by GEN in an ER-dependent 
fashion. Soluble epoxide hydrolase (sEH) was down-regulated by GEN without ERA 
co-incubation. Soluble epoxide hydrolase metabolizes the cardioprotective 
epoxyeicosatrienoic acids (EET) which derived from endogenous arachidonic acid by 
cytochrome P450 [46, 47]. Deficiency of sEH and pharmacological inhibition of sEH 
elicit cardiac resistance to ischemia via EET-mediat  STAT3 signaling in vitro and in 





novel target of GEN for cardioprotection. However, another protein T-complex 
protein 1 (TCP-1) subunit delta was significantly down-regulation in the GEN treated 
group. The TCP-1 is one of the eight subunits forming cytosolic chaperone 
heterooligomeric complex and specifically involves with actin and tubulin 
polymerization, which suggest its importance for the maintenance of cytoskeleton 
integrity.   
 
4.3. ER-independent genes 
Our analysis of proteomic expression pattern also reveals a list of proteins that are 
regulated by GEN via ER-independent routes. However, some proteins were also 
regulated by GEN treatment alone indicating the coexist nce of both ER-dependent 
and ER-independent effects of GEN.  
 
Genistein has been reported to modulate steroidogenesis in both an inhibitory [50, 51] 
and stimulatory [52] fashion. Genistein is known to inhibit the activity of aromatase 
[53], which converts androgens to estrogens [54, 55]. Additionally, GEN was reported 
to inhibit the expression of hydroxysteroid dehydrogenases (HSDs) which convert 
estradiol to the less active estrone. Impairment of HSD gene expression has been 
reported as the result GEN treatment in porcine granulosa cells [56, 57]. Our data 
show a 1.05-fold decrease in 3-hydroxyacyl-CoA dehyrogenase type-2 (or 17-beta-
hydroxysteroid dehydrogenase 10, HSD10) by GEN in the presence of ERA, 
suggesting an ER-independent mechanism. Interestingly, PTK inhibition has been 





hypothesize that the inhibition of HSD10 by GEN may result from the PTK inhibitory 
property of GEN. Moreover, our data suggest there are also ER-dependent effects that 
abolished the down-regulation of HSD 10 when CM are treated with GEN alone, 
suggesting GEN may trigger an ER-dependent action that antagonizes TK inhibitory 
action. Although the implication of these changes in steroidogenesis in CM is still 
unknown, but these data shed light on the complexity GEN induced changes in 
steroid metabolism.  
 
Consistent with the notion that GEN may impact cell signaling in ways similar to 
estrogen but independent of ER binding, we found GEN down-regulated the estrogen 
signaling protein, MACRO domain-containing protein 1 (or leukemia related protein 
16, LRP16). LRP16 has been shown to positively regulate estrogen signaling in 
cancer cells promoting cell growth [58]. Here we report an approximate 1.5 fold 
decrease in LRP16 with GEN regardless of whether an ER antagonist was present 
suggesting that the down-regulation of LRP16 in CM by GEN is via an ER 
independent mechanism. Interestingly, up-regulation of LRP16 by 17beta-estradiol 
through activation of estrogen receptors was reportd in human cancer cell lines [58-
60] and LRP16 has been shown take a role in a positive-feedback regulatory loop for 
estrogen signaling resulting in invasive growth of cancer cell [58]. Therefore, our 
results suggest LRP16 is a potential novel target for GEN to exert biological activity 
with importance in both CM and cancer cells.  
 





regulate protein folding and apoptosis pathways [61]. However, we report that heat 
shock protein 75 kDa (HSP75, HSP90L, Tumor necrosis factor type 1 receptor-
associated protein, TNFR-associated protein 1, TRAP1) was down-regulated by 
GEN+ERA but not by GEN alone. HSP90 class has been shown to be inducible by 
heat and I/R insults [62]. This group of chaperones specifically bind to steroid 
receptor complexes such as estrogen, androgen and progesterone receptors and 
function as negative regulators of their activity [63]. HSP90 overexpression was 
shown to afford cytoprotection against heat shock in H9c2 cultured CM [64] and rat 
primary CM [65] and against ischemic shock in mice heart [66]. HSP75 or TRAP1 is 
a HSP90 isoform that only found in mitochondria. Xiang et al reported that TRAP1 
plays a role in maintaining mitochondrial function a d preventing CM apoptosis by 
reducing the mitochondrial permeability during hypoxia [67]. Masuda et al also 
suggested that ROS can down-regulated of TRAP1 leading to apoptosis by releasing 
cytochrome c from mitochondria [68]. Interestingly, HSP90 was documented as an 
estrogen-responsive protein that can be up-regulated by estrogen in ovarian cancer 
cell line [69]. Considering our finding that GEN down-regulated the HSP90 ER-
independently while GEN alone did not affect the expr ssion level, we suspect that 
there might be a counteracting ER-dependent action of GEN to up-regulate the 
HSP90 in CM. However, the biological significance of TRAP1 down-regulation by 






5. Concluding Remarks  
Genistein and soy isoflavones have been suggested to provide direct protection for 
CM and have been advocated as an alternative HRT agent in replacement of 
conventional estrogen. However, the molecular impact of GEN is multifaceted and 
may be mediated by activation of ERs and/or other molecular targets concurrently. In 
this study, a high throughput shotgun proteomic investigation coupled with iTRAQ 
quantitation and advanced bioinformatic tools were applied to dissect the ER-
dependent and -independent effects of GEN treatment on CM. The use of a 
consensus-iterative searching strategy increased the sensitivity for protein 
identification with a total 691 protein IDs from two parallel iTRAQ experiments. A 
house-written Fortran 90 script was employed to facilit te the iTRAQ quantitation in 
this consensus-iterative searching protocol. As the result, 14 and 15 proteins were 
found differentially expressed from a total of 509 proteins quantified comparing GEN, 
and GEN+ERA treated CM to untreated controls. In those genes regulated by GEN in 
an ER-dependent manner, we found glycolysis proteins were up-regulated by GEN. 
Together with the modulation of mitochondrial fatty acid transportation related 
proteins, our proteomics data provide critical evidnce shown that the GEN may have 
complex influence on the myocardial energy metabolism. Additionally, we found the 
soluble epoxide hydrolase (sEH) was down-regulated indicating a novel target of 
GEN for the cardioprotection. From those gene regulated by GEN potential 
independent from ER binding, we discovered novel molecular targets in 
steroidogenesis and estrogen signaling pathways that were down-regulated by GEN. 





interpretation of the proteomics data collected andhelped develop an approach to 
recognize or predict the major pathways affected by GEN treatment. According to 
IPA analysis, GEN appears to exert a crucial role on glucose and fatty acid 
metabolism in both ER-dependent and –independent manner. Although the 
proteomics discovery and resulting hypothesis will require validation and test by 
further studies, but we hope they serve as an important step stone to the 






Fig 4.1, Overall iTRAQ LC-MS/MS experiment design. Two separate 8plex iTRAQ sets were used 
to accommodate samples from 4 biological replicates each with 3 treatments. In each run, pooled 
iTRAQ-tagged peptides will be fractionated by HILIC into 25 fractions, which will be further 












Fig 4.2 Overview of consensus-iterative search strategy. The Scaffold was used for compiling search 
results from Mascot and X!tandem against a target-reverse concatenated IPI rat database. Scaffold was 
also used to export good quality spectrum with no matches for iterative search which is later combined 
with previous search results. A Fortran 90 script was ritten to extract iTRAQ raw intensity directly from 
















Fig 4.3, Summary of protein identification via the consensus-iterative search strategy. Using 90% peptide 
probability and 20% protein probability and at least 2 peptides IDs across 2 iTRAQ runs as the criteria for 
identification, Fig 4.3A shown that totally 691 protein IDs was detected after consensus-iterative search 
strategy from the targeted database, while Mascot and X!Tandem alone gave 365 and 521 IDs, 
respectively. Fig 4.3B shown that iTRAQ run A and B results in 568 and 632 unique protein IDs 
respectively. We choose to do iTRAQ quantitation on the 509 common IDs from both runs for reliable 

































Fig 4.4 Example MS/MS spectra from a mitochondrial c rnitine/acylcarnitine carrier protein that down-
regulated by GEN treatment. Both spectra from run A and B shown consistent fragmentation pattern which 
gives the same peptides ID with same series of y and b ions. Close-in view of the iTRAQ report ion region 











Fig 4.5, Summary of iTRAQ raw data directly extracted from raw MS/MS spectrum. Instrumental 
variance between run A and B was corrected by normalizing the intensity of each channel against the 
reference channel. Fig 4.5A shown the relative intensi y of 11x/reference in both runs. The log2 relative 
intensity of all channels shown symmetric distributon around 0. Labeling variance was then corrected 
by forcing the medium value of log2 relative intensity to be 0 as shown in Fig 4.5B in assumption that









Fig. 4.6 Volcano plot of differential expressed proteins comparing GEN treated group (A) and 
GEN+ERA treated group (B) verses the control group. The horizontal axis represents the both up and 
down fold changes in log2 scale while the vertical axis measures the change significance according the 




















Table 4.2 Identification Statistics for consensus-iterative database searching strategy. The identification 
acceptance criteria were set to 90% peptide probability, 20% protein probability and at least 2 
independent observations of the same protein from either run A and B.  
  Run A Run B 
total protein ID 586 646 
Target protein ID 568 632 
Decoy protein ID 8 14 
FDR 1.43% 2.26% 
Unique peptide IDs 2478 2583 
Peptide-spectrum matches 60741 63443 
Total number of search queries 134508 146552 
spectrum identification rate 45% 43% 
Overall statistics for quantitation 
Protein detected by both runs 511 
Target ID in both runs 509 
Decoy ID in both runs 2 





Table 4.3. Differentially altered proteins by GEN via ER-dependent and –independent mechanisms in 
primary rat CM were grouped for GeneGO MetaCore pathw y analysis. A hypergeometric distribution 
probability test was carried out to decide if the experimentally identified proteins (objects) were 
involved with a particular biological pathway in the GeneGO MetaCore database. The p-value 
represents the odds of having a given pre-built network be associated with the list of experimentally- 
identified proteins simply by chance. 






Glycolysis/gluconeogenesis 134 3 1.97E-05 
Fatty Acid Metabolism 184 2 2.46E-03 
Inositol Metabolism 18 1 3.72E-03 
Phenylalanine, Tyrosine and 
Tryptophan Biosynthesis 
67 1 1.05E-02 






Glycolysis/gluconeogenesis 134 2 1.64E-03 
Fatty Acid Elongation in 
Mitochondria 
47 1 1.29E-02 
Citrate Cycle 57 1 1.96E-02 
Bile Acid Biosynthesis 106 1 3.63E-02 
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 CHAPTER 5 
QUANTITATIVE PERFORMANCE OF SEQUENTIAL IMMOBILIZED METAL 
AFFINITY CHROMATOGRAPHIC ENRICHMENT FOR PHOSPHOPEPTIDES 
 
1. Introduction 
Reversible phosphorylation of serine (Ser), threonine (Thr) and tyrosine (Tyr) residue is 
involved with the regulation of many critical biological processes and is a highly 
dynamic aspect of the proteome. In recent years, mass spectrometry based 
phosphoproteomics has emerged as a useful tool to survey the phosphorylation state of a 
complex protein mixture in a large-scale and high-throughput fashion. However, given 
the fact that most phosphoproteins are in low abundance with phosphorylation in low 
stoichiometry, enrichment technique(s) before MS analysis become a necessary step to 
separate phosphopeptides from a complex background s ch as a total cell lysate. 
Immobilized metal affinity chromatography (IMAC) based on ferric ions has long been 
used to capture phosphopeptides non-specifically [1]. Over the years, new IMAC 
chemistry based on various multivalent metal cations, such as gallium [2], zirconium [3], 
and titanium [4] has been introduced with varying selectivity and efficiency. Much 
attention has also been drawn to the use of metal oxide affinity chromatography (MOAC) 
for phosphopeptide enrichment due to its alleged higher recovery rate and selectivity 
compared to IMAC [5-14]. Numerous MOAC protocols based on different multivalent 





aluminum oxide (Al2O3) [17] have been widely adopted with promising enrichment 
efficiency. Interesting, it was reported recently that IMAC is less efficient for enrichment 
of mono-phosphorylated peptides than for multiple-phosphorylated species [18-20]. In 
contrast, MOAC was shown to be more efficient for capturing mono-phosphorylated 
peptides [21]. This is probably due to the fact that IMAC provides weaker affinity that 
mono-phosphorylated peptides may have poor retention on IMAC material while MOAC 
provides strong interaction that it become difficult to elute multiple-phosphorylated 
peptides. Therefore, Thingholm et al. introduced a novel sequential elution protocol from 
IMAC (SIMAC) that uses MOAC as the secondary enrichment step to capture mono-
phosphorylated peptides left out by IMAC enrichment [21]. The application of this 
SIMAC protocol on whole cell lysate from human mesenchymal stem cells provided 
more phosphopeptide identifications than using MOAC or IMAC alone [21].  
Despite the fact that IMAC- or MOAC-based protocols have been used in large-scale 
phosphoproteomics studies in recent years, questions about the reliability of these 
methods remain. In particular, there have been veryfew investigations of whether metal-
based affinity enrichment techniques can be used in quantitative phosphoproteomics 
scenarios. Attention has usually been given to test the selectivity and sensitivity of the 
enrichment methods but not of quantitative performances such as the repeatability, 
dynamic range and linearity. In a typical large-scale phosphoproteomics study, a liquid 
chromatographic separation step such as SCX, HILIC or ERLIC is usually performed as a 
peptide fractionation procedure to reduce the sample complexity followed by metal-based 
affinity chromatography to isolate phosphopeptides from each fraction. However, each 





complexity. Such dynamic sample characteristics have made the estimation of the 
quantitative performance of metal-based affinity chromatography even more difficult in a 
real large-scale phosphoproteomics application.  
 
In this study, we evaluated the repeatability, dynamic range and linearity of metal-
based affinity chromatography for quantitative phosphoproteomics applications. The 
testing protocol was modified from the SIMAC procedure in which both IMAC and 
MOAC were performed sequentially as described by Thingholm et al. [21]. For 
IMAC, a gallium-based IMAC method was selected as gllium has been shown to 
have higher selectivity and sensitivity than other metal-based IMAC methods in a 
recent study [22]. The MOAC procedure was based on the most widely used TiO2-
MOAC protocol as described in [18]. Glycolic acid was used to prevent non-specific 
binding of non-phosphorylated peptides with acidic amino acid residues. Glycolic 
acid was introduced as an effective alternative to 2,5-dihydroxybenzoic acid (DHB) 
and phthalic acid as an acidic quenching agent [18].  
 Two experiments were performed. First, to test the enrichment repeatability of 
SIMAC with varying background, we constructed a series of peptide mixtures with a 
variety of loading conditions and complexity to mimic sample characteristic of 
peptide mixture as the result of LC pre-fractionation. In the second experiment, a 
series of phosphopeptide standard mixtures with different concentrations were spiked 





overall SIMAC shows limited performance on repeatability. The linearity test shown 




HPLC-grade acetonitrile (ACN), water and acetic acid were obtained from Thermo 
Fisher (Waltham, MA, USA). Urea, dithiothreitol (DTT), iodoacetamide (IAA), 
sodium dodecyl sulfate (SDS) and 2DE Ready Prep clean up kits were purchased 
from Bio-Rad (Hercules, CA, USA). Bovine serum albumin (BSA), α-casein and β-
casein, ammonium bicarbonate (ABC), formic acid (FA), trifluoroacetic acid (TFA), 
glycolic acid and ammonium hydroxide were purchased from Sigma (St. Louis, MO, 
USA). Sep-Pak SPE column with 200 mg C18 resin were obtained from Waters 
(Milford, MA, USA). Spin columns with filter (Cat# M105010S) were purchased 
from Boca Scientific (Boca Raton, FL, USA). Ga(II)-IMAC Nutip (part No.TT2GAA) 
from Glygen (Columbia, MD, USA) and Titansphere TiO2 beads from GL Science 
(Tokyo, Japan) were used as enrichment media in all SIMAC experiments. Trypsin 
was purchased from Promega (Fitchburg, WI, USA). Phosp opeptide standard 
mixture (P33357) was purchased from Invitrogen (Carlsb d, CA, USA), and another 
phosphopeptide standards mixture (PHOSPHOSTD01) was from Glygen. Table 5.1 
provided a detailed description of these peptide standards.  
2.2. Protein preparation and digestion  





then directly reduced by 10 mM DTT for 1 h and alkylated by 40 mM IAA for 30 min 
in dark. Alkylation was quenched by adding DTT to the final concentration of 20 mM. 
Protein was then precipitated using 2DE Ready Prep cl an up kits according to the 
manufacturer’s protocol. The resulting protein pellet was reconstituted in 25 mM 
ABC and digested with trypsin at a 30:1 protein:protease ratio. Digestion was carried 
out in 37 ºC for 5 h and stopped by acidification using TFA. Tryptic peptides were 
purified using a 200 mg C18 Sep-Pak SPE column and dried with a Speed Vac 
(Thermo Electron).  
2.3. Experiment 1 
BSA was chosen to create a non-phosphopeptide background as it is rich in acidic 
amino acids such as Asp and Glu, which compete withphosphopeptides during 
SIMAC enrichment. For practical purpose, three different loading amounts (100, 200, 
and 500 µg) were tested. These values were selected because mo t large-scale 
phosphoproteomics studies start with 1-5 mg of total lysate and most LC-
prefractionation procedures generate 10-20 fractions. I  each loading amount test, 
two different levels of sample complexity were created by mixing tryptic peptides 
from caseins:BSA at 1:49 or 1:99 w/w ratio to mimic the low abundance of 
phosphopeptides in real samples from cell lysate. In all experiments, caseins consist 
of equal amount of α and β isoforms. All six tests were repeated in triplicate to 
estimate the repeatability of SIMAC procedure with different loading background.  
2.4. Experiment 2 
To test the linearity and dynamic range of phosphopeptides enrichment using SIMAC, 





µg tryptic peptides from caseins:BSA at ratio of 1:49. The amounts of spiked 
phosphopeptides are summarized in Table 5.3. All phos opeptides were spiked prior 
to IMAC enrichment.  
2.5. Phosphopeptide enrichment by SIMAC 
The sequential elution protocol employed the Ga(II)-IMAC Nutip as the first stage of 
enrichment and then used Titansphere TiO2 beads as a second enrichment step to 
further enrich phosphorylated peptides from the flow-through of IMAC as 
summarized in Fig 5.1. Solution components in each step during SIMAC enrichment 
can be found in Table 5.4. During the IMAC enrichment, the Nutips were first 
equilibrated twice with 150 µL IMAC Binding Solution and then loaded with peptide 
mixture in 150 µL IMAC Binding Solution. Eluate was collected and reloaded again 
for complete binding. Two step of washing each with 150 µL IMAC Washing 
Solution 1 and 2 were performed followed by a 100 µL water wash to remove acid. 
Phosphopeptides were then eluted by 100 µL Elution Solution 1 and 2 sequentially. 
Flow-through fractions from IMAC loading and all washing steps were combined and 
dried by Speed Vac for MOAC enrichment. For the MOAC enrichment, the 2 mg 
TiO2 beads were aliquoted into a spin column filter and equilibrated with 300 µL 
MOAC Binding Solution twice and then loaded with drie  IMAC flow-through in 
300 µL MOAC Binding Solution. Eluate was collected and reloaded again for 
complete binding. Washing steps with 300 µL MOAC Washing Solution 1 and 200 µL 
MOAC Washing Solution 2 were performed followed by 100 µL water wash to 
remove acid. Phosphopeptides were then eluted with 100 µL Elution Solution 1 and 2 





dried and re-dissolved in 10 µL of 3% ACN with 0.1% formic acid for LC-MS 
analysis. 
2.6. Casein peptide identification by LC-MS/MS  
The tryptic peptides mixture from α-casein and β-casein were injected in triplicates 
onto a G4240-62001 C-18 HPLC-Chip (40 nL enrichment column, 75 µm x 43 mm 
analytical column, 5 µm C-18SB-ZX, 300 Å, Agilent) hyphenated with a 6150 hybrid 
ESI-Q-TOF (Agilent). Nano-LC was performed with a 30-min gradient of 16–90% 
ACN in 0.1% FA at 0.5 µL/min. Mass spectrometric analysis was performed uner 
positive mode with nanoelectrospray generated at 2.1 kV  The m/z response of the 
instrument was calibrated regularly with standards f om manufacturer. Precursor scan 
and product ion spectra were acquired in centroid mode using data dependent 
acquisition in MassHunter (Agilent) with mass ranges for MS and MS/MS at m/z 
250–2400 and 59–3000, respectively. Every second, a MS spectrum was scanned, 
followed by maximum of five product ion spectra. The switching from TOF-MS to 
MS/MS is triggered by precursors with ion intensity >1000 counts with dynamic 
exclusion for 30 sec. The collision energy was set with 5 V/100 Da slope offset with 
2.5 V.  
 
Spectra were searched by Spectrum Mill 3.3.084 (Agilent) at local server in Colorado 
State University against a SwissProt protein database under the taxonomy of Bos 
taurus. The search parameters were set to allow for up to two missed cleavages, 
carboxyamidomethylation on Cys as fixed modification, oxidation on Met, 





and MS/MS mass tolerance with decoy search mode. Autovalidation was performed 
using default setting within the Spectrum Mill (see supplementary material) to qualify 
confident identifications.   
 
2.7. LC-MS quantitation of phosphopeptides 
For both Experiment 1 and Experiment 2, 2 µL of the tryptic peptides mixture from α/
β-casein and BSA spiked with phosphopeptide standards were injected in triplicate 
for LC-MS analysis on a Q-TOF instrument. The LC setting and LC-gradient were 
the same as described in Section 2.6 except that the Q-tof was operated in the MS 
scan only mode. Data were collected in centroid mode with MS m/z ranges set to 
250–2400. Raw LC-MS data were then convert to mzData format using MassHunter 
(Agilent) for further analysis. 
 
2.8. Data analysis 
All mzData files from both Experiment 1 and 2 were loaded into MZmine 2 [23] to 
quantify phosphopeptide abundance based on LC-MS peak area. Briefly, compounds 
from each LC-MS run were recognized by their unique m/z and retention time values, 
isotopic peaks of each compound were then grouped to give reliable quantitation. 
Chromatograms of each compound were then aligned across samples/injections for 
comparison. Phosphopeptide species were searched using nique m/z values, and 
their peak areas from each samples/injections were exported to Excel for further 






For Experiment 1, the repeatability of SIMAC in each loading condition was 
evaluated based on each enriched casein phosphopeptide by SIMAC across the 
repeats with peptide mixture at different starting amount and mixing ratio. For 
Experiment 2, the signal linearity of each spiked phosphopeptides was analyzed 
individually.  
 
3. Results  
3.1. Protein identification  
As expected, most qualified peptide IDs were from BSA or the caseins. Non-
phosphorylated peptides from both BSA and caseins were observed in relatively high 
abundance in all experiments (data not shown), indicating that non-specific binding is 
still an issue with the SIMAC procedure. Phosphopeptid s from caseins with 
confident identification (see Appendix VII) were used for the LC-MS quantitative 
analysis in Experiment 1 as summarized in Table 5.2. Some phosphopeptide isoforms 
such as DIGSESpTpEDQAMEDIK and DIGSpESTpEDQAMEDIK, which have 
identical molecular weight and also similar retentio  time as they has very similar 
sequences, were grouped into one m/z species for LC-MS quantitation. In contrast, 
phosphopeptides containing oxidized Met or additional missed cleavage sites were 
considered as separate m/z species for LC-MS quantitation. As a result, five, three 
and one phosphorylation sites from casein αSI, αSII and β were identified from which 
13 different m/z species were generated. All casein phosphopeptides are summarized 





3.2. SIMAC repeatability  
In our hands, for most casein phosphopeptides been qua tified, the SIMAC procedure 
demonstrated overall limited repeatability for quantit tive purposes (Fig 5.2). The 
biggest variance came from the difference between individual phosphopeptides. For 
example, phosphopeptide ions such as CP1, CP2-1, CP5-1, CP6-1 have significantly 
higher MS response than other ions. Moreover, CP3-1 and CP3-2 were not detectable 
in most LC-MS runs and were not included in quantittion analysis. Significant signal 
variation for most casein phosphopeptides were observed regardless of the changes in 
loading amount and sample complexity. As the signal variation between replicate 
injections in LC-MS is relatively small (data not shown), we postulate that the major 
MS signal variance was introduced by SIMAC enrichment. Thus, our data suggesting 
this SIMAC protocol may generate unreliable phosphopeptides quantitation. However, 
phosphopeptide CP1, CP4, CP5-5 and CP6-2 in 1:49 caseins:BSA test and CP2-2, 
CP4, CP5-3, CP5-5, and CP6-2 in 1:99 caseins:BSA shown incremental MS signal 
differences as expected when increasing amount of peptide mixture were enriched by 
the SIMAC. With the same loading amount, the MS signal of all casein 
phosphopeptides been investigated were higher when SIMAC were loaded with 1:49 
caseins:BSA than loaded with 1:99 caseins:BSA as expected. Therefore, our results 
suggested SIMAC can only be used as semi-quantitative method with limited 
repeatability. Additionally, to this point, we concluded that there is no significant 






3.3. SIMAC linearity and dynamic range 
In the second experiment, four Invitrogen phosphopeptid  standards (P1-P4) were 
spiked at 10-80 pmol, P5, P7 were spiked at 1-50 pmol, P6, P8 were spiked at 1-500 
pmol into the sample, respectively. Satisfactory linear response was observed on the 
MS signal of P4+3 (Fig 5.3B, R2=0.98) when spiked from 10-80 pmol and P8+3 (Fig 
5.3F, R2=0.99) spiked from 1-500 pmol for SIMAC enrichment. However, none of 
other standard phosphopeptides been investigated shown linear response over the 
spiked range, despite the overall trends of increasing MS signal intensity over spiked 
concentrations. The MS signals of P1+2, P1+3 (Fig 5.3A), P2+3 (Fig 5.3B) and P5+2 
(Fig 5.3C) only showed linear trends in the first three concentration tiers but showed 
signal saturation spiked with high concentrations. MS signals of standard P3+3 even 
level off after 20 pmol of loading amount. On contrary, multiple-phosphorylated 
peptides standard P6+2 (Fig 5.3E) and P7+3 (Fig 5.3D) showed low MS response at 
lower spiking amount (Fig 5.3C). Our data suggests that for different 
phosphopeptides, the linearity range of SIMAC-LC-MS varies from peptide to 
peptides. It is also noticeable that the signals observed showed significant differences 
between phosphopeptide species even though some of th m were spiked with exactly 
the same amount in the same SIMAC repeat. However, it is unclear whether this is 
caused by different efficiency of SIMAC enrichment or of electrospray ionization 






4. Discussion  
Metal-based phosphopeptides enrichment techniques such as IMAC and MOAC have 
been successfully employed for large-scale phosphoproteomics studies. However, 
IMAC and MOAC method development has primarily focused on the selectivity and 
sensitivity but not the quantitative attributes of the method. In a typical large-scale 
phosphoproteomics study, LC-based peptide fractionati  usually generates multiple 
peptide mixture fractions with varying peptides amount and complexity from which 
phosphopeptides are enriched. Here, we evaluated whether dynamic characteristics 
such as loading amount and sample complexity can affect the performance of metal-
based affinity chromatography.  
 
Overall, the SIMAC method demonstrated limited repeatability in our hands between 
repeats regardless of loading amount and sample complexity. Thus, it is 
recommended that technical replicates be included at enrichment step to prevent 
detection of false changes. It is still unknown if the poor repeatability issue was the 
result of competitive binding of non-phosphorylated peptides to the SIMAC materials 
or just the result of severe ion suppression during electrospray with a more complex 
background. Nevertheless, to avoid both possible inhib tion mechanisms, 
prefractionation is recommended to simplify the sample for both SIMAC enrichment 
and MS analysis. It is also notable that for phosphpeptide species such as CP4 and 
CP5-5 in the repeatability test, the difference of a MS signal due to 2-fold and 5-fold 
increase in loading amount falls into the same magnitude of SIMAC technical 





used with no technical replicates. The linearity test also has shown that different 
peptide species may have dramatically different linear relationships and linear range 
correlating the MS signal and their concentration. This means that not all 
phosphopeptides can be quantified at the same time from a complex sample in a real 
phosphoproteomics application by LC-MS coupled with enrichment techniques. 
 
Although SIMAC procedures were designed to effectively enrich both mono-
phosphorylated peptides and multiple- phosphorylated p ptides [21], we experienced 
severe signal suppression of multiple-phosphorylated species such as CP3-2 from 
casein in Experiment 1 and P8 in Experiment 2. It is known that electrospray 
ionization is biased against multiple-phosphorylated peptides [7]. However, all 
multiple-phosphorylated peptides were detectable using Q-TOF if a casein digest or 
phosphopeptide standards were injected alone without a complex background (data 
not shown). Thus, we suspect that severe ion suppression in electrospray is at least in 
part responsible for the observed signal loss. Furthermore, we suspect that the severe 
ion suppression could be the result of non-phosphorylated peptides left-over from 
SIMAC when the enrichment began with low phosphopeptid  abundance and a 
highly complex background. Glycolic acid was used to minimize non-phosphorylated 
peptides binding [18]. Despite the widespread impleentation of ‘acidic peptide 
quenching’ agent, studies still report discrepant results on optimal enrichment 
conditions. Recent reports indicated that the addition of glycolic acid may hamper the 
selectivity [7, 24] and DHB can introduce bias against multiple-phosphorylated 





our study.  
 
5. Concluding Remarks  
Our data suggest that overall the SIMAC procedure is insensitive to loading 
conditions and can be used as a semi-quantitative method with limited repeatability 
and linearity. We also show that the variance generated by the SIMAC procedure 
cannot be ignored, in particular without sufficient technical repeats. Therefore, careful 
evaluation of phosphopeptides enrichment techniques is recommended if they will be 





















Fig 5.1, Schematic diagram of sequential IMAC workflow for phosphopeptides enrichment using Ga-
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Fig 5.2, Repeatability test of SIMAC in experiment o e. Plot A/B and C/D shown enrichment results 
from 1:49 and 1:99 caseins:BSA background, respectively. Each cluster of bars represents one casein 
phosphopeptide been quantified using LC-MS. Peak areas from replicate injections were averaged. 
The height of each bar represents the average peak ar s of 3 enrichment replicates with standard 










Fig 5.3, linearity test at different dynamic range. Each data points represent the averaged peak areas 






Table 5.1 list of phosphopeptide standards used in this study. Actual M/Z species observed in Q-tof 
were shown here in bold.   
Name Sequence # 
Phosphor 
(M+H)1+ (M+2H)2+ (M+3H)3+ 
Invitrogen P33357 mixture standard 
NP1 DRVYIHPF 0 1046.54 523.77 349.52 
NP2 DRVYIHPFHL 0 1296.69 648.85 432.90 
NP3 GKGRGLSLSRFSWGA 0 1578.85 789.93 526.95 
P1 DHTGFLpTEpYVATR 2 1669.67 835.34 557.23 
P2 TRDIpYETDYYRK 1 1702.75 851.87 568.25 
P3 VPIPGRFDRRVpTVE 1 1720.89 860.95 574.29 
P4 DLDVPIPGRFDRRVpSVAAE 1 2192.09 1096.53 731.37 
Glygen PHOSPHOSTD01 standard 
P5 WWGSGPSGSGGSpGGGK 1 1500.60 750.80 500.87 
P6 WWGSGPSGSpGGSpGGGK 2 1580.58 790.78 527.53 
P7 WWGSGPSpGSpGGSpGGGK 3 1660.53 830.77 554.18 
P8 WWGSpGPSpGSpGGSpGGGK 4 1740.45 870.75 580.82 
 
Table 5.2 list of phosphopeptides from Casein digest on. Actual M/Z species observed in Q-tof were 
shown here in bold.   
Name Sequence # 
Phosphor 
Casein (M+H)1+ (M+2H)2+ (M+3H)3+ 
CP1 (K)VNELSpK(D) 1 
αS1 
 








1 1951.95 976.48 651.32 































































1 2432.05 1216.53 811.35 
 
Table 5.3 Experiment 2 test linearity and dynamic range of SIMAC enrichment using 200 µg 
casein:BSA tryptic peptides (1:49) spiked phosphopeptid s p33357 contains equal molar of P1-P4. The 
order of spiking series were randomized. Unit: pmol 
Sample P33357 P5 P6 P7 P8 
#1 10 5 50 1 500 
#2 80 10 500 50 100 
#3 20 1 10 5 50 
#4 40 50 100 10 10 
 
Table 5.4 Enrichment steps and solutions used for SIMAC procedure 
Steps IMAC MOAC 
Binding Solution 
150 µL  5% acetic acid, 5% ACN 
300 µL 1M Glycolic acid, 5% 
TFA, 80% ACN Washing Solution 1 
Washing Solution 2 150 µL  0.1% acetic acid, 60% ACN 200 µL 1% TFA, 80% ACN 
Water wash 100 µL HPLC grade water 
Elute Soltuion 1 100 µL 0.3N NH4OH 
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 CHAPTER 6 
QUANTITATIVE PHOSPHOPROTEOMIC ANALYSIS OF SIGNALING 
PATHWAY PERTURBATION BY GENISTEIN EXPOSURE: AN INITIAL 




Epistemological evidences have suggests that soy-derive  phytoestrogens exhibit 
benefits for cardiovascular heath [1-5]. Genistein or GEN, the most abundant 
isoflavone synthesized by soybean, has been postulated to provide direct 
cytoprotection for cardiomyocytes against ischemic stresses [6-9]. Like other plant 
isoflavones, GEN is a weak estrogenic compound and can effectively binds to 
estrogen receptors (ER) at physiological relevant concentration (1-10 µM) [10-12]. 
This estrogenic property has been shown to contribute to the cardioprotective action 
of GEN [6, 7]. However, GEN at pharmacological relevant concentration (>10 uM) 
was also shown to be an effective pan-specific protein yrosine kinases (PTK) 
inhibitor. It is postulated that the ER-independent PTK inhibition can possibly abolish 
the cardioprotection afforded by GEN. Genistein were used methodologically to 
block key PTK functions that mediate the cytoprotection pathways triggered by 
ischemic preconditioning procedure [13-17]. Genistein at 50 µM have shown to block 





inhibition of downstream tyrosine kinase which appears to be a MAP kinase [13]. It is 
also shown that EGFR-mediated TK activation contribu ed to the cardioprotection in 
rat heart triggered by the ischemic/reperfusion preconditioning and thus can be 
blocked by GEN [14]. In a most recent study, GEN was also used as a receptor 
tyrosine kinase inhibitor to block the upstream signaling of zinc-induced 
cardioprotective Akt pathway in a cultured cardiomyoc te model [18]. Another study 
shown that 50 µM of GEN can effectively block pro-apoptosis Fas signaling triggered 
by hypoxia in murine ventricular myocytes [19]. Apart from these reports, most 
signaling cascades modulated by GEN in cardiomyocytes are largely unknown. 
 
MS-based phosphoproteomics has become a valuable tool for characterizing protein 
phosphorylation in large-scale. To understand the impact of GEN on signaling 
pathways in cardiomyocytes, we introduced a high throughput phosphoproteomic 
approach based on phosphopeptides enrichment and label-free quantitation using 
electron transfer dissociation (ETD) mass spectrometry to globally identify the 
phosphorylated proteins and sites regulated by GEN in cardiomyocytes. To resolve 
the signaling alteration due to TK inhibitory effects and other ER-independent effects 
of GEN, primary ventricle myocytes isolated from male SD rat were incubated with 







2. Material and Methods 
2.1. Isolation of rat primary cardiomyocytes  
The use of animal in this experiment was approved by the CSU Institutional Animal 
Care and Use Committee in accordance with the Nation l Institutes of Health Guide 
for the Care and Use of Laboratory Animals. Primary cardiomyocytes were isolated 
from 6 month old male Sprague-Dawley rats weighing 300-350 g (n=3). Hearts were 
surgically removed according to the protocol described previously [20]. Excised 
hearts were subject to retrograde-perfusion of Joklik solution (Sigma, MO) containing 
0.8 mg/ml type II collagenase (Worthington Biochemical, NJ). Following tissue 
digestion, the cell suspension was filtered and pelleted in a solution containing 10% 
bovine serum albumin (BSA, Sigma, MO), 111 mM NaCl, 5mM KCl, 10 mM 
NaH2PO4, 1 mM MgSO4, 50 uM CaCl2, 5mM HEPES, 60 mM taurine and 20 mM 
creatine. The myocytes pellet was then resuspended i  Joklik solution with 6% BSA 
and gradually reintroduced CaCl2 to final concentration of 1 mM. After incubation 
with CaCl2 for 20 mins, cells collected by centrifuge (~300 rpm for 3 min) and 
resuspended in M119 medium supplemented with 10% fetal bovine serum (Sigma, 
MO), 10 mM butanedione monoxime (Sigma, MO), 2 mM glutamine (Invitrogen, 
CA), 100 U penicillin and 100 mg/ml streptomycin (Ivitrogen, CA). Cells were then 
plated on 0.01% laminin-coated dishes followed by incubation at 37°C, 5% CO2 for 4 
hrs.  
 
2.2. Treatment protocols 





The treatment group was replenished with fresh supplemented containing 10 µM 
genistein with 10 µM ICI 182,780 (Tocris Bioscience, MO), a full estrogen receptor 
antagonist (GEN+ERA). The control (Con) group was treated with DMSO vehicle 
only. Myocytes were then incubated in at 37°C with 5% CO2 for 15 min. 
  
2.3. Protein extraction 
Following treatments, cells were gently washed by 5 mL PBS twice each for 10 sec. 
Lysis solution (1 ml) containing 10 mM Tris-HCL (pH 8.0), 7 M urea, 2 M thiourea, 
1X protease inhibitor cocktail (Sigma, MO), 1X HALT phosphatase inhibitor cocktail 
(Thermo Fisher Scientific, IL), 5 mM magnesium acett  and 1% CHAPS (Sigma) 
were then directly applied to the cells for quick protein extraction. Protein solutions 
were then subjected to ultrasonication for 5 min in ice bath. Protein samples were 
centrifuged at 17 000 x g and the supernatant was collected. Total protein 
concentration for each sample was determined using the RC-DC protein assay kit 
(Bio-Rad, CA) according to manufacturer’s instruction. Bovine serum albumin 
(Sigma, MO) was used as protein assay standard.  
 
2.4. Protein digestion and HILIC separation  
A total of 2 mg of protein from each sample was directly reduced by 10 mM 
dithiothreitol for 1 h in lysis buffer and alkylated by 40 mM iodoacetamide for 30 
min in dark. Alkylation was quenched by adding dithio reitol to final concentration 
of 20 mM. Protein was then precipitated by 2DE Ready Prep clean up kits (Bio-Rad) 





urea in 50 mM ABC stock with 0.17% ProteaseMAX (Promega, WI). Once the 
pellets were dissolved completely by votexing, 5 mL 50 mM ABC stock was added to 
the sample to dilute the urea. In order to break down the DNA and RNA, samples 
were first incubated with 250 U/ml of benzonase (Sigma, MO) with 1mM MgCl2 for 
1.5 h at 37 ºC. For protein digestion, 100 µg trypsin (Promega) was added to the 
sample. Digestion was carried out in 37 ºC for 4h and stopped by acidification using 
trifluoroacetic acid. Tryptic peptides were cleaned up by 500 mg C18 Sep-Pak SPE 
column (Waters), then dried by Speed Vac (Thermo Electron) and reconstituted in 
HILIC buffer B. 
 
Peptides were fractionated using a PolyHYDROXYETHYL A column (4.6 mm × 200 
mm, 5 µm particle size, 200 Å pore size) (PolyLC, Columbia, MD) on a 1050 HPLC 
system (Agilent, CA) at flow rate of 0.5 mL/min. To prevent column overloading, 2 
mg of peptide was separated into 3 different each wit  approximately 667 µg peptides. 
A 60 min slow gradient designed for phosphopeptides separation using a combination 
of 0.1% TFA (Buffer A) and 0.1 %TFA in 85 % ACN (Buffer B) was created. The 
gradient started with 95% B for 5 min; then dropped to 70% B for 42.5 min; followed 
by 70-0% B for 5 min; then maintained at 0% B for 2.5 min; finally came back to 
95% B within 2.5 min. The column was conditioned in 95% B for 20 min after each 
gradient and before the next run to ensure reproducibility. A total of 15 fractions were 
collected with 3.27 min intervals and a few (begin a d end fractions) at 5 min 
intervals. Identical fractions from 3 replicate runs were combined, dried via Speed 






2.5. Phosphopeptides enrichment using SIMAC 
Phosphopeptides from HILIC peptide fractions were enriched by sequential elution 
protocol from IMAC (SIMAC) modified from the procedure described by Thigholm 
et al [21]. This approach employed Ga(II)-IMAC Nutip (part No.TT2GAA, Glygen 
MD) as the first stage enrichment for multiple-phosphorylated peptides and then 
Titansphere TiO2 beads (GL Science, Japan) as a second enrichment step o enrich 
mono-phosphorylated peptides from the flow-through of IMAC. During the IMAC 
enrichment, the Nutips were first equilibrated twice with 150 µL IMAC binding 
solution containing 5% acetic acid, 5% ACN and then loaded with peptide mixture in 
150 µL IMAC binding solution. Eluate was collected and reloaded again for complete 
binding. Tips were then washed with 150 µL IMAC binding solution and 150 µL 
0.1% acetic acid in 60% ACN. Tips were then washed by100 µL HPLC-grade water 
to remove acid. Phosphopeptides were then eluted by 100 µL elution solution 1 
containing 0.3N NH4OH and then elution solution 2 containing 0.3N NH4O  in 60% 
ACN sequentially. Flow-through fractions from IMAC loading and all washing steps 
were combined and dried by Speed Vac for MOAC enrichment. For the MOAC 
enrichment, the 2 mg TiO2 beads were aliquoted in spin column filter (Cat# 
M105010S, Boca Scientific FL) and equilibrated twice with 300 µL MOAC binding 
solution containing 1M glycolic acid, 5% TFA in 80% ACN. Prepared TiO2 beads 
were then loaded with dried IMAC flow-through in 300 µL MOAC binding solution. 
Eluate was collected and reloaded again for complete binding. Two step of washing 





were performed followed by 100 µL water wash to remove acid. Phosphopeptides 
were then eluted by 100 µL elution solution 1 and 2 sequentially. Enrichment 
fractions from both IMAC and MOAC were then combined and dried and re-
dissolved in 10 µL of 3% ACN, 0.1% formic acid for ETD-MS/MS analysis. 
 
2.6. Protein identification by ETD MS/MS  
Each SIMAC-enriched HILIC fraction was injected in triplicates onto the G4240-
62010 LC-chip (Agilent) interfaced to a Agilent 6340 ion trap mass spectrometer 
(Agilent) equipped with an ETD source. LC separation was performed by an Agilent 
1100 Series HPLC-Chip system with a 25 min gradient flowing at 450 nL/min 
starting with 97% solvent A (0.1% FA) and 3% solvent B (0.1% FA in 90% ACN) for 
1 min and increase to 40% B over 11 min and from 40 to 80% B over the next 3 min, 
and maintained 80% B for 5 min, and finishing up by drop back to 3% B. Peptides 
eluent was analyzed by ion trap MS under the ETD only mode. The m/z response of 
the instrument was calibrated regularly with standards from manufacturer. Precursor 
scan and product ion spectra were acquired in centroid mode using data dependent 
data acquisition in MassHunter DataAnalysis (Agilent) with the following parameters: 
mass ranges for MS and MS/MS were m/z 250–4000 and 50–2000, respectively. 
Every 3 seconds, a MS spectrum was scanned, followed by two product ion spectra. 
The switching from MS to MS/MS is triggered by precursors with ion 






2.7. Spectrum analysis  
Peak lists in mgf format were extracted from .d files by Mascot Distiller 2.3.2 (Matrix 
Science) for peak deisotope and charge state determination and then submitted to 
Mascot v2.3 (Matrix Science) in local server at CSU and X!Tandem Cyclone v 
2010.06.01.6 for consensus search against a target-rev rse concatenated International 
Protein Index (IPI , European Bioinformatics Institute, http://www.ebi.ac.uk/IPI) rat 
protein database (v3.70, 79158 sequences). The search p ameters were set to allow 
for up to two missed cleavages, carboxyamidomethylation on Cys as fixed 
modifications, oxidation on Met, phosphorylation on Thr/Ser/Tyr as variable 
modifications, a MS and MS/MS mass tolerance of 2.5 Da and 0.7 Da, respectively. 
Searches were done using monoisotopic mode. Mascot search was set to use ETD-
TRAP mode and X!Tandem was instructed to do search based on c, z and y ions. A 
consecutive second round X!Tandem search was automatically done with more 
variable modifications: oxidation on Trp and dioxidation on Met. All search hits from 
both Mascot and X!Tandem were compiled by Scaffold v3.00.03 (Proteome Software, 
OR) for peptide and protein probability calculation [22]. Peptide spectrum matches 
(PSMs) were first screened with a preliminary filter of 90% peptide probability and 
80% protein probability in prior to following phosphorylation sites analysis. All 
qualified PSMs in each sample will be further loaded into ScaffoldPTM v1.0.3 
(Proteome Software, OR) for phosphorylation site assignment. To assess the 
assignment ambiguity of a phosphorylation site, theAscore developed by Sean 
Beausoleil et al were used to calculate the location probability of the phosphorylation 





phosphorylation site were filtered by 90% peptide probability and 90% Ascore 
probability and exported to Excel for further statistical analysis. The false discover 
rate (FDR) was calculated dividing the number of false hits by the number of all hits 
as summarized by table 6.1: 
All target hits = all hits above the filtering criteria 
False positives (FP) = Decoy hits 
True positives (TP) = All target hits - FP 
FDR = FP/(FP+TP) 
Within each sample, spectrum gave the identification of the same phosphorylation 
site were counted and compared between 3 GEN+ERA samples and 3 Con samples 
using paired t-test to select significant (p < 0.1) changes of phosphorylation due to 
GEN+ERA treatment.  
 
3. Results and Discussion 
3.1. Phosphopeptides identification  
Using preliminary filter of peptide 90% probability and 80% protein probability, 7296 
PSMs were assigned with peptide FDR of 1.7%. These p ptide IDs give identification 
of 229 proteins. Within those PSMs, only 890 PSM matched to phosphorylated 
peptides which gave 57 unique phosphosites identifica ion from 49 phosphoproteins. 
However, it is notable that majority of those non-phosphorylated peptide IDs came 
from the abundant proteins such as myosin-6. In consistence with our conclusion 





spectral counting study. Out of 7296 total PSM in the whole experiment, the most 
abundant 10 proteins occupied 5324 (72.9%), in which 2727 (37.3%) PSMs came 
from myosin-6. Myosin-6 alone gave 41 phosphopeptid PSMs but 2686 non-
phosphopeptide PSMs. We suspected that the presence of high abundant proteins, in 
particular those myofibril proteins may significantly interfere with the MS 
characterization of phosphopeptides in low abundant simply by occupying a large 
portion of instrumental sampling cycles and introducing severe ion suppression 
during the electrospray ionization. Therefore, we suspect that the sensitivity of our 
protocol on detecting signaling phosphoproteins in cardiomyocytes can be improved 
dramatically by immunodepletion of abundant proteins l ke myosin-6, actin, myosin 
light chain 3, tropomyosin alpha-1 chain, myoglobin and titin as a sample preparation 
step before the proteomics analysis. However, it isworth to point out that protein 
phosphorylation is also a ubiquitous PTM found in those contractile proteins and may 
have implications of key functional regulation mechanisms.  
 
3.2. Efficiency of SIMAC enrichment 
The sequential elution protocol from IMAC (SIMAC) was developed to achieve 
better enrichment efficiency for both mono- and multiple-phosphorylated peptides 
[21]. Out of 890 PSMs assigned to phosphopeptides in the whole experiment, 52 
unique phosphopeptide species were identified including 40 mono- and 12 multiple-
phosphorylated peptides, respectively. Consider the relative low abundance of 
multiple-phosphorylated peptides and the fact that t ey are more difficult to be 





and multiple-phosphorylated peptides effectively. However, significant non-specific 
binding of non-phosphorylated peptides from abundant proteins indicated that the 
SIMAC protocol still lacks the selectivity when loaded with very complex sample. 
This conclusion is in consistence with our previous SIMAC test study. Although at 
this point we are unable to identify if the majority of non-phosphorylated peptides 
bind to IMAC or MOAC step, but considering the MOAC enrichment was carried out 
with the presence of 1 M glycolic acid as non-phosprylated peptide excluder, we 
suspect that an augmented selectivity of IMAC can sig ificantly improve the overall 
selectivity of SIMAC procedure.  
 
3.3. ETD performance 
Totally only 7296 PSMs were matched out of 1083104 spectra collected across the 
whole experiment which gave a relatively low overall identification rate (0.67%). 
One issue of spectra interpretation was the relatively low identification rate of +2 
charged ions compare to +3 charge ions (Fig 6.1). When parsing through all spectra 
collected by the ion trap in the whole experiment, +2 and +3 ions both accounted for 
20% of all charged species. However, after database searching, +2 and +3 charged 
ions generated 38.7% and 54.6% of the total successful identifications, respectively. 
As most peptides should form +2 or +3 charged ions during ESI, these statistics have 
clearly shown a systematic bias in ETD data interpretation against the +2 charged 
species. However, we are unable to identify whether this bias is due to the 
unfavorable fragmentation of +2 ions in ETD trap or differential interpretation of ions 





have suggested that ETD is an ineffective fragmentatio  method for peptide dications 
[24-26]. We suspect this issue can be solved by employ complementary CID collision 
mode either by alternating the ion trap in CID-ETD mix mode to get better 
characterization of +2 ions or add a supplementary CAD fragmentation during ETD 
for +2 ions described as the ETcaD protocol [26].  
 
Another problematic issue with ETD data was the presence of dominant precursor 
species, specifically, the precursor ions itself (M+nH)n+, charge reduced precursors 
(M+nH)(n-1)+ in the MS/MS spectrum as exemplified in Fig 6.2. Such phenomenon 
has been described by Good, et al in the ETD MS/MS spectrum generated by a 
ThermoFisher’s hybrid QLT-Orbitrap instrument [27]. This group developed a script 
to remove those dominant precursor peaks and have demonstrated much improved 
peptide identification rate using open mass spectrometry search algorithm (OMSSA) 
after precursor species reduction [27]. However, due to the proprietary nature of MS 
data generated in the Agilent 3D ion trap we are unable to try if a script can be written 
to remove the dominant precursors in the MS/MS spectra, nor we know how the 
Mascot and X!tandem remove those precursor species if there is any procedures in 
those algorithms.  
 
3.4. Consensus database search performance 
Most search engines including Mascot and X!tandem were originally written to 
process CID-based data and have been adapted to accept ETD-based data in recent 





interpretation using Mascot and X!tandem as their core algorithm is proprietary. Even 
using a consensus search strategy to combine search results from both Mascot and 
X!tandem, overall identification rate for the whole experiment only reach 0.67% 
indicating a poor performance of the search engines. However, we believe that low 
MS accuracy, and the presence of dominant precursor species in MS/MS spectra may 
partly contributed the discover power of search engines.   
 
Compare the performance of both search engines, Mascot identified more PSMs and 
phosphopeptide PSMs than X!tandem even with 2nd round search (Fig 6.3). However, 
both search engines contribute significantly amount of PSMs that otherwise would 
not be detectable in the other search engine which highlighted the effectiveness of the 
consensus search strategy. Furthermore, we also found that both Mascot and 
X!tandem shown no bias towards phosphopeptides as pho phopeptide PSMs and 
other PSMs shown comparable Mascot ion score and X!tandem -log(e) score 
distribution as summarized by Fig 6.4.  
 
3.5. Differential phosphorylation due to non-estrogenic action of GEN 
Despite the difficulty of resolve protein phosphorylation in this study, we still 
observed 3 phosphorylation sites in 2 proteins inhibited by GEN treatment in the 
presence of ERA as summarized in table 6.2. The phosphorylation on the 117T site of 
‘myosin-binding protein C, cardiac-type’ was complete y abolished by GEN via non-
estrogenic mechanism. Protein phosphorylation at 6722S and 6740S in ‘similar to 





mechanism. All three identified phosphorylation site  are novel discoveries and have 
not been reported in protein phosphorylation database such as phosphor.ELM 
(http://phospho.elm.eu.org) [28]. However the biological functions related to those 
phosphorylation sites are still unclear.  
 
4. Concluding Remarks  
In this project, a phosphoproteomic approach based on HILIC peptide fractionation, 
SIMAC phosphopeptides enrichment, and label-free quantitation using electron 
transfer dissociation (ETD) mass spectrometry was tested to understand impact of 
GEN on the global protein phosphorylation in rat cardiomyocytes. However, only 57 
unique phosphosites from 49 phosphoproteins were identified in the whole 
experiment which gave us very limited resolving power to see the phosphoproteome 
alteration in response to GEN treatment. Several potential pitfalls of this 
phosphoproteomics application on cardiomyocytes have been identified. The presence 
of high abundant proteins, in particular the myofibril proteins in the sample strongly 
limit the phosphoproteomics power to identify phosphorylation events which is in 
low abundance and low stoichiometry. With such complex sample background, the 
risk of having non-specific binding of unphosphorylated peptides in SIMAC 
procedure and electrospray ion suppression is conceivabl  high. Enrichment using 
SIMAC still shown low selectivity when loading samples with such noisy 
background and further optimization, in particular the IMAC step is recommended. 





multiple-phosphorylated peptides as expected. In order to characterize more 
phosphopeptides species, it is also recommended to use complementary CID 










Fig 6.1 Distribution of charge states of all ions i the raw MS spectra (A) and that 












Fig 6.2 Example of ETD spectra showing the presence of dominant precursor peak (A) and charge 



















Fig 6.3 Number of total PSMs (A) and number of phosphopeptides PSM (B) identified by Mascot and 





Fig 6.4 Frequency histogram of Mascot ion score (A) and X!tandem -log(e) score (B) for all PSM pass 
the 90% peptide probability and 80% protein probability filter. PSMs gave phosphopeptide IDs from 
both search engines (the upper panels), shown no difference in score distribution from all other PSMs 










Table 6.2, Protein phosphorylation identified in response to GEN+ERA treatment. Peptide sequences 
were listed with # following the phosphorylated amino acid. CON and GEN+ERA column shown the 
spectral counting result for the corresponding phosrylation sites in control and GEN+ERA treated 
group. Three numbers each represent the number of spectra found in samples from rat 1,2,3.   
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Chapter 7 
Conclusion Remarks and Future Directions 
 
1. Project Significance and Contributions 
 
Genistein (GEN) has been postulated to provide direct cytoprotection for 
cardiomyocytes against adverse stress. However, the mol cular mechanism of such 
benefit of GEN is still uncharacterized. This dissertation aimed to use functional 
proteomics approaches to identify key downstream effectors of GEN which may 
mediate the cardioprotection. The merit of using proteomics is two-fold. First, it 
allowed us to comprehend the extent and the complexity of molecular action of GEN 
in cardiomyocytes from a global angle. Second, it allowed us to identify novel 
molecular targets of GEN that may otherwise be out of the scope of conventional 
reductionist investigations. Proteomics approaches ar  valuable for generating new 
hypotheses from which new research direction can be rationaled to identify 
cardioprotective action of GEN.  
 
In our first study, we investigated the concentration-dependent proteome changes in 





physiologically relevant concentration (1 µM), the expression of heat shock proteins 
and anti-apoptotic proteins was up-regulated. However, at a pharmacological 
concentration (50 µM), GEN down-regulated several glycolytic proteins and 
antioxidant enzymes. These concentration-dependent pro ein expression trends 
indicate a biphasic action of GEN that at low dose it can potentially protect the 
cardiomyocytes while at high dose it may make cardiomyocytes more susceptible to 
energy depletion and apoptosis during ischemic insults.  
 
In our second study, we investigated the proteome changes in rat primary 
cardiomyocytes in response to ER-dependent and ER-independent actions of GEN. 
Our proteomics data suggested that GEN may have a critical influence on myocardial 
energy metabolism, in particular by up-regulation of glycolytic proteins via ER 
binding. We also found a novel anti-cardioprotective gene the soluble expoxide 
hydrolase can be down-regulated by GEN in an ER-dependent manner. Independent 
of ER binding, we identified novel molecular targets in steroidogenesis and estrogen 
signaling pathways that were down-regulated by GEN. 
 
Although most proteomics data from this project need to be further validated, we 
believe several interesting hypotheses can be drawn based on the major discovery 
from our proteomics study to explain the cardioprotective role of GEN. First, we 
suspect that GEN provides cardioprotection only at low concentration but not at high 
pharmacological concentration. Second, at low concentration, GEN confers 





compromise the glycolytic pathway in an ER-independent fashion, making the 
cardiomyocytes more susceptible to energy depletion under ischemic stress. Fourth, at 
high concentration, GEN may trigger pro-apoptotic event in an ER-independent 
fashion making the cardiomyocytes more susceptible apoptosis under ischemic stress. 
To our best knowledge, this project is the first attempt to investigate the cellular 
effects of GEN in cardiomyocytes from a systems biology perspective. 
 
In addition to interesting biological discoveries, this dissertation also focused on the 
development and optimization of proteomic applications to study protein expression 
in cardiomyocytes. Conventional 2DE protein separation was coupled with a two-
stage hydrophilic and hydrophobic protein prefractionation method to provide broad 
coverage of cardiac proteome. Over 2300 protein spots were visualized by 2D gel. 
Further, a quantitative shotgun proteomic protocol was established coupling newly 
introduced HILIC separation and 8plex iTRAQ quantitation technology. A consensus-
iterative searching strategy, that increased the sensitivity for protein identification was 
established with an independent house-written script to facilitate the iTRAQ 
quantitation. The whole protocol can be used for multiple parallel iTRAQ 
experiments to accommodate more samples. Pathway anl ses including GeneGO 
MetaCore and Ingenuity IPA were applied to enrich pathways and cellular functions 
overrepresented by the differentially expressed protein influenced by GEN treatment 
in our experiment. These in silico pathway analyses have confirmed pathways that 
were significantly influenced by GEN such as anti-apoptosis, glycolysis, fatty acid 





phosphorylation patterns impacted by the GEN by developing a HILIC-SIMAC 
phosphopeptides fractionation and enrichment protocol.  
 
 
2. Challenges and Unsolved Problems 
Despite being used for cardiovascular research for nearly two decades, proteomics 
methodology still faces great challenges when applied to complex samples such as 
mammalian cells or tissues. Both mouse and rat genom s contain around 22,000 
protein coding genes according to the gene ensemble database (www.ensembl.org). 
Additionally, the presence of differential slicing and post-translational modification 
makes the proteome even more complex. Such a large number of protein species has 
made it almost impossible to cover the whole proteom  completely using the current 
2DE or shotgun protocols. Therefore, further improvement on the resolving capacity 
of gel-based or LC-based separation techniques should result in expanded lists of 
proteins for analysis. Other than having huge variety of protein species, mammalian 
proteomes were also characterized by the huge differenc s in copy numbers among 
different proteins. Current 2DE-MS and shotgun-MS based protocols are usually 
biased against low abundant proteins many of which are involved with key signaling 
and regulatory processes. Our shotgun proteomics data and phosphoproteomics data 
suggested that highly abundant proteins, in particular the myofibril proteins such as 
myosin can dramatically decrease the discovery power f proteomics methods. In our 





immortalized cardiomyocyte line. Therefore, it is highly recommended for future 
proteomics studies on cardiomyocytes, that an immunodepletion step be established 
to prefractionate the abundant proteins from the rest of the less abundant proteins. 
Mammalian proteomes also contain large numbers of protein isoforms which in these 
experiments caused some incidences of identification ambiguity. Both 2DE and 
shotgun proteomics workflows typically identify proteins only with partial sequence 
coverage and also depend on protein databases which still contain inaccurate 
sequence information especially on protein isoforms. Such identification ambiguity 
may restrict the specificity of subsequent functional interpretation. It is always 
challenge to differentiate protein isoforms which rely on the identification of unique 
peptides especially in shotgun experiments. We believ  a thorough separation of 
peptide species can improve the chance to detect unique peptides to distinguish 
protein isoforms.  
 
The dynamic range of protein expression alteration in cells can be huge. However, 
our experience indicating the dynamic range of proteomics quantitation using 2DE or 
iTRAQ was compressed. Gel-based quantitation suffers rom high variability, uneven 
image background, spots co-migration and low dynamic range of staining protocol, in 
particular the silver stain protocol. Shotgun based iTRAQ technology also has the 
problem with co-elution of similar m/z species in LC-MS analysis. All those 
disadvantages may interfere with quantitation and generate weak statistics to discover 
biological differences between samples. Therefore, it is vital to use other method such 





a proteomics study. In recent years, MS-based validation strategy described as 
multiple reaction monitoring technology (MRM) has been evaluated as an alternative 
approach to ELISA or western blotting. The MRM typically operates on a triple 
quadrupole mass spectrometry and have advantages of high dynamic range, high 
specificity, high throughput and no need for antibodies.  
 
Identification and quantitation of protein phosphorylation in large-scale is a 
challenging task. Key technical difficulty we encountered was in simplifying the 
proteome prior to phosphopeptide enrichment. Our experience suggests that simply 
separating the whole lysate digestion into 15 fractions may be insufficient for 
effective enrichment. Based on these experiences, we recommended using 
immunodepletion to remove abundant contractile proteins prior to phosphopeptide 
enrichment. Second, we found that the SIMAC enrichment can only be used in a 
semi-quantitative study with limited selectivity, reproducibility and linearity. We 
consider all other types of IMAC or MOAC based enrichment techniques may also 
have poor quantitative performance as non-specific binding is a ubiquitous side-effect 
in all enrichment protocols. However, we believe with a simplified loading 
background, one might be able to improve the quantitative performance of metal 
based enrichment. Third, the choice of mass spectrometry for phosphopeptides is 
critical as no instrument type or collision mode has shown absolute superiority over 
others. ETD instrument was still considered one of the most promising strategies to 
analyze phosphopeptides as it prevents the neutral loss of phosphor groups from the 





data is challenging and the understanding of the knowledge about the fragmentation 
behavior of peptides in ETD is still incomplete. Further, current database search 
engines are designed to interpret CID data with recent adaptation for ETD data. 
However, very little is known about their performance on ETD data interpretation so 
far.  
 
A final challenge in proteomics research is the data in erpretation. Proteomics per se 
only measures the relative expression level of multiple protein species. These –omics 
type of data usually are noisy and contain many unexpected discoveries such as 
protein never been characterized before. Even proteins that have been extensively 
studied are often involved in multiple cellular processes that may make the biological 
interpretation of proteomic data unspecific. Therefo , in addition to thorough 
literature reviews on each identified protein, a meta-analysis approach using 
MetaCore or IPA pathway analysis package was carried out to highlight important 
pathways in which differentially expressed proteins play biological roles. However, 
one limitation to these softwares is that they were initially written for mRNA 
microarray data which usually has much wider coverag  of gene expression profile 
than proteomics. Our experience suggested that proteomics data are relative sparse 
and usually generate unspecific pathway analysis results with weak statistics. 
Moreover, both literature review on single protein or meta-analysis approach can only 
serve to generate researchable hypotheses for future investigation. Therefore, 
proteomics analyses should ideally be accompanied by mechanistic studies to test the 






3. Future Directions 
Given what we have learned from the current proteomics projects, mechanistic study 
can be launched to investigate the GEN cardioprotecti n in the following direction:  
1, confirm in which concentration/dose range does th  GEN provide cardioprotection 
against hypoxic/ischemic stress. Proteomics approach c n further help to locate key 
cardioprotective proteins modulated by GEN during the ischemic/hypoxic stress.  
 
2, identify whether ER binding is a key intermediate s ep for GEN cardioprotection 
against hypoxic/ischemic stress. Proteomics approach c n also help to select key 
cardioprotective proteins modulated by GEN during the ischemic/hypoxic stress via 
ER-dependent mechanism.  
 
3, identify whether glycolytic activity of cardiomyocytes can be inhibited by high 
concentration of GEN. Other type of pan-specific PTK inhibitor and isoflavones with 
no PTK inhibitory effects such as daidzein can be us d for comparison. Radiolabeling 
can be used for glycolytic flux analysis. Possible expression changes of glycolytic 
proteins can be measured via MRM approach.  
 
4, identify whether pro-apoptotic pathway in cardiomyocytes can be activated by high 
concentration of GEN in an ER-independent fashion. Again, other type of pan-






5, identify phosphorylation pattern changes due to the ER-independent action of GEN 
in cardiomyocytes. Improvement on phosphopeptides enrichment technique and mass 
spectrometry data interpretation has to be made in order to identify and quantify 
protein phosphorylation successfully. Alternatively, since GEN is a pan-specific PTK 
inhibitor, it will also be interesting to use Tyr-specific immunoprecipitation to focus 
the phosphoproteomics survey on the direct impact of GEN on tyrosine kinase 
signaling. Differentially phosphorylated sites can lso be confirmed by MRM 
approach.  
 
Other than those specific aims for the future studies, it will also be interesting to study 
the proteome changes triggered by other isoflavone, soy phytoestrogen extract or 
isoflavone cocktails in cardiomyocytes. Differential proteomics can also be taken to 






Abbreviations and Acronyms 
2DE 2-dimensional electrophoresis 
ABC ammonium bicarbonate 
ACN acetonitrile 
AMT accurate mass and retention time tag 
BSA bovine serum albumin 
CID collision induced dissociation 
CVD cardiovascular disease 
DDA data dependent acquisition 
DHB 2,5-dihydroxybenzoic acid 
DTT dithiothreitol 
ER estrogen receptor 
ERA estrogen receptor antagonist 
Erk1/2 p42/p44 extracellular signal-regulated kinases 
ERLIC electrostatic repulsion hydrophilic interaction chromatography 
ESI-MS/MS electrospray ionization tandem mass spectrometry 
ETD/ECD electron transfer/capture dissociation 
FA formic acid 
FDR false discovery rate 
GEN genistein 
GO gene ontology 
HCD higher-energy C-trap dissociation 
HILIC hydrophilic interaction liquid chromatography 
I/R ischemia/reperfusion 
IAA iodoacetamide 
ICAT isotope-coded affinity tags 
IEF iso-electric focusing 
IMAC immobilized metal affinity chromatography 
IPG immobilized pH gradient 
IPI international protein index 
IT ion trap mass spectrometry 





m/z mass to charge ratio 
MALDI-
MS/MS 
matrix assisted laser desorption/ionization ionization tandem mass 
spectrometry 
MAPKs mitogen-activated protein kinases 
MDLC multidimensional liquid chromatography 
MOAC metal oxide affinity chromatography 
MSA multi-stage activation 
MudPIT multidimentional protein identification technology 
PAC phosphoramidate chemistry 
PI3K phosphatidylinositol-3-OH kinase 
PQD pulsed-Q dissociation 
Q-tof quadrupole time of flight mass spectrometry 
RPLC reverse phase liquid chromatography 
SAX strong anion exchange 
SCX strong cation exchange chromatography 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SILAC stable isotope labeling by amino acids in cell culture 
SIMAC sequential immobilized metal affinity chromatography 
TFA trifluoroacetic acid 
TK tyrosine kinase 






Appendix I  
Table of differentially expressed proteins in Chapter 3 
 
Differentially altered proteins identified in 1µM and 50 µM GEN treated cardiomyocytes 
compared with control cells. Proteins were grouped according to their major biological functions. 
Spots quantification was evaluated as the averaged fold-changes ± pooled standard deviation 
based on percent spot volume (% voli = voli/∑voln), NS means no significant changes. The prefix 








Spot ID Protein identification IPI IDs unique peptides MW 
GEN 1 vs 
Control 
GEN 50 vs 
Control Biological Process 
Stress response and protein folding machinery 
phi_32 Heat-shock protein beta-1 (HspB1) 
(Heat shock 27 kDa protein) (HSP 27) 






anti-apoptosis/response to stress/apoptosis 
and survival FAS signaling/signal 
transduction ESR-1 pathway 
phi_63 5 NS 1.36±0.04 
phi_65 3 1.33±0.03 NS 
pho_32 2 -1.36±0.09 NS 
pho_28 
78 kDa glucose-regulated protein 
precursor (GRP 78) (Heat shock 70 
kDa protein 5) (Immunoglobulin heavy 
chain-binding protein) (BiP) 
IPI00319992 6 72492 NS 1.53±0.02 
Signal transduction ESR 1 pathway/anti-
apoptosis/cellular response to glucose 
starvation/negative regulation of caspase 
activity 
phi_51 
Alpha-synuclein (Non-A beta 
component of AD amyloid) (Non-A4 
component of amyloid precursor) 
(NACP) 
IPI00115157 3 14476 NS 1.30±0.06 
cellular response to oxidative stress/fatty 
acid metabolic process/mitochondrial ATP 
synthesis coupled electron transport 
phi_07 
Stress-70 protein, mitochondrial 
precursor (75 kDa glucose-regulated 





protein folding/response to stress 
phi_08 7 NS -2.10±0.01 
phi_20 5 NS 2.96±0.02 
phi_74 2 1.62±0.03 NS 
pho_01 
Heat shock cognate 71 kDa protein 






dependent protein refolding/ response to 
stress 
phi_31 11 NS -2.17±0.03 
phi_37 3 -1.70±0.02 -5.26±0.02 
phi_53 2 1.75±0.03 NS 
phi_62 9 NS 1.61±0.06 
phi_27 
60 kDa heat shock protein, 
mitochondrial precursor (Hsp60) (60 
kDa chaperonin) (CPN60) (Heat shock 
protein 60) (HSP-60) (Mitochondrial 





Protein folding/activation of caspase 
activity/anti-apoptosis 
pho_27 14 NS 1.64±0.02 
phi_03 
Phosphatidylethanolamine-binding 





aging/response to oxidative stress phi_56 2 NS -1.64±0.02 
phi_40 3 NS -2.29±0.04 
phi_02 
Nascent polypeptide-associated 
complex subunit alpha, muscle-specific 
















Protein NDRG1 (N-myc downstream-
regulated gene 1 protein) (Protein 
Ndr1) 
IPI00125960 5 43437 1.38±0.03 NS Response to metal ion/response to hypoxia 
Cellular redox balance 
pho_29 
Peroxiredoxin-4 (EC 1.11.1.15) (Prx-
IV) (Thioredoxin peroxidase AO372) 
(Thioredoxin-dependent peroxide 
reductase A0372) (Antioxidant enzyme 
AOE372) 
IPI00116254 4 31261 -1.31±0.02 NS cell redox homeostasi /oxidation reduction 
phi_11 
Glutathione synthetase (EC 6.3.2.3) 
(Glutathione synthase) (GSH 
synthetase) (GSH-S) 
IPI00127691 2 52442 NS 3.65±0.02 
Glutathione biosynthetic process/response 
to cadmium ion 
phi_24 
Protein disulfide-isomerase precursor 
(EC 5.3.4.1) (PDI) (Prolyl 4-




2 57507 NS -3.39±0.02 cell redox homeostasis 
phi_54 Protein disulfide-isomerase A3 
precursor (EC 5.3.4.1) (Disulfide 
isomerase ER-60) (ERp60) (58 kDa 





cell redox homeostasis/positive regulation 
of apoptosis 
phi_78 6 NS -1.56±0.02 
Apoptosis 
pho_17 Voltage-dependent anion-selective 





NS 1.36±0.06 anion transport/survival regulation of 
apoptosis pho_18 3 1.52±0.03 NS 
pho_21 
BAG family molecular chaperone 
regulator 2 (BCL2-associated 
athanogene 2) (BAG-2) 
IPI00130304 6 23630 NS -1.72±0.02 Apoptosis 
phi_66 Cathepsin D precursor IPI00111013 2 45381 NS 1.61±0.04 Proteolysis 
pho_08 
Import inner membrane translocase 
subunit TIM50, mitochondrial 
precursor 
IPI00111045 5 39980 1.38±0.04 NS 
mitochondrial membrane 






isomerase, mitochondrial precursor 
IPI00130804 4 36437 NS 1.52±0.02 fatty acid metabolic process 
phi_52 






phi_69 4 NS -1.99±0.02 







phi_73 3 1.27±0.02 NS 
pho_30 
Pyruvate dehydrogenase E1 component 
alpha subunit, somatic form, 
mitochondrial precursor (EC 1.2.4.1) 
(PDHE1-A type I) 
IPI00337893 3 43888 1.59±0.02 2.34±0.03 glycolysis/oxidation reduction 
phi_70 
Alpha-enolase (EC 4.2.1.11) (2-
phospho-D-glycerate hydro-lyase) 
(Non-neural enolase) (NNE) (Enolase 
1) 
IPI00462072 7 47453 NS -1.72±0.06 glycolysis 
phi_26 





phi_71 8 NS -1.63±0.03 





Ribose-5-phosphate isomerase (EC 
5.3.1.6) (Phosphoriboisomerase) 
IPI00113408 3 26098 -1.39±0.02 NS pentose-phosphate s unt 
phi_19 
Aspartate aminotransferase, 
cytoplasmic (EC 2.6.1.1) 
(Transaminase A) (Glutamate 
oxaloacetate transaminase 1) 
IPI00877205 5 46488 NS 2.33±0.01 
cellular amino acid metabolic process/fatty 
acid homeostasis 
phi_64 Electron transfer flavoprotein subunit 
beta (Beta-ETF) 
IPI00121440 3 27834 NS 1.65±0.02 electron transport chain/transport 
phi_35 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial precursor 
(EC 1.6.5.3) (EC 1.6.99.3) (NADH-






electron transport chain/transport 
pho_35 3 NS -1.24±0.04 
DNA integrity and RNA transcription/translation 
pho_04 Heterogeneous nuclear 





RNA splicing/mRNA processing 
pho_07 7 1.48±0.04 NS 
pho_38 Elongation factor 1-beta (EF-1-beta) IPI00320208 3 24849 NS 1.44±0.06 translational elongation 
phi_55 Prohibitin (B-cell receptor-associated 






pho_19 2 NS -2.19±0.02 
pho_12 
60S acidic ribosomal protein P0 
(L10E) 
IPI00314950 5 34366 NS 1.44±0.07 
ribosome biogenesis/translational 
elongation 
pho_05 RuvB-like 2 (EC 3.6.1.-) (p47 protein) IPI00123557 10 51252 NS 1.74±0.03 
DNA recombination/DNA 
repair/regulation of transcription 







(PCNA) replication/intracellular protein transport 
phi_77 
Heterogeneous nuclear 
ribonucleoprotein A/B (hnRNP A/B) 
(CArG-binding factor-A) (CBF-A) 
IPI00117288 4 30926 -1.97±0.02 NS 
positive regulation of gene-specific 
transcription/transcription 









intermediate filament-based process 
 
phi_57 12 NS 1.61±0.05 
pho_41 2 NS -1.68±0.03 
pho_13 4 NS -2.00±0.05 
pho_14 







1.32±0.09 NS cardiac muscle contraction/positive 
regulation of heart rate by 
epinephrine/ventricular cardiac muscle 
tissue morphogenesis 
pho_16 6 NS -1.61±0.03 
phi_58 
Tropomyosin beta chain (Tropomyosin 
2) (Beta-tropomyosin) 
IPI00874728 3 32931 NS -1.47±0.03 muscle contraction 
phi_10 Actin-related protein 2/3 complex 





NS 2.27±0.03 Regulation of actin filament 
polymerization pho_10 2 1.52±0.07 NS 
pho_24 Myosin regulatory light chain 9 IPI00750595 4 19898 NS 1.79±0.11 motor activity/calcium ion binding 




Myosin-6 (Myosin heavy chain 6) 
(Myosin heavy chain, cardiac muscle 





NS 6.47±0.01 cardiac muscle fiber 
development/regulation of ATPase 
activity/regulation of heart rate/ regulation 
of the force of heart contraction/sarcomere 
organization 
pho_26 8 1.49±0.04 NS 
phi_34 
Myosin light polypeptide 4 (Myosin 





2 21260 NS -2.18±0.02 N/A 
phi_47 
Myosin light polypeptide 6 (Smooth 
muscle and nonmuscle myosin light 
chain alkali 6) (Myosin light chain 
alkali 3) (Myosin light chain 3) (MLC-
3) 
IPI00354819 2 17090 NS 1.39±0.06 muscle filament sliding 
pho_43 Calponin-3 IPI00119111 4 36577 NS -1.47±0.03 actomyosin structure organization 
phi_75 Vinculin (Metavinculin) IPI00405227 8 
11721
5 
NS -1.80±0.02 cell adhesion 







Low molecular weight phosphotyrosine 
protein phosphatase 
IPI00134135 2 18636 2.14±0.02 2.34±0.02 protein amino acid dephosphorylation 
pho_20 
Growth factor receptor-bound protein 2 
(Adapter protein GRB2) (SH2/SH3 
adapter GRB2) 
IPI00119058 3 25336 NS -2.59±0.02 
MAPKKK cascade/Ras protein signal 
transduction/cell differentiation 
pho_39 
14-3-3 protein zeta/delta (Protein 
kinase C inhibitor protein 1) (KCIP-1) 
(SEZ-2) 
IPI00116498 2 27925 -3.67±0.02 1.98±0.03 
protein targeting/anti-apoptosis/signal 
transduction/mRNA metabolic process 
pho_42 
COP9 signalosome complex subunit 4 
(Signalosome subunit 4) (SGN4) 
(JAB1-containing signalosome subunit 
4) 
IPI00131871 3 46541 NS 1.53±0.04 Signal transduction 
others 
phi_49 
Uncharacterized protein C15orf38 
homolog 
IPI00461011 2 65696 NS 1.33±0.02 N/A 
pho_31 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L5 
IPI00124938 4 37878 -1.75±0.02 NS 
ubiquitin-dependent protein catabolic 
process 
pho_36 
COMM domain-containing protein 3 
(Bmi-1 upstream gene protein) (Bup 
protein) 





















Protein identification reports for Chapter 3 
 
Mascot identification reports for differentially expressed proteins identified from HL-1 
cardiomyocytes in response to low and high concentration of GEN treatment. Each Mascot report 
was generate using the Select Summary (protein hits) format. Each PDF file was named after the 




Available online: http://www.dropbox.com 
User name: zeyusun@engr.colostate.edu 
Password: proteomics 
File name: Appendix 2. rar 
Note: Appendix 2 rar package contains all Mascot prtein identification in PDF format. Use 






Table of GO processes relavent to differentially expressed proteins in Chapter 3 
 
GeneGO enriched GO processes that associated with the differentially expressed proteins in 
response to 1 µM (Part A) and 50 µM Genistein (Part B) treatement. Detailed description of GO 
processes can be found in GeneGO metacore database (http://www.genego.com/genego_lp.php). 
A hypergeometric distribution probability test was carried out to decide if the experimentally 
identified proteins (objects) were involved with a p rticular biological pathway in the GeneGO 
MetaCore database. The p-value represents the odds of having a given pre-built network be 









# Processes pValue 
1 regulation of ATPase activity 1.234E-07 
2 sarcomere organization 1.234E-07 
3 small molecule catabolic process 2.331E-07 
4 organelle organization 3.815E-07 
5 muscle filament sliding 4.387E-07 
6 ventricular cardiac muscle tissue morphogenesis 4.764E-07 
7 actin-myosin filament sliding 4.764E-07 
8 regulation of heart rate 5.165E-07 
9 ventricular cardiac muscle tissue development 5.165E-07 
10 myofibril assembly 5.591E-07 
11 actin-mediated cell contraction 6.520E-07 
12 actomyosin structure organization 9.341E-07 
13 cardiac ventricle morphogenesis 1.142E-06 
14 cardiac muscle tissue morphogenesis 1.298E-06 
15 muscle tissue morphogenesis 1.470E-06 
16 positive regulation of heart rate by epinephrine 1.583E-06 
17 cytoskeleton organization 1.682E-06 
18 actin filament-based movement 1.759E-06 
19 anti-apoptosis 1.823E-06 







# Processes pValue 
1 muscle filament sliding 9.583E-20 
2 actin-myosin filament sliding 1.227E-19 
3 actin-mediated cell contraction 3.122E-19 
4 actin filament-based movement 5.800E-18 
5 regulation of ATPase activity 8.730E-17 
6 muscle contraction 3.822E-16 
7 muscle system process 2.632E-15 
8 glycolysis 8.670E-13 
9 actomyosin structure organization 1.001E-12 
10 glucose catabolic process 5.283E-12 
11 actin filament-based process 7.591E-12 
12 ventricular cardiac muscle tissue morphogenesis 2.270E-11 
13 ventricular cardiac muscle tissue development 2.626E-11 
14 hexose catabolic process 2.758E-11 
15 myofibril assembly 3.030E-11 
16 cardiac muscle tissue development 3.178E-11 
17 monosaccharide catabolic process 3.967E-11 
18 small molecule catabolic process 4.854E-11 





20 cardiac muscle tissue morphogenesis 1.377E-10 
21 muscle tissue morphogenesis 1.721E-10 
22 generation of precursor metabolites and energy 2.088E-10 
23 alcohol catabolic process 2.256E-10 
24 muscle organ morphogenesis 3.920E-10 
25 cellular carbohydrate catabolic process 4.435E-10 
26 cardiac muscle contraction 5.032E-10 
27 glucose metabolic process 7.174E-10 
28 cardiac ventricle development 8.902E-10 
29 muscle tissue development 9.046E-10 
30 regulation of system process 9.497E-10 
31 heart contraction 1.039E-09 
32 heart process 1.039E-09 
33 cardiac chamber morphogenesis 2.152E-09 
34 carbohydrate catabolic process 2.248E-09 
35 tissue development 2.629E-09 
36 muscle organ development 2.783E-09 
37 positive regulation of ATPase activity 2.901E-09 
38 cardiac chamber development 3.331E-09 
39 hexose metabolic process 5.048E-09 





41 regulation of the force of heart contraction 1.278E-08 
42 cellular component assembly involved in morphogenesis 1.872E-08 
43 sarcomere organization 2.019E-08 
44 monosaccharide metabolic process 2.232E-08 
45 regulation of muscle contraction 3.482E-08 
46 regulation of heart contraction 3.482E-08 
47 muscle cell development 3.840E-08 
48 regulation of hydrolase activity 4.058E-08 
49 catabolic process 5.589E-08 
50 gluconeogenesis 7.213E-08 
51 regulation of muscle system process 8.726E-08 
52 small molecule metabolic process 9.361E-08 
53 anatomical structure morphogenesis 9.625E-08 
54 muscle structure development 1.138E-07 
55 regulation of heart rate 1.225E-07 
56 actin cytoskeleton organization 1.501E-07 
57 regulation of nucleotide catabolic process 1.536E-07 
58 regulation of purine nucleotide catabolic process 1.536E-07 
59 alcohol biosynthetic process 1.608E-07 
60 regulation of biological quality 1.650E-07 





62 hexose biosynthetic process 2.161E-07 
63 cellular component organization at cellular leve 2.488E-07 
64 cerebellar Purkinje cell layer development 2.699E-07 
65 heart morphogenesis 2.815E-07 
66 ATP metabolic process 2.860E-07 
67 cellular component organization 2.996E-07 
68 cellular component organization or biogenesis at cellular level 4.730E-07 
69 cellular carbohydrate metabolic process 5.238E-07 
70 cellular component organization or biogenesis 5.659E-07 
71 heart development 7.200E-07 
72 monosaccharide biosynthetic process 7.538E-07 
73 cell projection organization 7.684E-07 
74 cellular component morphogenesis 8.839E-07 
75 blood circulation 9.613E-07 
76 response to external stimulus 9.621E-07 
77 circulatory system process 9.831E-07 
78 alcohol metabolic process 1.178E-06 
79 atrial cardiac muscle tissue morphogenesis 1.420E-06 
80 atrial cardiac muscle tissue development 1.420E-06 
81 pyruvate metabolic process 1.466E-06 





83 elastic fiber assembly 1.949E-06 
84 myosin filament assembly or disassembly 1.949E-06 
85 regulation of cellular component size 2.138E-06 
86 cerebellar cortex development 2.258E-06 
87 cellular component biogenesis 2.323E-06 
88 cellular component assembly at cellular level 2.881E-06 
89 exocytosis 3.258E-06 
90 regulation of cellular catabolic process 3.486E-0  
91 cytoskeleton organization 3.654E-06 
92 cellular component assembly 3.822E-06 
93 response to wounding 4.116E-06 
94 extracellular matrix assembly 4.279E-06 
95 muscle cell differentiation 4.522E-06 
96 regulation of nucleotide metabolic process 5.130E-06 
97 regulation of protein folding in endoplasmic reticulum 5.338E-06 
98 positive regulation of heart rate by epinephrine 5.338E-06 
99 anti-apoptosis 5.781E-06 
100 response to chemical stimulus 6.076E-06 
101 cardiac myofibril assembly 6.561E-06 
102 protein refolding 6.561E-06 





104 multicellular organismal development 6.888E-06 
105 anatomical structure development 7.175E-06 
106 monocarboxylic acid metabolic process 7.184E-06 
107 organ development 7.808E-06 
108 carbohydrate metabolic process 8.168E-06 
109 negative regulation of caspase activity 8.213E-06 








Table of identified peptides in Chapter 4 
 
Complete list of all peptides identified for 509 quantified proteins in Chapter 4. Database search 
parameters of both Mascot and X !Tandem were included.  
 
Available online: http://www.dropbox.com 
User name: zeyusun@engr.colostate.edu 
Password: proteomics 









Table of differentially expressed protein in Chapter 4 
 
Differentially altered proteins identified using pair wise t-test. All protein IDs were categorized 
into 5 groups according to the expression patterns implicating possible ER-dependent or –
independent mechanism by which GEN triggers the expression alternation. Note, the MW refer to 
molecular weight of the protein, and GO annotation on biological process was extract from the 
public Uniprot database, NS means no significant changes was observed. The peptides/spectra 
column was format as the unique number of peptide ID from run A + run B| the total number of 












IPI00195593 74,094.50 7+8|53+60 
fatty acid beta-oxidation, long-chain fatty 
acid transport 




IPI00205413 33,137.30 2+2|42+71 transmembrane transport -1.21 NS -1.27 
RCG20659, isoform CRA_b IPI00766463 38,086.30 1+1|35 response to stress -1.31 NS -1.37 
ER-dependent, possibly with ER-independent in synergism 
Fructose-bisphosphate aldolase A IPI00231734 39,334.50 11+12|119+107 
glycolysis, protein homotetramerization, 
response to estrogen stimulus, response to 
heat, response to hypoxia, response to 
lipopolysaccharide,response to nicotine 
1.08 NS NS 
alpha-enolase IPI00464815 47,111.00 12+12|209+173 glycolysis 1.22 NS NS 
myosin-6 IPI00189809 223,508 
141+134|9578+858
9 
muscle myosin complex, myofibril,myosin 
filament, perinuclear region of cytoplasm 
-1.04 NS NS 
ATP synthase subunit b, 
mitochondrial 
IPI00196107 28,851.50 9+7|121+85 ATP synthesis coupled roton transport -1.07 NS NS 
Elongation factor 1-α 2 IPI00325281 50,436.60 6+5|48+92 respons to inorganic substance -1.13 NS NS 
Epoxide hydrolase 2 
IPI00195735 62,323.80 1+1|2+1 
aromatic compound catabolic process, 
linoleic acid metabolic process, positive 
regulation of blood pressure, prostaglandin 
production involved in inflammatory 
response, response to toxin, sensory 
perception of pain 
-1.38 NS NS 
RCG62645, isoform CRA_b IPI00372407 30,873.50 1+1|1 N/A -1.41 NS NS 
T-complex protein 1 subunit delta IPI00337168 58,083. 0 1+1|2+3 
chaperone mediated protein folding 
requiring cofactor 
-2.07 NS NS 
ER-independent and ER-dependent in antagonism 
3-hydroxyacyl-CoA 
dehydrogenase type-2 IPI00886470 28343.9 9+6|141+173 
cell aging, oxidation-reduction process, 
protein homotetramerization, tRNA 
processing 





IPI00395281 68,181.00 5+5|57+63 
electron transport chain, response to 
oxidative stress, transport 
1.14 1.14 NS 
similar to AHNAK nucleoprotein 
isoform 1 
IPI00207069 27,442 1+1|14+5 N/A -1.17 -1.21 NS 
MACRO domain-containing 
protein 1 
IPI00203232 35,290.20 2+1|4+2 N/A -1.59 -1.54 NS 
ER-independent, possibly with ER-dependent in antagonism 
Stomatin-like protein 2 IPI00203528 38396 1+1|2+1 N/A NS 1.53 NS 








similar to isochorismatase domain 
containing 2 isoform 1 
IPI00764444 24,651.70 2+3|4+18 N/A NS 1.10 NS 
similar to Nebulette IPI00565256 116173.6 2+3|23+20 NA NS 1.05 NS 
60S ribosomal protein L13 IPI00230916 24,292.50 1+1|2  translation NS 1.05 NS 
similar to titin isoform N2-B IPI00554003 
1409058 
81+76|594+847 N/A NS -1.05 NS 
Isoform Mitochondrial of 
Fumarate hydratase, 
mitochondrial 
IPI00231611 54,446.30 9+10|174+217 
fumarate metabolic process, malate 
metabolic process, tricarboxylic acid cycle 
NS -1.11 NS 
Phosphoglycerate mutase 1 IPI00421428 28,814.80 2+2|14 2 glycolysis NS -1.11 NS 
Heat shock protein 75 kDa, 
mitochondrial 
IPI00369217 80,445.90 1+1|1+1 protein folding NS -1.25 NS 
Trimeric intracellular cation 
channel type A 
IPI00189667 33,396.10 3+2|39+73 ion transport, potassium transport, transport NS -1.61 NS 











MZmine2 LC-MS data processing protocol 
 
This protocol was written for SIMAC LCMS data processing using MZmine2. Data was collected 
from Agilent 6150 Q-tof. For data collected from other sources, it is highly remembered to check the 
following aspect of raw data: 1, mass accuracy, 2, chromatogram baseline and noise, average 
chromatogram peak span and intensity, 3, mass spectrum baseline and noise, overall peak intensity. 4, 








1 Data loading 
Format: mzData, mzXML, mzML 
 
2 Crop filter: RT 0:40 – 14 min  
 
3 Chromatogram builder setting: 
Centroid mode 
Noise level: 2000 counts 
Filtering: None 
Chromatogram Construction: highest data point 
Minimum time Span: 0:15 min,  
Minimum height 3000 counts,  
m/z tol: 0.02 
 
4 chromatogram deconvolution: 
Use the local minimum search algorithm 
Chromatographic threshold: 70%,  
Search minimum in RT range: 0.1 
Minimum relative height: 5%,  
Minimum absolute height: 100  
Minimum ratio of peak top/edge: 2,  
Remove source peak list after filtering? yes 
 
5 Isotopic peaks grouper setting:  
m/z tol: 0.02  
RT tol: 0:10 
Monotonic shape? No 
Maximum charge= 5 
Representative isotope: highest intensity  
Remove source peak list after filtering? yes 
 
 
6 Peak list rows filter setting:   
Minimum peak in a row: 1  
Minimum peaks in an isotope pattern: 1 
Min/Max m/z: 400/1300 
Min/Max RT: 0:40/14:00 min 
Remove source peak list after filtering? Yes 
 
7 RANSAC aligner setting,  
m/z tol: 0.02 da 
RT tol: 1:00 (before alignment) 
RT tol after correction: 0:15 min 
RANSAC iteration: 10 
Minimum number of points: 50% 
Threshold value: 0:15 min 
Linear model? No 







Table of identified peptides in Chapter 5 
 
This table contains the complete list of all peptides identified from tryptic caseins and BSA 










sequence z m/z  score ∆R1-R2 %SPI RT(min) Protein 
(K)HIQKEDVPSER(Y) 3 446.5659 16.22 8.38 90.4 3.33 α-S1-casein  
(K)SCQAQPTTMAR(H) 2 625.7847 13.25 4.28 79.7 3.53 κ-casein  
(K)AVPYPQR(D) 2 415.7299 13.95 8.7 94.3 3.76 β-casein  
(K)VLPVPQK(A) 2 390.7546 11.4 3.77 75.8 4.2 β-casein   
(K)FQsEEQQQTEDELQDK(I) 2 1031.419 20.9 20.9 74.9 4.3 β-casein   
(K)FQsEEQQQTEDELQDK(I) 3 687.9475 16.09 16.09 80.5 4.31 β-casein   
(K)TVDmEsTEVFTK(K) 2 741.8061 17.33 6.89 84.5 4.49 α-S2-casein  
(K)AEFVEVTK(L) 2 461.7479 15.08 15.08 76.4 4.64 
Serum 
albumin  
(K)VIPYVR(Y) 2 373.7308 15.35 7.94 97.1 4.99 α-S2-casein  
(K)TVDMEsTEVFTKK(T) 2 797.8547 14.88 7.88 79.1 5.35 α-S2-casein  
(R)NAVPITPTLNR(E) 2 598.3423 15.14 4.75 89.6 5.52 α-S2-casein  
(K)DIGsEsTEDQAMEDIK(Q) 2 964.3484 18.41 18.41 63.5 5.64 α-S1-casein  
(K)DIGsEsTEDQAMEDIK(Q) 3 643.2349 13.88 5.9 76.6 5.66 α-S1-casein  
(K)TVDMEsTEVFTK(K) 2 733.8091 15.01 8.55 72 5.82 α-S2-casein  
(K)VPQLEIVPNsAEER(L) 2 830.8999 18.29 18.29 91.4 6.85 α-S1-casein  
(K)VPQLEIVPNsAEER(L) 3 554.2693 15.2 15.2 75.6 6.85 α-S1-casein  
(K)LVNELTEFAK(T) 2 582.3188 17.7 11.06 89.5 7.57 
Serum 
albumin  
(K)YKVPQLEIVPNsAEER(L) 3 651.3224 14.28 14.28 70.8 7.64 α-S1-casein  
(K)YKVPQLEIVPNsAEER(L) 2 976.4783 16.31 10.48 89.2 7.68 α-S1-casein  
(K)FALPQYLK(T) 2 490.2807 12.41 3.81 78.6 8.49 α-S2-casein  
(K)LGEYGFQNALIVR(Y) 2 740.4046 13.89 13.89 61.4 9.16 
Serum 
albumin  
(R)YLGYLEQLLR(L) 2 634.3556 20.3 7.78 95.2 11.82 α-S1-casein  
(R)FFVAPFPEVFGK(E) 2 692.8673 23.68 23.68 98.7 12.73 α-S1-casein  
(R)DMPIQAFLLYQEPVLGPVR(G) 3 729.3947 20.93 15.65 88.9 14.11 β-casein   
(R)DMPIQAFLLYQEPVLGPVRGPFPIIV(-
) 3 970.5386 16.48 16.48 85.3 16.24 β-casein   
(K)HIQKEDVPSER(Y) 3 446.5663 14.85 6.3 84.6 3.32 α-S1-casein  
(K)AVPYPQR(D) 2 415.7293 16.02 10.27 96.1 3.74 β-casein   
(K)FQsEEQQQTEDELQDK(I) 2 1031.42 23.65 23.65 82.8 4.26 β-casein   
(K)FQsEEQQQTEDELQDK(I) 3 687.9476 16.41 13.01 80 4.29 β-casein   
(K)TVDmEsTEVFTK(K) 2 741.8057 22.2 9.72 94.1 4.44 α-S2-casein  
(K)VIPYVR(Y) 2 373.7316 13.84 5.75 94.9 4.96 α-S2-casein  
(K)TVDMEsTEVFTKK(T) 2 797.8559 17.14 5.58 90 5.31 α-S2-casein  
(R)NAVPITPTLNR(E) 2 598.3432 16.94 7 91.3 5.48 α-S2-casein  
(R)NAVPITPTLNR(E) 3 399.2308 11.69 5.12 76.4 5.55 α-S2-casein  
(K)DIGsEsTEDQAMEDIK(Q) 2 964.3483 21.2 21.2 70.7 5.58 α-S1-casein  
(K)DIGsEStEDQAMEDIK(Q) 3 643.2352 15.4 6 82.3 5.6 α-S1-casein  
(K)TVDMEsTEVFTK(K) 2 733.809 18.32 9.88 78.2 5.77 α-S2-casein  
(K)VPQLEIVPNsAEER(L) 3 554.2697 14.58 14.58 73.6 6.79 α-S1-casein  
(K)VPQLEIVPNsAEER(L) 2 830.9 19.52 19.52 97.4 6.8 α-S1-casein  
(K)VPQLEIVPNsAEER(L) 2 830.9001 11.08 11.08 60.8 7.09 α-S1-casein  
(K)LVNELTEFAK(T) 2 582.3152 17.59 9.74 84.5 7.53 
Serum 
albumin  
(K)YKVPQLEIVPNsAEER(L) 2 976.4808 15.99 15.99 69.4 7.63 α-S1-casein  





(R)YLGYLEQLLR(L) 2 634.3543 17.03 4.24 88.4 11.78 α-S1-casein  
(R)FFVAPFPEVFGK(E) 2 692.8679 22.58 22.58 97.8 12.71 α-S1-casein  
(R)DMPIQAFLLYQEPVLGPVR(G) 3 729.3939 19.95 15.84 90.1 14.09 β-casein   
(R)DMPIQAFLLYQEPVLGPVR(G) 2 1093.589 18.01 18.01 85.4 14.17 β-casein   
(R)DMPIQAFLLYQEPVLGPVRGPFPIIV(-
) 3 970.5362 14.78 14.78 82.3 16.24 β-casein   
(K)HIQKEDVPSER(Y) 3 446.5658 16.03 8.28 90.6 3.29 α-S1-casein  
(K)SCQAQPTTMAR(H) 2 625.7841 13.12 13.12 72.2 3.5 κ-casein   
(K)AVPYPQR(D) 2 415.7298 16.03 10.57 95.9 3.74 β-casein   
(K)FQsEEQQQTEDELQDK(I) 2 1031.422 24.22 16.96 89.6 4.27 β-casein   
(K)FQsEEQQQTEDELQDK(I) 3 687.9485 15.21 11.58 77.9 4.29 β-casein   
(K)TVDmEStEVFTK(K) 2 741.8059 12.61 4.47 67.5 4.44 α-S2-casein  
(K)AEFVEVTK(L) 2 461.7488 12.78 4.63 73.9 4.63 
Serum 
albumin  
(K)VIPYVR(Y)  2 373.7314 13.69 6.03 93.9 4.95 α-S2-casein  
(K)TVDMEsTEVFTKK(T) 2 797.8553 15.49 5.66 71.3 5.29 α-S2-casein  
(R)NAVPITPTLNR(E) 2 598.3426 11.7 2.32 86.1 5.47 α-S2-casein  
(K)DIGsEsTEDQAMEDIK(Q) 2 964.3505 17.81 17.81 69.7 5.58 α-S1-casein  
(K)DIGSEstEDQAMEDIK(Q) 3 643.2356 15.06 6.49 79.1 5.61 α-S1-casein  
(K)DIGsESTEDQAMEDIK(Q) 2 924.3613 11.45 11.45 64.6 5.65 α-S1-casein  
(K)TVDMEsTEVFTK(K) 2 733.8096 15.34 6.61 72.3 5.76 α-S2-casein  
(K)VPQLEIVPNsAEER(L) 2 830.9007 20.2 20.2 100 6.79 α-S1-casein  
(K)VPQLEIVPNsAEER(L) 3 554.27 15.25 15.25 75.2 7 α-S1-casein  
(K)YKVPQLEIVPNsAEER(L) 2 976.4794 19.11 12.65 92.7 7.64 α-S1-casein  
(K)FALPQYLK(T) 2 490.2845 16.48 7.71 81.7 8.43 α-S2-casein  
(R)YLGYLEQLLR(L) 2 634.3555 20.52 7.06 94 11.78 α-S1-casein  
(R)YLGYLEQLLR(L)  3 423.2383 13.13 13.13 71.8 11.9 α-S1-casein  
(R)FFVAPFPEVFGK(E) 2 692.8688 23.45 23.45 100 12.71 α-S1-casein  
(R)DMPIQAFLLYQEPVLGPVR(G) 3 729.3938 19.33 13.59 88 14.07 β-casein   
(R)DMPIQAFLLYQEPVLGPVRGPFPIIV(-
) 3 970.5394 14.91 14.91 79.1 16.26 β-casein   
(K)KTVDmEsTEVFTK(K) 3 537.5738 11.57 10.04 65.1 2.64 α-S2-casein  
(K)KTVDmEStEVFTK(K) 3 537.5725 11.31 8.77 63.6 2.64 α-S2-casein  
(K)KTVDmEStEVFTK(K) 3 537.5768 10.6 9.84 62.6 2.65 α-S2-casein  
(K)KTVDMEStEVFTK(K) 3 532.2421 15.21 7.72 60.1 3.13 α-S2-casein  
(K)KTVDMEStEVFTK(K) 3 532.2431 12.36 7.69 67.9 3.12 α-S2-casein  
(K)TVDmEsTEVFTKK(T) 3 537.5737 11.98 9.53 64.2 2.64 α-S2-casein  
(K)TVDmEStEVFTKK(T) 3 537.5729 13.64 13.47 66.3 2.66 α-S2-casein  
(K)NMAINPsKENLCSTFCK(E) 3 698.6386 9.31 9.31 60.8 5.9 α-S2-casein  
(K)NMAINPsKENLCSTFCK(E) 3 698.6375 8.82 8.82 60.9 5.89 α-S2-casein  
(K)NMAINPsKENLCSTFCK(E) 2 1047.446 6.34 0.16 65.3 5.96 α-S2-casein  
(K)KTVDMEsTEVFTKK(T) 3 574.943 14.34 14.34 66.8 4.1 α-S2-casein  
(K)IEKFQsEEQQQTEDELQDK(I) 3 811.3593 12.39 12.39 65.8 4.13 β-casein   









Table of identified phosphopeptides in Chapter 6 
 
This table contains the complete list of all phosphopeptides identified by ETD-MS/MS from 





Sample Protein Peptide Modifications 
Spectrum 
counts 
Con1 similar to proteasome (prosome, macropain) activator subunit 4 SVWGVSLVPRGQPRVETtAADTK T18 1 
Isoform 1 of Tropomyosin alpha-1 chain 
AISEELDHALNDMTsI S15 10 
AISEELDHALNDMtSI T14 11 
30 kDa protein 
sPPNPENIAPGYSGPLK S1 9 
IDGSNLEGGSQQAPStPPNtPDPR T20 2 
IDGSNLEGGSQQAPStPPNTPDPR T16 3 
77 kDa protein 
ASSEGTQGSVsPK S11 4 
ASSEGTQGsVSPK S9 1 
DPSLDTNSSLATPsPSPEAR S14 19 
DPSLDTNSSLATPSPsPEAR S16 5 
DPSLDTNSSLAtPSPSPEAR T12 15 
71 kDa protein 
ASSEGTQGSVsPK S11 4 
ASSEGTQGsVSPK S9 1 
DPSLDTNSSLATPsPSPEAR S14 20 
DPSLDTNSSLATPSPsPEAR S16 5 
DPSLDTNSSLAtPSPSPEAR T12 16 
Troponin I, cardiac muscle 
ADEsSDAAGEPQPAPAPVR n-term acetyl, S4 7 
ADESsDAAGEPQPAPAPVR n-term acetyl, S5 1 
RRssANYR S3 , S4 1 
similar to titin isoform N2-A 
VKsPETVKsPK S3 , S9 21 
AVsPTETKPTEK S3 6 
TRPRsPsPVSSER S5 , S7 3 
AVSPtETKPTEK T5 2 
SRPQPAEEYEDDTERRsPTPER S17 2 
35 kDa protein 
ASSEGTQGSVsPK S11 4 








DPSLDTNSSLATPsPSPEAR S14 20 
DPSLDTNSSLATPSPsPEAR S16 5 
DPSLDTNSSLAtPSPSPEAR T12 16 
Heat shock protein HSP 90-beta IEDVGsDEEDDSGKDK S6 7 
myosin-binding protein C, cardiac-type 
TSDsHEDAGTLDFSSLLK S4 7 
RTSDsHEDAGTLDFSSLLK S5 4 
AESAVAPTSMEAPEtPK T15 5 
RTsDSHEDAGTLDFSSLLK S3 1 
myozenin 2 
sPPNPENIAPGYSGPLK S1 9 
IDGSNLEGGSQQAPStPPNtPDPR T20 2 
IDGSNLEGGSQQAPStPPNTPDPR T16 3 
Con2 30 kDa protein sPPNPENIAPGYSGPLK S1 18 
Myosin regulatory light chain 2, ventricular/cardiac muscle 
isoform 
LEGGSsNVFSMFEQTQIQEFK S6 15 
LEGGSSNVFsMFEQTQIQEFK S10 1 
LEGGsSNVFSMFEQTQIQEFK S5 1 
tropomyosin 1 alpha chain isoform i 
AISEELDHALNDMtSI T14 19 
AISEELDHALNDMTsI S15 23 
AIsEELDHALNDMTSI S3 1 
similar to titin isoform N2-A 
VKsPELVASHPK S3 42 
VKsPETVKsPK S9 35 
AVsPTETKPTEK S3 8 
AVSPtETKPTEK T5 6 
RVKsPELVASHPK S4 3 
RRTPsPDyDLYYYR S5 , Y8 1 
SLGDIsDEELLLPIDDYLAMK S6 1 
sPELVASHPK S1 1 








YSsPPAHVK S3 1 
Heat shock protein HSP 90-beta IEDVGsDEEDDSGKDK S6 11 
myosin-binding protein C, cardiac-type 
RTsDSHEDAGTLDFSSLLK S3 17 
RTSDsHEDAGTLDFSSLLK S5 8 
TSDsHEDAGTLDFSSLLK S4 3 
AESAVAPTSMEAPEtPK T15 2 
RtSDSHEDAGTLDFSSLLK T2 1 
myozenin 2 sPPNPENIAPGYSGPLK S1 18 
Con3 
Pyruvate dehydrogenase E1 component subunit alpha, somatic 
form, mitochondrial 
YHGHsMSDPGVsYR S12 15 
YHGHsmSDPGVsYR S5 20 
YHGHsmSDPGVSyR Y13 2 
YHGHSmsDPGVSyR S7 1 
YGMGTsVER S6 2 
Isoform 1 of Tropomyosin alpha-1 chain 
AISEELDHALNDMTsI S15 16 
AISEELDHALNDMtSI T14 5 
Troponin I, cardiac muscle 
RRSsANYR S4 28 
RRssANYR S3 13 
similar to titin isoform N2-A 
VKsPETVKsPK S9 12 
VKsPELVASHPK S3 18 
RVKsPELVASHPK S4 6 
AVsPTETKPTEK S3 5 
AVSPtETKPTEK T5 2 
SRPQPAEEYEDDTERRsPTPER S17 7 
SRPQPAEEYEDDTERRSPtPER T19 3 
TRPRsPsPVSSER S5 , S7 2 
similar to Pyruvate dehydrogenase E1 component alpha 
subunit, somatic form, mitochondrial precursor (PDHE1-A 
YHGHsMSDPGVsYR S5 20 







type I) isoform 1 YHGHSMsDPGVsYR S12 19 
YGMGTsVER S6 4 
YHGHSmsDPGVSyR S7 1 
myosin-binding protein C, cardiac-type 
RTSDsHEDAGTLDFSSLLK S5 9 
AESAVAPTSMEAPEtPK T15 4 
AESAVAPTSmEAPEtPK M10 oxi, T15 3 
RTsDSHEDAGTLDFSSLLK S3 3 
TSDsHEDAGTLDFSSLLK S4 1 
113 kDa protein RVKsPELVASHPK S4 7 
AVSPtETKPTEK T5 2 
AVsPTETKPTEK S3 5 
TRPRsPsPVSSER S5 , S7 2 
SRPQPAEEYEDDTERRsPTPER S17 7 
SRPQPAEEYEDDTERRSPtPER T19 3 
VKsPETVKsPK S3 , S9 12 
VKsPELVASHPK S3 6 
ERA+GEN1 
Isoform 1 of Tropomyosin alpha-1 chain 
AISEELDHALNDMtSI T14 14 
AISEELDHALNDMTsI S15 3 
30 kDa protein sPPNPENIAPGYSGPLK S1 3 
similar to titin isoform N2-A 
AVSPtETKPTEK T5 6 
VKsPELVASHPK S3 2 
Heat shock protein HSP 90-beta IEDVGsDEEDDSGKDK S6 3 
myosin-binding protein C, cardiac-type 
RTSDsHEDAGTLDFSSLLK S5 4 
RTsDSHEDAGTLDFSSLLK S3 1 
RtSDSHEDAGTLDFSSLLK T2 1 
113 kDa protein 
AVSPtETKPTEK T5 6 







141 kDa protein 
RTSDsHEDAGTLDFSSLLK S5 4 
RTsDSHEDAGTLDFSSLLK S3 1 
RtSDSHEDAGTLDFSSLLK T2 1 




S17 , Y19 , M21 
oxi 
8 
KLAEQELIETSERVQLLHsQ S19 1 
NKDPLNETVVGLYQKssLK S16 , S17 1 
Isoform 2 of Basigin GSGsHLNDKDK S4 7 
30 kDa protein 
sPPNPENIAPGYSGPLK S1 8 
IDGSNLEGGSQQAPStPPNTPDPR T16 3 
Troponin I, cardiac muscle RRSsANYR S4 7 
similar to Chromobox protein homolog 1 KADsDSEDKGEESKPK S4 11 
similar to titin isoform N2-A 
VKsPELVASHPK S3 13 
VKsPETVKsPK S9 12 
AVsPTETKPTEK S3 6 
AVSPtETKPTEK T5 1 
SRPQPAEEYEDDTERRsPTPER S17 4 
SRPQPAEEYEDDTERRSPtPER T19 1 
TRPRsPsPVSSER S5 , S7 4 
Heat shock protein HSP 90-beta IEDVGsDEEDDSGKDK S6 9 
similar to Chromobox protein homolog 1 KADsDSEDKGEESKPK S4 11 
113 kDa protein 
VKsPELVASHPK S3 1 
VKsPETVKsPK S3 , S9 11 
AVsPTETKPTEK S3 6 
SRPQPAEEYEDDTERRsPTPER S17 4 
TRPRsPsPVSSER S5 , S7 4 







SRPQPAEEYEDDTERRSPtPER T19 1 
myozenin 2 
sPPNPENIAPGYSGPLK S1 8 
IDGSNLEGGSQQAPStPPNTPDPR T16 3 
ERA+GEN3 
30 kDa protein 
sPPNPENIAPGYSGPLK S1 14 
IDGSNLEGGSQQAPStPPNTPDPR T16 4 
IDGSNLEGGSQQAPSTPPNtPDPR T20 3 
77 kDa protein 
DPSLDTNSSLAtPsPSPEAR T12 8 
DPSLDTNSSLATPsPsPEAR S16 2 
DPSLDTNSSLATPsPSPEAR S14 11 
71 kDa protein 
DPSLDTNSSLAtPsPSPEAR T12 8 
DPSLDTNSSLATPsPsPEAR S16 2 
DPSLDTNSSLATPsPSPEAR S14 11 
Troponin I, cardiac muscle RRSsANYR S4 16 
similar to titin isoform N2-A 
RVKsPELVASHPK S4 21 
VKsPELVASHPK S3 17 
VKSPETVKsPK S9 11 
YSsPPAHVK S3 2 
AVsPTETKPTEK S3 1 
AVSPtETKPTEK T5 1 
AVSPTEtKPTEK T7 1 
SRPQPAEEYEDDTERRsPtPER T19 1 
SRPQPAEEYEDDTERRsPTPER S17 5 
TRPRsPsPVSSER S5 , S7 1 
35 kDa protein 
DPSLDTNSSLAtPsPSPEAR T12 8 
DPSLDTNSSLATPsPsPEAR S16 2 
DPSLDTNSSLATPsPSPEAR S14 11 







myosin-binding protein C, cardiac-type 
RTsDSHEDAGTLDFSSLLK S3 14 
RTSDsHEDAGTLDFSSLLK S5 14 
TSDsHEDAGTLDFSSLLK S4 4 
TsDSHEDAGTLDFSSLLK S2 2 
tSDSHEDAGTLDFSSLLK T1 1 
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